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The adoptive transfer of human regulatory T cells (Tregs) in transplantation 
offers an attractive therapeutic alternative in the current struggle to improve long-term 
outcomes. 
CD4+CD25+FOXP3+ (Tregs) play an important role in immunoregulation and 
have been shown in animal models to promote transplantation tolerance. Phase I trials 
in bone marrow transplantation and type I diabetes have already shown that ex vivo 
expanded Tregs have an excellent safety profile, which is encouraging for the broader 
application of these cells. The clinical trials initiated at King’s College London, 
ThRIL and the ONE study, are the leading trials of autologous Treg immunotherapy 
worldwide in the setting of liver and kidney transplantation, respectively. The success 
of these trials is reliant on the implementation of protocols that comply with Good 
Manufacturing Practice (GMP) guidelines centered on the successful isolation and 
expansion of a functional and stable human Treg population from prospective 
transplant recipients.  
The main focus of this thesis has been the adoptive cell therapy of Tregs in the 
context of liver transplantation. In this regard, it was first pertinent to study the 
biology of Tregs from patients with alcohol related cirrhosis (ARC), representing the 
majority of patients on the liver transplant waiting list. As such, an in-depth 
phenotypic and functional characterisation of the isolated Tregs from these patients 
was carried out. The results shown herein demonstrate that Tregs from ARC patients 
display impaired suppressive function.  Based on this finding, a series of experiments 
were conducted in order to delineate the mechanism behind the apparent defect in 
Treg suppressive function. This led to a novel discovery of a defect in the expression 
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of the cytoprotective enzyme, heme oxgenase-1 (HO-1), by patient Tregs, in 
correlation with the apparent Treg dysfunction.  
Subsequently, adherence to a GMP compatible 36-day expansion protocol 
resulted in the enrichment of a pure population of Tregs (91.3% CD4+CD25+ and 
0.153% CD8+ cells), reaching numbers needed for their clinical translation. In 
addition, the protocol ensured the maintenance of FOXP3 expression (94.6% of the 
CD4+CD25+ cells expressed FOXP3 at the end of expansion) with an increase in the 
frequency of FOXP3Hi cells throughout expansion. Culture in the presence of 
rapamycin also confirmed the stability of the expanded Tregs, whereby the cells did 
not convert to Th17 cells when cultured in the presence of pro-inflammatory stimuli.  
More recently, in the context of solid organ transplantation, the superiority of 
murine Treg lines with specificity for the graft as compared to polyspecific Tregs, in 
the protection against allograft damage, has come to light. Here, further evidence was 
provided, using a humanized mouse model of skin transplantation, demonstrating that 
human Tregs with direct allospecificity are more potent, compared to polyclonal 
Tregs, at averting alloimmune mediated skin damage. The data further indicated that 
allogeneic B cells were highly effective antigen presenting cells in this setting and 
concluded that a fundamental prerequisite precluding this as a successful therapeutic 
option was the requirement of a highly pure population of Tregs prior to allospecific 
ex vivo expansion. 
The practicality of Treg adoptive cell therapy is now widely accepted, provided that 
tailor-made clinical grade procedures for the isolation and ex vivo cell handling are 
available. The work presented in this thesis has addressed the prospects of Treg cell 
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Chapter 1  





The introduction of T-cell directed immunosuppressive agents in the clinical 
transplantation of solid organs has advanced remarkably and is currently a well-
established treatment for end stage failure of several major organs. However, despite 
vast improvements in short-term survival rates, long-term survival remains poor 
owing to episodes of chronic rejection and the relative toxicity associated with life-
long immunosuppression (Meier-Kriesche et al. 2004). Thus, the definitive goal of 
transplantation is to achieve ‘tolerance’, a state in which the host’s immune system 
can be reprogrammed and subsequently directed to accept a transplant without the 
need for long-term immunosuppression.  
In this pursuit, a thorough understanding of the immune mechanisms implicated in 
transplant allograft rejection is essential so as to better dictate an approach to 




In an immunocompetent host, transplantation of an organ from a genetically identical 
(“syngeneic”) individual does not lead to immunological reactivity directed against 
the graft, in contrast to transplantation between genetically disparate, or “allogeneic”, 
individuals. Allorecognition is the term used to refer to identification of tissues of 
allogeneic origin by a recipient’s immune system through the engagement of a 
receptor-ligand system. As such, the T and B cell receptors (TCR and BCR 
respectively) are key to recognising tissue–expressed genetically encoded 
polymorphisms (ligands) between members of the same species. These 
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polymorphisms, determining compatibility of tissues (histocompatibility), can be 
divided into major (class I and II) and minor histocompatibility complex antigens 
(MHC and mHAg respectively). 
 
Receptor-ligand (MHC-TCR/BCR) interactions between histoincompatible 
individuals result in the initiation of an immune response, referred to as the 
“alloresponse”. The alloresponse in non-tolerant patients and in the absence of 
immunosuppression invariably leads to graft rejection. This is characterised by tissue 
inflammation, architectural distortion and infiltration by graft-reactive T cells with 
effector function into the graft. The vigor of alloresponsiveness is reflected in vitro by 
the mixed leukocyte reaction (MLR) and in vivo by the rapidity, provoked by MHC 
incompatibility, of early transplant rejection (Sherman and Chattopadhyay 1993). 
 
However, it is noteworthy to mention, that allorecognition does not always result in 
rejection of donor grafts. Indeed, in clinical organ transplantation, particularly 
following liver transplantation, normal allograft function has been reported despite 
complete discontinuation of all immunosuppressive drugs (Takatsuki et al. 2001, 
Lerut and Sanchez-Fueyo 2006, Tisone et al. 2006). Patients spontaneously accepting 
their grafts are conventionally considered as “operationally” tolerant and provide a 
proof of concept that immunological tolerance can actually be attained in humans. 
Furthermore, in experimental transplant models spontaneous transplant tolerance 
across a full class I/ class II MHC barrier has been observed in outbred pigs (Calne et 
al. 1969) as well as in a number of fully allogeneic rat strain combinations (Kamada 
1985). These divergent responses to transplanted tissues allow a distinction to be 
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made between “antigenicity”, referring to the likelihood of foreign peptide or MHC 
molecule immunological recognition, and “immunogenicity”, the capacity to elicit a 
destructive immune response.  
In the following sections the pathways of allorecognition will be reviewed with 





Three pathways of allorecognition have been described to date (Figure 1.1): the direct 
pathway, in which recipient T cells recognise intact allogeneic MHC-peptide 
complexes expressed by foreign cells, (Warrens et al. 1994, Whitelegg and Barber 
2004) the indirect pathway, whereby T cells recognise peptides derived from 
allogeneic MHC proteins presented by self- antigen-presenting cells (APC) (Lechler 
and Batchelor 1982) and the semi-direct pathway, where recipient dendritic cells (DC) 
acquire intact allogeneic MHC-peptide complexes from donor cells and present them 







FIGURE* 1.1.* DIRECT, INDIRECT, AND SEMIDIRECT PATHWAYS OF 
ALLORECOGNITION.  
A. In the direct pathway, intact MHC on donor APCs is recognized directly by recipient CD4+ 
and CD8+ T cells. B. The indirect pathway is characterized by recipient APC uptake of 
allogeneic donor MHC that has been shed through apoptosis or necrosis. This is then 
processed, resulting in presentation of donor antigens in the context of recipient MHC class II 
to recipient CD4+ T cells. C. Semidirect allorecognition results from the transfer of cellular 
membrane components, including intact donor MHC, from donor APCs to recipient APCs. 
This process may occur through mechanisms such as cell–cell contact or through the transfer 
of donor exosomes that fuse with recipient APC cell membranes. Recipient APCs are then 
chimeric for MHC, and are able to stimulate both CD4+ and CD8+ recipient T cells. 
Abbreviations: APC- Antigen presenting cell; CD-cluster differentiation; MHC- major 





1.1.2.1. DIRECT ALLORECOGNITION 
 
Data available by the end of the 1950s suggested that leukocytes inherently associated 
with the transplanted tissue were the major source of tissue immunogenicity (Snell 
1957). These findings implicated ‘passenger’ leukocytes as the major immunogenic 
component of the allograft (Talmage et al. 1977). In support of this, studies looking 
into the effects of depleting donor bone marrow-derived ‘passenger’ leukocytes by in 
vitro culture of thyroid (Talmage et al. 1976) or pancreatic islet (Bowen et al. 1980) 
allografts showed prolonged graft survival. Data to support that DCs are the principal 
APCs mediating the priming of naïve T-cells against graft antigens was conclusively 
demonstrated in 1982 by Lechler and Batchelor after it was shown that acceptance of 
rat renal allografts could be achieved by “parking” the kidney temporarily in an 
intermediate immunosuppressed recipient, leading to depletion of donor DCs before 
re-transplantation (Lechler and Batchelor 1982). 
T cells with direct allospecificity have a clear role in transplant rejection as 
demonstrated in a study by Gill’s group (Pietra et al. 2000). Here, immunodeficient 
severe combined immunodeficiency (SCID) or recombination-activating-gene-
deficient (Rag-/-) mice were reconstituted with syngeneic CD4+ T cells and were 
subsequently found to reject MHC class II-expressing cardiac allografts, but not MHC 
class II-deficient grafts. Furthermore, Rag-/-MHC class II-/- mice rejected allogeneic 
cardiac transplants when reconstituted with CD4+ T cells. Given that these mice have 
no CD8+ T cells and lack the capacity for self-MHC class II-restricted indirect 
allorecognition (see below), these results clearly indicate that direct pathway CD4+ T 




The strength of alloresponses triggered by the direct pathway is due in part to the very 
high frequency of T cells with direct allospecificity (Baker et al. 2001). There is 
evidence to indicate that this mode of allorecognition results from cross-reactivity by 
T cells specific for a self MHC molecule, ‘A’, with peptide ‘x’ on an allogeneic MHC 
molecule, ‘B’, with peptide ‘y’ (Rogers and Lechler 2001). In support of the cross-
reactive hypothesis it was evident that a large fraction of the direct alloresponse was 
derived from T cells with a memory phenotype, indicating that these cells had been 
primed against foreign antigens in the context of self-MHC molecules (Lombardi et 
al. 1990, Merkenschlager et al. 1991). Two models have been proposed to account for 
the high precursor frequency of alloreactive T cells within the direct pathway of 
allorecognition. These are the ‘high determinant density’ (Crispe et al. 1986, Baldwin 
et al. 2004) and ‘multiple binary complex’ (Matzinger and Bevan 1977) models. 
The high determinant density model proposes that alloreactive T cell receptors are 
able to directly recognise the exposed amino acid polymorphisms on intact foreign 
MHC and that the nature of the bound peptide is of secondary relevance (Warrens et 
al. 1994). Thus, if every MHC molecule on a cell’s surface can serve as a ligand for 
an allospecific T cell, this creates a high ligand density, implying that receptors with 
lower affinity can respond to the foreign MHC, leading to a higher frequency of 
alloreactivity. In support of this, several studies have shown inhibition of 
alloresponses after blocking TCR-contacting regions of allo-MHC using synthetic 
peptides and site-specific mutations, presumably through inhibition of TCR-MHC 
contact (Schneck et al. 1989, Lombardi et al. 1991, Villadangos et al. 1994). In 
addition, previous work has shown alloreactivity in the absence of peptide by 
analyzing the reactivity of several H-2Kb-alloreactive cytotoxic T cell (CTL) clones 
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against H-2Kb-expressing target cells, with and without acid treatment of target cells 
to remove bound peptide form the MHC binding groove. 
 
The multiple binary complex model proposes that the specificity of the alloreactive 
TCR for recognition of peptide (derived from a normal cellular or serum protein) 
bound by allogeneic MHC is of primary importance (Sherman and Chattopadhyay 
1993). This model is the equivalent of TCR recognition of conventional self-MHC 
restricted immune responses to foreign antigen (crystallographic studies over the last 
decade have provided significant insight into these unique recognition events). 
Differences in the allo-MHC peptide-binding groove causes binding of a different set 
of peptides from those of the self-MHC homologue, therefore each peptide-allo-MHC 
complex is recognised by a different alloreactive T cell and any one MHC mismatch 
will be able to stimulate a large number of diverse T cells responsive to different 
antigens. In support of this, displacement of endogenous peptides from allogeneic 
antigen presenting cells (APCs) by incubation with exogenous peptides leads to loss 
of allorecognition by allospecific T cells (Eckels et al. 1988). Furthermore, adding 
peptides, naturally processed and derived from a serum or cellular protein, has been 
shown to restore allorecognition, and many alloreactive T-cell clones exhibit selective 
peptide recognition, indicating that they are peptide specific (Rotzschke et al. 1991, 
Barber et al. 1995, Kuzushima et al. 1995). 
In practice, it is probable that both the high determinant density and multiple binary 
complex mechanisms contribute to direct allorecognition, the overall contribution of 
each being related to the site and magnitude of the structural differences in the MHC 
molecules between responder and stimulator cells. 
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The high frequency of direct alloreactivity suggests that it is likely to dominate 
priming of direct pathway alloreactive T cells in the immediate post-transplant period. 
This is supported by markedly elongated transplant survival in direct pathway-
incompetent animals. However, depletion of donor-derived DC through apoptosis and 
elimination by recipient immune reactivity is a process that begins shortly after 
engraftment. This is accompanied by a decline in frequency of recipient T cells with 
direct anti-donor allospecificity with time (Hornick et al. 1998), most pronounced in 
the CD4+CD45RO+ (memory) subset, consistent with the proposal that it is an 
encounter with co-stimulation deficient graft parenchymal cells that leads to the fall in 
frequency (Baker et al. 2001). These observations suggest that the crucial period for 
activation of recipient direct pathway memory T cells is the first few weeks following 
transplantation in response to donor DCs.  
+1.1.2.2.+INDIRECT+ALLORECOGNITION+
 
Indirect allorecognition was described as a separate entity over 20 years ago (Lechler 
and Batchelor 1982) following observations that passenger leukocyte-depleted rat 
renal allografts, weakly immunogenic via the direct pathway, were rejected albeit 
with slower kinetics than seen with direct responses. It was suggested that 
conventional antigen presentation pathways for nominal antigens could be responsible 
for mediating graft rejection in this setting. The “indirect” pathway model proposed 
that recipient DCs traffic through the graft, take up soluble MHC alloantigens and 
dead donor cells and process and present alloantigens as peptide on self MHC class II 
molecules to CD4+ cells in local lymphoid tissue. In support of this, when H2K DCs 
(expressing the H2-E molecule) were injected into H2b recipients (H2-E negative), 
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within two days the majority of recipient DCs in the draining lymph nodes could be 
stained by an antibody recognising a complex of H2-Ab with a peptide from H2-
Ea chain, indicating that H2-E molecules have been processed by trafficking host DCs 
and presented as peptides on self-MHC (Inaba et al. 1998). Indeed, MHC class I- 
deficient recipients, that lack CD8+ T cells are still capable of rejecting MHC class II 
negative grafts, through indirect presentation of peptides of graft-derived MHC class I 
to recipient CD4+ T cells (Auchincloss et al. 1993). In vitro studies have confirmed 
the presentation of donor MHC peptides by recipient APCs for both class I (Essaket et 
al. 1990) and class II (de Koster et al. 1989) peptides and T cell recognition of MHC 
class I and II antigens in the context of self-MHC class I has also been demonstrated 
(Kievits and Ivanyi 1991). In vivo, processing and presentation of MHC-derived 
peptides appear to be common physiological events (Hunt et al. 1992)  and self 
restricted T helper cells with indirect allospecificity can provide help for CTL 
induction during allograft rejection (Lee et al. 1994). In this model, recipient mice, 
depleted of CD8+ T cells (by in vivo treatment with anti-CD8 monoclonal antibody) 
and subsequently grafted with MHC class II deficient allogeneic skin, rejected the 
skin grafts rapidly through de novo generation of graft-reactive CD8+ CTL. These 
CD8+ CTL required in vivo help from indirect pathway-sensitized CD4+ cells. These 
results provide evidence that indirect recognition can provide effective help for CTL 
induction during graft rejection, even when the cytotoxic T cells are sensitized by 
determinants expressed only on the donor graft.  
The decline in direct pathway responses with time is as pronounced in patients with 
chronic rejection as those with stable graft function, indicating that the direct pathway 
of allorecognition is not as important for chronic rejection. The indirect alloresponse, 
on the other hand, founded on antigen capture and processing, is less rapid as 
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compared to the direct pathway and dominates reactivity to transplanted antigens in 
the long-term. The requirement for antigen processing and presentation in the context 
of self-MHC class II means that the indirect pathway is largely dominated by CD4+ T 
cells. The importance of the indirect pathway to transplant rejection is demonstrated 
by experimental systems whereby immunization with peptides of allogeneic MHC 
(eliciting only indirect pathway responses) is sufficient to mediate transplant rejection 
(Fangmann et al. 1993). Similarly, donor-specific hyporesponsiveness can be created 
by intrathymic injections of MHC peptides through down-modulation of indirectly-
responsive T cells (Sayegh et al. 1994). 
 
Indirectly alloresponsive CD8+ T cells are activated through “cross-priming”, 
whereby APCs process donor proteins, including alloantigens, and present them in 
peptide form in the context of self MHC class I molecules (Valujskikh et al. 2002). 
Interestingly, a recent study showed that recipient endothelium was able to present 
antigens of skin grafts in the context of recipient MHC class I molecules to TCR-
transgenic CD8+ T cells, and this indirect CD8+ pathway could result in an IFN-γ-
dependent skin graft rejection. However, the significance of this pathway of indirect 
recognition remains unclear since it has been found that the indirect pathway 
involving CD8+ cells has no effect on rejection or tolerance of vascularised cardiac 
allografts (Valujskikh et al. 2006).  
 
Despite dominant focus on host DCs and macrophages when elucidating mechanisms 
of indirect alloantigen presentation (Steinman 1991, Sayegh and Carpenter 1996), it 
has been noted that B cells have their own a special niche in indirect alloresponses, 
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due to the importance of T:B cell interactions. In this regard, B cells are known to 
constitutively express MHC class II and costimulatory molecules, which enable them 
to act as potent APCs for alloreactive CD4 T cell activation (Janeway et al. 1987, Ron 
and Sprent 1987, Wilson et al. 1995). Moreover activated alloreactive B cells, by 
virtue of their antigen- specific BCR, have the capacity to selectively concentrate 
specific antigens, making them a repository of alloantigen- presenting APCs. Indeed, 
the presence of circulating, class-switched, donor-specific antibody suggests that 
indirect antigen presentation to T cells has occurred via B cells that have captured 
alloantigen through their surface BCR. T cell help, in turn, then ensures that B cells 
produce high affinity, class-switched alloantibodies (Steele et al. 1996, Taylor et al. 
2007). In murine models of cardiac transplantation, containing targeted deficiencies of 
MHC class II-mediated Ag presentation confined to the B cell compartment, absent B 
cell-mediated Ag presentation disrupts both alloantibody production and the 
progression of CD4+ T cell activation, leading to prolonged cardiac allograft survival 
(Noorchashm et al. 2006). These findings demonstrated that indirect alloantigen 
presentation by the recipients' B cells plays an important role in the efficient 
progression of acute vascularised allograft rejection. These experiments support the 
growing appreciation of B cells and T:B cell interactions in chronic rejection.  
+
1.1.2.3. THE SEMI-DIRECT PATHWAY 
 
The traditional model of cross-talk between CD4+ and CD8+ T cells during the 
generation of an immune response relies on the “three-cell” or “linked” model (Ridge 
et al. 1998). In this model, the generation of pathogen-specific cytotoxic CD8+ T cells 
requires help from CD4+ T cells activated by the same APC. Observations in 
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transplantation, however, present an apparent paradox in this model as cross-talk 
between the direct and indirect pathways (e.g. indirect pathway CD4+ T cells 
amplifying or regulating direct pathway-responsive CD8+ T cells) necessitate a “four 
cell” or “unlinked” model (i.e. that each T cell type is activated by a different APC). 
  
The ‘semi-direct’ pathway (Herrera et al. 2004) (Figure 1.1) resolves the four cell 
problem by stipulating that intact surface donor MHC:peptide complexes are acquired 
by recipient APCs either through a cell-cell contact (Game et al. 2005) or via 
exosomes, small vesicles produced by cells in a non-haphazard fashion (Morelli et al. 
2004). In this way, recipient DCs acquire and present intact donor MHC class I 
molecules to direct pathway CD8+ T cells, as well as internalised and processed donor 
MHC molecules as peptides to CD4+ T cells with indirect allospecificity (Brown et al. 
2011). Therefore, presentation to both direct and indirect pathway-responsive T cells 
occurs in a linked or three-cell manner.  
   
Although there is no direct evidence for an in vivo role of this pathway in the context 
of allograft rejection, it does provide an alternative explanation for several findings 
that are difficult to understand if only the direct and indirect justifications of 
allorecognition apply. For instance, embryonic thymic epithelium, naturally devoid of 
APCs, can be acutely rejected in the absence of the indirect pathway, a phenomenon 
difficult to explain without the semi-direct pathway of allorecognition (Pimenta-
Araujo et al. 2001). Similarly, recipients lacking the indirect pathway (MHC class II-
deficient) reject co-stimulation deficient (CD80-/-CD86-/-) allogeneic cardiac grafts as 
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rapidly as wild-type transplants (Mandelbrot et al. 2001). This can be explained by the 
semi-direct presentation of MHC from the graft rather than trans co-stimulation.  
 
1.1.3. THE ALLORESPONSE AND EFFECTOR CELLS 
 
The central determinant of alloresponsiveness, whether recognition occurs through the 
direct, indirect or semi-direct pathways, is the APC, which readies recipient T cell 
responses. In this setting, immunological priming is most likely to occur in secondary 
lymphoid tissues. In support of this, donor DCs from cardiac allografts migrate to 
recipient spleen after transplantation (Larsen et al. 1990) and mice lacking secondary 
lymphoid organs are unable to mount immune responses against transplanted tissues 
(Lakkis et al. 2000). Additionally, using TCR-transgenic mice it can be appreciated 
that adoptively transferred CD4+ T cells with direct allospecificity expand initially in 
the draining lymph nodes and spleen in response to the presence of the alloantigen on 
transplanted skin. The expanded CD4+ T cells upregulate CD69 and CD25 expression 
and produce effector cytokines, but downregulate CD45RB and CD62L expression, 
hallmarks of an effector and/or memory phenotype. After clonal expansion, they 
infiltrate the graft and this correlates with the timing of graft rejection (Reed et al. 
2003, Sandner et al. 2003). 
Following alloantigen recognition, in the absence of mitigating immune mechanisms 
or pharmacological intervention with immunosuppressive drugs, intense infiltration of 
lymphokine-secreting alloreactive T cells occurs in the graft, inducing the expression 
of MHC class II on endothelial and epithelial cells, conferring the ability to present 
antigen to CD4+ T cells (Bal et al. 1990). As passenger leucocytes are depleted with 
time post-transplantation, endothelial and epithelial cells remain as the only graft-
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derived cells expressing donor MHC class II. Direct pathway presentation through 
these non-professional APCs results in the deletion of naïve T cells, silencing and/or 
switching to a Th2 phenotype (in antigen-specific T-cell clones), and anergy in 
memory cells with failure to secrete interleukin (IL) 2 (Lombardi et al. 1997, Marelli-
Berg et al. 1997). The lack of proliferation of alloreactive T cells can be overcome by 
the addition of B7 (CD80/CD86) – expressing cells, suggesting that non-professional 
APCs lack effective co-stimulatory ability (Marelli-Berg et al. 1996). 
 
The requirement of previously activated CD4+ T cells for B7-mediated co-stimulation 
is controversial. In some in vitro systems, it appears that the requirement of such cells 
for co-stimulation is less stringent. However, other data suggests that full activation 
does not occur unless co-stimulation is provided. For example, co-culture of 
CD4+CD45RO+ T cells with HLA-mismatched, IFN-γ treated primary epithelial cells 
(from human thyroid or kidney) has been reported to induce allospecific 
hyporesponsiveness (Malissen et al. 1988). In the context of an immune response, the 
purpose of the endothelial cells appears to be to facilitate the entry of activated T cells 
into the tissue without altering its functional behaviour or activation status (Marelli-
Berg et al. 2004). Once in the tissue, antigen-specific T cells could either interact with 
recruited monocytes and macrophage APCs to be reactivated or, alternatively, with 
the parenchymal cells to be functionally inactivated. In transplantation, once the 
donor leukocytes have left the allograft, antigen recognition via parenchymal cells 
may lead to a form of donor-specific tolerance in T cells previously activated by the 
direct pathway. This is supported by the reduced frequency of direct pathway reactive 




Clearly, as effector cells in the immune response against transplanted organs, T cells 
play a central role and as such an understanding of T cell phenotypes and diversity is 
key to developing novel strategies of tolerance induction. 
 
1.1.3.1 T CELL DIFFERENTIATION 
 
Activation of naïve CD4+ T cells results in T cell maturation and differentiation to 
phenotypes with effector functionality. Individual CD4+ T cell subsets are defined by 
expression of a combination of specific cytokines, surface markers and transcription 
factors, and the signalling pathways through which their differentiation is mediated 
(Atalar et al. 2009). One caveat should be inserted here that accumulating evidence 
suggests that terminal differentiation of T cells towards a single phenotype may not be 
absolute and that multi-potency may be retained after differentiation to a given subset. 
O’Shea et al. have provided an up to date article discussing these implications and 
possible mechanistic insights (O'Shea and Paul 2010). This caveat notwithstanding, 
both human and murine CD4+ T cells can differentiate from pluripotent naïve cells 
(Thp) into at least four types of committed helper T cells, namely Th1, Th2, Th17 and 
regulatory T cells (Tregs) (Figure 1.2). Pathways of differentiation and the required 
signals are very similar between the two species, with only small distinguishing 





FIGURE 1.2. CD4+ T CELL SUBSET DIFFERENTIATION.  
Upon encountering foreign antigens presented by APCs, naïve CD4+ T cells can differentiate 
into several different T cell subsets, Th1, Th2, Th17, Tregs, and several novel subsets, Tfh 
and Th9 cells, all heralding distinct immunological roles. These differentiation programs are 
controlled by different cytokines and each separate CD4 T cell subset can be identified from 
their lineage specific transcription factors responsible for the regulation and maintenance of 
their individual functions; T-bet (Th1 cells), GATA3 (Th2 cells), RORγt (Th17 cells), FOXP3 
(Tregs), Bcl6 (Tfh) and IRF4 (Th9). Each subset has its own immunological role in vivo: TfH 
cells produce IL-21 and synergistically interact with B cells in secondary lymphoid tissue.  
Th1 cells secrete IFNγ, controlling immunity to foreign pathogens. Th2 cells produce various 
cytokines including: IL-4, IL-5, IL-13, IL-10, which are primarily involved in promoting 
humoral immunity, protecting against infection. Th17 cells produce predominantly the 
inflammatory cytokine IL-17 and play an important role in controlling pathogens especially at 
environmental surfaces. Th9 cells have been shown to be important in protection against 
helminth infections. Despite the apparent terminal differentiation of all these cells, they 
cannot be considered to be committed to one cell fate. Lineage plasticity following 
differentiation is depicted by the dotted arrows. This diagram is far from comprehensive; it is 
most likely that the future will see various changes and additions to this diagram concerning 
the differentiation of CD4+ T cells. Abbreviations:  APC- Antigen presenting cells; Bcl6- B 
cell lymphoma-6; Follicular helper T (Tfh) cells, FOXP3- Forkhead Box P3; IFN- Interferon; 
IL- Interleukin; IRF-Interferon regulatory factor; RORγt -retinoid related orphan receptor γ; 
Tbet- T box transcription factor; Tfh- T follicular helper; TGF- β- Transforming growth 
factor-β; Th- T Helper cell; TNFα- tumour necrosis factor-α; Treg- Regulatory T cell. 




The evidence for Th1 and Th17 responses in allograft rejection will be reviewed in 




 The defining features of Th1 cells are the expression of Interferon (IFN)-γ and 
differentiation mediated via the signal transducers and activators of transcription 
(STAT) 1 and STAT4 proteins (Weaver et al. 2007). Th17 cells may be defined by 
expression of the cytokine interleukin 17 (IL-17) and differentiation through the 
STAT3 pathway (McGeachy and Cua 2008).  
Once differentiated, each lineage is characterised by its own transcription factor - 
Tbet for Th1 cells (Szabo et al. 2000) and retinoic acid-related orphan receptor 







Th1 cells are the classical pro-inflammatory T cell, central to delayed type 
hypersensitivity responses and critical to the response to intracellular pathogens such 
as Mycobacteria sp. As such, many studies of transplant rejection have concentrated 
predominantly on Th1 responses and IFN-γ production. Although this cytokine is 
undoubtedly elevated in murine models of active transplant rejection, IFN-γ is 
produced by a number of cell types other than Th1, including natural killer cells (NK) 
cells, Tregs and CD8+ T cells (Martin-Fontecha et al. 2004, Sawitzki et al. 2005). 
Therefore, IFN-γ detection does not necessarily denote Th1 activity. Several studies 
question the role of Th1 cells in allograft rejection (O'Connell et al. 1993, Nickerson 
et al. 1994) but none so poignantly as rodent heart and kidney transplantation 
experiments in knockouts of IFN-γ where accelerated graft rejection is invariably the 
outcome (Miura et al. 2003). Despite the studies outlined above supporting the role of 
Th1 cells in human transplant rejection, it is important to mention the studies that 
question this. In paediatric liver transplant patients who tolerated their graft without 
episodes of rejection, IFN-γ levels remained low, (Gras et al. 2007) however serum 
IFN-γ concentrations remained significantly elevated at 24 months following renal 
transplantation in patients without episodes of rejection when compared with healthy 
controls (Sadeghi et al. 2007). This discrepancy in cytokine levels in tolerant patients 
questions the role of Th1 cells in rejection. Furthermore, although T-bet, the signature 
transcription factor of Th1 cells can be identified in renal transplant biopsies during 
episodes of acute rejection (Hoffmann et al. 2005), in similar fashion to IFN-γ, T-bet 
is pleiotropic and also expressed by many other cell types including dendritic cells 
(Alcaide et al. 2007) and NK cells (Townsend et al. 2004) and therefore not specific 
to Th1 cells during rejection. 
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Th17 cells produce the highly pro-inflammatory cytokine, IL-17, and are central to 
the response to extracellular pathogens. These cells have accumulated a wealth of 
literature as a result of a strong association with autoimmune diseases. Indeed, Th17 
cells are now considered principal mediators in the pathogenesis of human 
autoimmune diseases (Afzali et al. 2007). In the transplant setting, an elevation in IL-
17 mRNA in rejecting rat renal allografts and IL-17 protein in infiltrating 
mononuclear cells can be seen as early as 2 days post transplantation (Loong et al. 
2002) while IL-17 protein is elevated in human renal allografts during subclinical 
rejection together with detectable IL-17 mRNA in urinary sediments (Van Kooten et 
al. 1998, Loong et al. 2002). An early report of antagonising IL-17 in rat cardiac 
transplantation concluded significantly prolonged transplant survival yet categorical 
demonstrations that Th17 cells are capable and sufficient to mediate allograft 
rejection on their own have only recently been published (Yuan et al. 2008, Yuan et 
al. 2009). In these models of murine cardiac transplantation, T-bet knockout (devoid 
of Th1 responses) and T-bet IFN-γ double-knockout recipients of MHC class II-
mismatched grafts showed accelerated graft rejection relative to wild-types as a result 
of profuse tissue infiltration of Th17 cells. In both models, antagonism of IL-17 









1.2 REGULATORY T CELLS AND TRANSPLANTATION TOLERANCE +
1.2.1 MECHANISMS OF TOLERANCE 
 
Tolerance mechanisms that operate in the thymus before the maturation and 
circulation of T cells are referred to as ‘central tolerance’. Whilst the thymus holds a 
substantial library of self-antigens, maturing T cells may still hold a degree of 
autoreactivity, suggesting that central tolerance mechanisms alone are insufficient in 
entirely educating their development. Additional tolerance mechanisms exist which 
restrain the number and/or function of T cells slipping through the net of tolerance 
laid down in the thymus. These mechanisms act on mature circulating T cells and are 




Circulating bone marrow derived common lymphoid progenitors (CLP) home to the 
thymus, generating a copious population of thymocytes, which give rise to T 
lymphocytes (Kondo et al. 1997, Kondo et al. 2000). The thymus is composed of 
contiguous micro-environmental niches that contain the cues necessary to produce 
fully mature T cells with functional TCRs (Germain 2002, Takahama 2006). 
Primordial thymocytes are initially CD4 and CD8 double negative (DN). After T 
lineage commitment and expansion, TCR gene rearrangement ensues, giving rise to 
either γδ  or αβ progenitors at the CD4 and CD8 DN stage. Successful αβ 
commitment of the DN cells gives rise to a large number of CD4 and CD8 double 
positive (DP) thymocytes with somatic recombination of TCR genes resulting in a 
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broad repertoire of distinct αβ  TCR of random specificity. The TCR affinity for self-





FIGURE 1.3. THYMOCYTE SELECTION AFFINITY MODEL.  
The strength of the interaction between T cell receptors, expressed on thymocytes, and self-
peptide MHC determines the fate of these cells. Positive selection of thymocytes occurs 
following weak- intermediate interactions with self-MHC whereas those which have zero 
affinity for self-MHC die by neglect. Thymocytes with a high affinity for self-MHC are 
subject to negative selection. Clonal diversion, redirecting cells to take up an 
immunoregulatory lineage (Tregs), and deletion are the two main forms of negative selection. 
Clonal diversion is said to occur at an optimal affinity where positive selection and deletion 
sit either side. In addition, thymocytes that are negatively selected may be subject to receptor 
editing and/or anergy in order to avert any possibility of autoimmunity. Abbreviations: TCR- 




DP thymocytes expressing TCRs that do not bind self-peptide MHC complexes die by 
neglect. Those with a low affinity for self-peptide MHC complexes are positively 
selected to differentiate into CD4 or CD8 single positive (SP) thymocytes. However, 
thymocytes with high affinity for self peptide-MHC undergo negative selection, thus 
preventing the development of autoimmunity. Following negative selection cells are 
subject to revisory alterations in order to avert autoimmunity. 
Receptor editing, is a process whereby the thymocytes with high affinity for self-
peptide MHC are instructed to generate a second rearrangement of the TCR α loci, 
thereby altering the specificity of the TCR (Wang et al. 1998, McGargill et al. 2000, 
Santori et al. 2002, Mayerova and Hogquist 2004).  
Anergy, or a state of induced unresponsiveness has also been implicated (Hammerling 
et al. 1991). Although, the relative contribution of the receptor editing and anergy to 
central tolerance is thought to be minimal, with anergy described most commonly as a 
tolerance mechanism operating in the periphery.   
Instead, clonal diversion and deletion of high affinity thymocytes determines their 
predominant fate. The former describes the diversion of high affinity thymocytes into 
lineages that attain immunoregulatory function, whilst the latter involves the 
induction of apoptosis in self-reactive clones. Of note, clonal deletion is the 
predominate mechanism by which central tolerance is achieved (Liston and Rudensky 




1.2.1.2 PERIPHERAL TOLERANCE +
Peripheral tolerance mechanisms exist, namely deletion of self-reactive T cells, 
anergy and regulation, to ensure the continuation of tolerance when lymphocytes first 
encounter their cognate self-antigens outside of the thymus.  
1.2.1.2.1. PERIPHERAL DELETION +
Clonal deletion of autoreactive T cells has been shown to occur through apoptosis via 
activation of the Fas/FasL pathway and the Bim dependent mitochondrial pathway 
(Mueller 2010). In agreement, Bim deficient and Fas deficient (lpr/lpr) mice display 
defects in peripheral tolerance, leading to lymphadenopathy, splenomegaly and the 
development of autoimmunity suggesting the involvement of both molecules in the 
peripheral deletion of T cells (Hutcheson et al. 2008, Weant et al. 2008).  
1.2.1.2.2. T CELL ANERGY AND COSTIMULATORY SIGNALS +
T cell activation primarily involves the TCR signal. However, T cells are not able to 
mount an immune response without a second costimulatory signal. This signal 
involves the interaction of the CD28 receptor on T cells with two ligands, B7.1 
(CD80) ad B7.2 (CD86), expressed on APCs, promoting T cell activation, 
proliferation and survival, after T cell interaction with APC (Figure 1.4). In parallel 
activation of T cells in the absence of CD28 has been shown to result in an anergic 
state (Bour-Jordan et al. 2011), with animal models reporting that inhibition of the 
CD28/B7 interaction results in transplantation tolerance (Li et al. 1999). A concept 
already discussed in section 1.1.3 concerning the direct pathway of presentation 





















FIGURE 1.4. T CELL ACTIVATION 
 Interaction between naïve T cells and APCs initiates T cell activation. Stimulation begins 
following contact of the TCR with antigen-bound MHC. This interaction is considered as 
signal 1. However, for complete activation of the T cell, additional costimulatory signals are 
required. Primarily, the interaction between CD28 and CD80/86, expressed on the T cell and 
APC respectively, is the most important co-stimulatory signal, identified as signal 2. Various 
other additional signals are also thought to be involved in T cell activation including 
CD40/CD40L ligation. The interaction between CTLA-4 and CD80/86 has been shown to 
inhibit T cell activation by out competing CD28 for its ligand on APCs, thus preventing 
signal 2 from propagating. Abbreviations: Ag- antigen; APC- antigen presenting cell; CD-
cluster differentiation; CTLA-4-cytotoxic T-lymphocyte-associated protein 4; L- ligand; 
MHC- major histocompatibility complex; PD-Programmed death; PDL-1- Programmed 




Autoreactive T cells also express a number of immunosuppressive molecules 
including programmed dealth-1 (PD-1), CD5 (Hawiger et al. 2004), T cell 
immunoglobulin and mucin domain-3 (TIM-3) (Anderson and Anderson 2006) and 
cytotoxic T lymphocyte antigen-4 (CTLA-4) (Eggena et al. 2004, Mallone et al. 2005) 
(mentioned in detail in section 1.2.4.1).  
Consequently autoreactive T cells with relative low avidity for their cognate antigen 
have a high threshold for activation and are functionally anergic (Mallone et al. 2005). 
In contrast those with a high avidity are particularly sensitive to Fas and Bim 
dependent apoptosis, therefore, these potentially pathogenic cells are quickly removed 
from the T cell pool (Marrack and Kappler 2004) Of note, also within the periphery, 
autoreactive T cells are constrained, by a group of regulatory immune cells.  
 
1.2.1.2.3.%SUPPRESSION%OF%IMMUNE%RESPONSES;%REGULATORY%CELLS%+
The proposal of the existence of a distinct subset of T cells able to suppress immune 
responses was first put forward in the 1970s which led to extensive research in order 
to identify these ‘suppressor T cells. (Gershon and Kondo 1970). It was not till the 
mid 90’s when, a thymic derived lymphocytic population, coined Tregs, were first 
defined. These cells play a major role in the development of tolerance by suppression 
of immune responses (Wing and Sakaguchi 2010). 
The past two decades have seen the discovery of many different types of regulatory 
cells including; CD8+ T cells (Reibke et al. 2006), CD4-CD8- double negative T cells 
(Zhang et al. 2000), CD8+CD28- (Haribhai et al. 2007), NK T cells (Monteiro et al. 
2010), and γδ T cells (Hayday and Tigelaar 2003), but these are less well studied 
compared to their CD4+ regulatory T cells counterparts, further characterised by high 
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and stable expression of surface interleukin-2 receptor α chain (IL-2Rα, CD25hi) 





Tregs are divided into two main subsets, based on their site of differentiation, namely 
thymus derived natural Tregs (tTregs) and peripherally induced Tregs (pTregs), 
(Fehervari and Sakaguchi 2004). tTregs are spawned from negatively selected 
thymocytes, whereas the conditions favoring the generation of  pTregs include 
suboptimal DC activation, sub-immunogenic doses of agonist peptide, mucosal 
administration of peptide and antigenic encounter in the presence of environmental 
cytokines: transforming growth factor-β (TGF-β) , IL-2 and retinoic acid (Povoleri et 
al. 2013).  
 
There are at least two well defined populations of pTregs; Th3, first identified from 
their role in oral tolerance through the secretion of TGF-β (Chen et al. 1994) and Tr1, 
characterised on the basis of their role in preventing autoimmune colitis (Groux et al. 
1997) and their ability to secrete large amounts of IL-10 (Levings et al. 2001, Barrat 
et al. 2002). As such pTregs are implicated in the induction of oral and gut tolerance 
(Coombes et al. 2007) and generated in chronically inflamed and transplanted tissues 




Of note, the functional distinction of thymic and peripherally derived Tregs has not 
been clearly established, posing challenges in classifying the definitive proportions of 
these two subsets in secondary lymphoid organs and non-lymphoid tissues alike. 
Despite great interest in identifying surface markers that differentiate these Tregs, no 
marker has been conclusively identified to date. In mouse, neuropilin (Nrp-1) 
expressed on tTregs can differentiate these cells from their peripherally derived 
counterparts, which do not express this molecule (Weiss et al. 2012, Yadav et al. 
2012). However, this distinction does not hold true for human Tregs. 
 
Although, it should be noted that other than their different sites of differentiation, 
Tregs, particularly those in humans, are highly heterogeneous. Various different 
surface and intracellular immunological markers have been studied, defining Tregs 






The IL-2 receptor α chain, CD25, is undoubtedly the most useful marker for Treg 
identification and isolation in view of its extracellular expression. Despite its transient 
presence on activated effector T cells (Sakaguchi et al. 1995, Kmieciak et al. 2009) a 
high constitutive expression of CD25 is commonly used to define and isolate 




The integral expression of CD25 introduces the critical role of IL-2 in the 
development and survival of Tregs (Bensinger et al. 2004, Fontenot et al. 2005). In 
this regard, IL-2 neutralisation (Setoguchi et al. 2005) and deficiency (Kramer et al. 
1995) has been shown to result in Treg defects and ultimately the onset of 




Further characterisation and understanding of Treg cell biology came from the 
discovery of FOXP3, an intracellular transcription factor known to play a crucial role 
in the development and function of Tregs in a highly specific manner (Hori et al. 
2003). Rare mutations of the FOXP3 gene have been linked with the development of 
immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX), 
leading to organ-specific autoimmune diseases including insulin-dependent diabetes 
mellitus and various hematological disorders (Hori et al. 2003). Furthermore, the 
importance of FOXP3 in the safeguarding of Treg phenotype and function has been 
reiterated in studies where a loss/diminution of FOXP3 expression in Tregs has been 
shown to affect the competency of these cells acquiring certain effector T cell 
properties, including production of cytokines such as IL-2, IL-4, IL-17 and IFN-γ 
(Wan and Flavell 2007). Described in detail in section 1.2.5. 
Additionally, while FOXP3 has been termed a ‘master control gene’, specifically with 
regards to Treg development, its expression is not uniformly homogenous. In contrast 
to mice, where foxp3 is expressed purely on Tregs, in humans, increasing evidence 
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has shown that effector cells can transiently express FOXP3, with no associated 
regulatory activity. Based on such studies and taking also into account its intracellular 
expression, this marker in isolation cannot be considered to be entirely sufficient in 
demarcating Tregs (Huehn et al. 2009). 
 
CD127++
Tregs are typically described as CD127Lo, based on reports that expression of the 
α chain of the IL7 receptor, CD127, inversely correlates with FOXP3 expression and 
functional suppressive capabilities (Liu et al. 2006). As such, the combination of 
CD25, FOXP3 and CD127 are considered to be the most stringent markers in defining 
Tregs in the research setting. 
 
CD45RA++
The classification of human Tregs into both tTregs and pTreg subsets infers that these 
cells cannot be considered to be functionally homogeneous. Following the recent 
discovery of naïve suppressive FOXP3+ cells (CD45RA+) present in the cord blood 
and in adult blood, and FOXP3+ cells which express a memory-like phenotype 
(CD45RA-), it has been proposed that three phenotypically and functionally distinct 
sub-populations based on the differential expression of CD25, FOXP3 and CD45RA 
can be defined: Population I (CD25++FOXP3+CD45RA+) classified as resting Tregs, 
population II (CD25+++FOXP3hiCD45RA-) termed activated Tregs and population III 
(CD25++FOXP3+CD45RA-) which was proposed to consist of non-suppressive 
FOXP3Lo cells (Miyara et al. 2009). Further analysis of the three populations by 
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Miyara et al. revealed that population I and II were both able to suppress in vitro with 
population II displaying a higher expression of CTLA-4, suggesting a more prevalent 
role in cell-mediated immunological suppression (described in detail in section 
1.2.4.1). Population III however was shown to be non-suppressive (Miyara et al. 
2009).  
Demarcation of these three populations was also able to depict the differentiation 
dynamics of FOXP3+ Tregs.  Resting Tregs, following stimulation in vivo upregulate 
their FOXP3 expression and mature to terminally differentiated activated Tregs 
maintaining its apoptotic pool. Miyara et al. suggested that population III had the 
greatest potential to differentiate into inflammatory Th17 cells, inferred from their 
relative IL-17 production following cytokine stimulation (Treg plasticity is discussed 
in section 1.2.5). The three comparative populations are found in different proportions 
in certain biological environments and their analysis can prove to be instrumental in 
identifying the immunological pathophysiology of disease.  
It should, however, also be noted that the functional characteristics of population III 
are debated. Booth et al. and data from my laboratory indicated that both CD45RO+ 
and CD45RA+ Treg subsets are equally suppressive, population III representing a 
bona fide Treg subpopulation, bearing T cell memory markers (Booth et al. 2010). 
 
HLAYDR++
The human MHC can be divided into two distinct subsets of human leukocyte antigen 
(HLA) class I (HLA-A,-B and–C) and class II (HLA-DP,-DQ and–DR) and is known 
to play a central role in the presentation of peptide to T cells. The expression of 
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MHC-II DR has primarily been seen as a marker of ‘activated’ T cells. However, the 
two subsets, HLA-DR+ and HLA-DR-, have been used to define two functionally 
distinct Treg subsets. Baecher-Allan et al. defined the HLA-DR+ (MHCII) Treg 
subset as a functionally mature subpopulation associated with early-contact dependent 
suppression, however, contact mediated suppression was not constrained by the class 
II dimer (Baecher-Allan et al. 2006). In a follow up study, Beriou et al. found that 
HLA-DR- Tregs, although retaining their suppressive function, produced IL-17 in an 
inflammatory setting (Beriou et al. 2009). 
 
CD27++
The co-stimulatory molecule CD27 is member of the TNF receptor superfamily, 
known to bind its ligand CD70. This interaction is important in the co-stimulation of 
T cells. CD27 is initially upregulated following TCR engagement, however, following 
repeated antigenic stimulation, levels drop (Hintzen et al. 1995). As a result, it has 
been proposed that CD27 can be used as a marker of stable Tregs since cells 
expressing CD27Lo may represent a subset of previously activated cells (De Jong et al. 
1992). Furthermore, the co-expression of CD27 and CD62L, a marker known to be 
involved in Treg lymph node homing, has been used to identify a population of Tregs 







In homeostatic conditions Tregs suppress effector T cell activation in lymphoid tissue. 
However, it has been reported that following a state of chronic inflammation, Tregs 
are found at the inflammatory site where they are able to directly suppress immune 
responses. In order to migrate from secondary lymphoid tissue to peripheral sites, 
Tregs must down regulate their relative expression of CCR7 and CD62L (Oo et al. 
2010) that are known to be specific lymphoid homing molecules. The upregulation of 
various specific chemokine receptors also aids the positioning and recruitment of 
Tregs to chronically inflamed tissue. The chemokine receptor CXCR3, has recently 
been proposed to be expressed on a subset of liver-infiltrating Tregs allowing 
transendothelial migration across the hepatic sinusoids, which was further supported 
by the observation of increased numbers of CXCR3 ligands, CXCL9, 10 and 11 in 




In vitro studies have demonstrated that the immunosuppressive qualities native to 
Tregs manifest through a variety of mechanisms (Figure 1.5), namely; modulation of 
APC maturation and function, anti inflammatory cytokine production, induction of 
apoptosis in target cells and disruption of metabolic pathways.
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FIGURE'1.5.'MECHANISMS OF REGULATORY T CELL SUPPRESSION 
A. Modulation of APC maturation and function. The interaction of CTLA-4 on Tregs with its ligand CD80/86 on APCs, delivers a negative signal for T 
cell activation. CTLA-4’s mechanism of action is varied including: the capture of its APC expressed ligands and subsequent trans-endocytosis and also the 
upregulation of IDO and the generation of kynurenines. B. Anti-inflammatory cytokine production. The secretion of anti-inflammatory cytokines such as: 
IL-10, IL-35 and TGF- β has been linked with inhibition of T cell activation in vivo C. Induction of apoptosis. Tregs have the capacity to directly induce 
apoptosis via granzyme A/B and perforin, TRAIL, the Fas/Fas-ligand pathway, the galectin-9/TIM-3 pathway, or the production of galectin-1. D.  Disruption 
of metabolic pathways. The ectoenzymes CD39 and CD73, expressed on Tregs, result in the metabolism of ATP to AMP and in turn producing the 
immunoregulatory purine, adenosine. Tregs have also been found to express high levels of intracellular cAMP. This is transferred to Teffector cells through 
gap junctions which leads to the upregulation of ICER and in turn the inhibition NFAT and Il-2 transcription leading to apoptosis by IL-2 deprivation. 
Abbreviations: APC- Antigen presenting cell; AMP- Adenosine monophosphate; ATP- Adenosine triphosphate; cAMP- cyclic adenosine monophosphate; 
CD- Cluster differentiation; CTLA-4-cytotoxic T lymphocyte antigen-4; DC- dendritic cells; ICER- inducible cAMP early repressor, IDO- indoleamine 2,3-
dioxygenase IL- interleukin; NFAT- nuclear factor of activated T cells; TGF β -transforming growth factor-β, TIM-3- T cell immunoglobulin and mucin 





The expression of CTLA-4 on both murine and human Tregs (Read et al. 2000, 
Takahashi et al. 2000, Qureshi et al. 2011) has been linked with Treg mediated 
immune suppression. In this regard, it has been demonstrated that CTLA-4 deficiency 
or blockade in mice results in spontaneous autoimmunity, which can be ameliorated 
by Tregs (Bachmann et al. 1999, Takahashi et al. 2000). Further supporting studies 
have reported that CTLA-4 blockade abrogates the protective effects of Tregs in 
murine colitis models (Read et al. 2000). However, there is contradictory evidence 
surrounding the definitive weight of CTLA-4 in Treg immunosuppression following 
reports that CTLA-4 deficient Tregs could still suppress through the compensatory 
mechanisms involving TGF-β and IL-10 in vitro and in vivo (Tang et al. 2004, Read 
et al. 2006). Similarly, Baecher-Allan et al. did not find an involvement of CTLA-4 in 
Treg mediated suppression of Teffector proliferation (Baecher-Allan et al. 2001, 
Levings et al. 2001). 
Despite these studies, the most recognised molecular mechanism behind Treg 
mediated suppression through CTLA-4 is centered on the disruption of the co-
stimulatory signal (Cederbom et al. 2000). Mechanistically, downregulation of 
CD80/CD86 on target APCs by CTLA-4 expressing Tregs involves the ‘capture’ of 
these ligands by CTLA-4, a process known as trans-endocytosis (Qureshi et al. 2011), 
thereby indirectly inhibiting T effector activation by APCs in vitro (Oderup et al. 




However, other proposed mechanisms of action of CTLA-4 have included the 
upregulation of IDO (indoleamine 2, 3-dioxygenase) expression in DCs, an enzyme 
involved in the degradation of tryptophan to kynurenine, in turn starving effector T 





Whilst in vitro studies have highlighted the importance of cell-to-cell contact in the 
materialization of Treg suppression (Shevach et al. 2001, Kullberg et al. 2005), in 
vivo models have also stressed the involvement of anti-inflammatory cytokines, TGB- 
β, (Powrie et al. 1996, Fahlen et al. 2005) IL-10 (Hara et al. 2001) and IL-35 
(Collison et al. 2007) in Treg mediated suppression. 
In this regard, it has been shown that Tregs can produce high amounts of membrane-
bound and soluble forms of TGF-β with in vitro studies confirming the role of this 
cytokine in suppression of T cell proliferation (Nakamura et al. 2001, Levings et al. 
2002) and its production by Tregs necessary to prevent colitis (Read et al. 2000). In 
the same setting, Asseman et al. provided evidence for the role of IL-10 in Treg 
mediated suppression, whereby blocking of IL-10 or using IL-10 deficient Tregs 
abolished the protective effects of Tregs in colitis (Asseman et al. 1999).  
IL-35 is a recently discovered cytokine implicated in Treg mediated suppression and 
has been shown to directly inhibit T-effector proliferation (Collison et al. 2007). Its 






Human Tregs expressing the serine protease granzyme A have been reported to kill 
CD4+ T cells and other target cells in a perforin-dependent cytotoxic manner 
(Grossman et al. 2004). In another report contact dependent suppression of T-effector 
proliferation by activated murine Tregs in vitro was described to be partially 
granzyme B dependent; however in contrast to the results of Grossman et al., perforin 
was not involved (Gondek et al. 2005).  
In line with this, studies have further shown that Tregs express the death ligands: 
tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) (Ren et al. 
2007) and Fas-ligand (Strauss et al. 2009), which upon binding of the death receptors 
expressed by their target, induce the formation of the death domain, in turn endorsing 
the initiation of the caspase cascade (Dubin and Kolls 2008).  
Wang et al. also showed that Tregs expressed galectin-9, which binds to TIM-3, 
expressed by activated effector T cells, leading to intracellular calcium influx and the 
activation of the calpain caspase-1 pathway (Wang et al. 2009). The expression of 
galectin-1 on Tregs has also been demonstrated (Garin et al. 2007), but the 
mechanism by which galectin-1+ Tregs induce T cell apoptosis is not fully understood 




Extracellular adenosine triphosphate (ATP) serves as an indicator of tissue damage in 
the immune system. It can be released from cells following an inflammatory response 
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and binds to purinergic receptors (P2) which are highly expressed on immune and 
epithelial cells, potentiating a pro-inflammatory response with the secretion of 
inflammatory cytokines including IL-1β (Imai et al. 2000). Kobie et al. showed that 
Tregs express high levels of the cell surface enzyme ecto-5-nucleotide CD73 (Kobie 
et al. 2006) and that this molecule converts extracellular adenosine-5-monophosphate 
(AMP) to adenosine, which is known to have immunosuppressive and anti-
proliferative effects (Robson et al. 2006). Of note, however, the ectonucleotide 
triphosphate diphosphohydrolase-1, CD39, also found on Tregs, provides the 
substrate for CD73, hydrolyzing extracellular adenosine-5-triphosphate (ATP) into 
the nucleotide AMP (Deaglio et al. 2007).  
CD4+CD25hiCD39+, predominantly expressing FOXP3, were also found to suppress 
the release of the pro-inflammatory cytokine IL-17 alongside IFN-γ and IL-2 from 
Th17 cells while CD4+CD25hiCD39− T cells had an increased propensity to produce 
IL-17 (Fletcher et al. 2009). Furthermore, the reconstitution of positively selected 
CD39-null mouse cells with apyrase (involved in the catabolism of ATP) reversed 
their increased susceptibility to develop auto-immune diseases and a Th-1 skewed 
immune response (Dwyer et al. 2007). 
 
Moreover, studies have proposed that Tregs express high levels of intracellular cyclic 
adenosine monophosphate (cAMP) with implications in Treg suppressive ability 
(Bopp et al. 2007). Bopp et al, proposed that cAMP is an important component of 
Treg mediated suppression since suppression of IL-2 transcription and proliferation 
could be partly abrogated by a cAMP antagonist or a gap junction inhibitor (Bopp et 
al. 2007).  In this regard, Fassbender et al. showed that the induction of cAMP in 
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murine DCs upon Treg co-culture contributed to the suppression of DCs (Fassbender 
et al. 2010). Bodor et al. further proposed that cAMP can be directly transferred to 
effector T cells via gap junctions, leading to the upregulation of the inducible cAMP 
early repressor (ICER) (Bodor et al. 2000), which limits nuclear factor activated T 






Exosomes are lipid-bound nanovesicles formed by the inward budding of endosomal 
membranes (Cho et al. 2009). It has been found that many cells can secrete exosomes, 
such as tumor cells, DCs, lymphoid cells, mesothelial cells, epithelial cells, and cells 
from different tissues or organs (Admyre et al. 2007). Although their precise function 
in vivo is still unknown, exosomes have been proposed to play a role in antigen 
presentation, immunoregulation, and signal transduction (Chaput et al. 2004). Some 
studies have supported the view that exosomes contribute to the induction and 
maintenance of transplantation tolerance. In this regard, in a rat model of allogeneic 
heart transplantation, intravenous inoculation of DC cell-derived exososmes resulted 
in a delay of acute allograft rejection and the induction of a significant propagation of 
allograft survival (Peche et al. 2003). Interestingly, it has also been proposed that 
Tregs release exosomes and this is one mechanism by which they modulate immune 
responses. In agreement, a recent study, using a rat model of kidney transplantation, 
Yu et al. showed that autologous Treg derived exososmes postponed allograft 
rejection and prolonged the survival of transplanted kidney (Yu et al. 2013). From 
their in vitro analysis of the function of the exososmes, they further concluded that the 
exososmes possessed the capacity to suppress T cell proliferation. Of note, recently 
my laboratory have further supported that Treg derived exosomes display immune-
modulating properties in vitro, which is attributed to the production of adenosine by 







There is now growing evidence that Tregs are plastic with a potential to convert into 
proinflammatory cells (Zhou et al. 2009). In agreement, the presence of a population 
of FOXP3+ T cells capable of secreting the pro-inflammatory cytokine, IL-17, has 
been observed in human peripheral blood, thus questioning the stability of these cells. 
In this regard, the importance of assessing Treg stability has been proposed, especially 
in view of the clinical application of these cells. 
As eluded to in section 1.2.3 the stability and function of Tregs has been shown to 
depend on high expression of FOXP3, which is controlled at an epigenetic and protein 
level. It has been demonstrated that between the FOXP3 promoter and the first exon 
lies a stretch of highly conserved, non coding sequence, that is differentially 
methylated in tTregs, pTregs and Teffectors (Baron et al. 2007, Polansky et al. 2010). 
This sequence, referred to as the Treg-specific demethylated region (TSDR) is crucial 
at maintaining high FOXP3 expression in Tregs (Zheng et al. 2010). Mechanistically, 
it has been proposed that the demethylated TSDR region allows binding of 
transcription factor complex that contains CREB/ATF, STA5, ETS-1 and FOXP3 
itself to maintain transcriptional activity (Baron et al. 2007, Polansky et al. 2010). 
In addition to this epigenetic mechanism in controlling FOXP3 expression, FOXP3 
function and expression is also controlled at the post translational level by acetylation 
of its many lysine residues (Wang et al. 2009, Xiao et al. 2010) Of note, it has been 
demonstrated that the acetylation of lysine residues in FOXP3 prevents their 
polyubiquination and subsequent degradation by proteasomes (van Loosdregt et al. 
2011), promoting subsequent DNA transcription. Such studies merely highlight that 
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the stability of FOXP3 expression in Tregs is controlled at both an epigenetic and 
translational level to ensure the stability of the lineage.  
 
Despite this strict government of FOXP3 expression, emerging data suggests that 
Tregs can downregulate FOXP3 in the presence of inflammatory cytokines. In 
agreement, Yang et al., have shown that exposure of Tregs to IL-6 and IL-1 in vitro 
results in the expression of IL-17 (Yang et al. 2008). In vivo, loss of FOXP3 has also 
been documented in the setting of autoimmune disease (Zhou et al. 2009) fetal acute 
infections (Oldenhove et al. 2009), TLR stimulation (Sharma et al. 2010) and 
homeostatic proliferation (Komatsu et al. 2009). Moreover, the study by Hoffman et 
al. further concluded that upon repeated antiCD3/CD28 stimulation in culture, Tregs 
parted with their constitutive expression of FOXP3, in turn forfeiting their stability 
(Hoffmann et al. 2009).  
As such, to determine the origin of the unstable Tregs, the extrinsic factors resulting 
in their instability and the fate of these ‘exTregs’ is of particular importance. 
 
In this regard, Hori et al. proposed a ‘heterogeneity model’, suggesting that FOXP3 
expression does not necessarily determine Treg lineage commitment. They showed 
that uncommitted FOXP3 positive cells can lose FOXP3 expression, acquiring 
transient activation-induced FOXP3 expression; converting to effector like ex-FOXP3 
cells under inflammatory conditions, or committing to a Treg fate (upon 
demethylation of TSDR) (Hori 2011). Consistent with this, epigenetic analysis shows 
that tTregs and pTregs have partially methylated TSDR, despite high levels of FOXP3 
expression (Floess et al. 2007, Wieczorek et al. 2009) with a proposal that lack of 
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further commitment cues and/ or exposure to inflammatory cytokines and/or IL-2 
deprivation at this developmental stage may cause these cells to abort Treg 
development program, lose suppressive function and take on an effector phenotype.  
 
Of note, however, it is important to make the distinction between Treg instability and 
functional specialisation. Studies have also shown that whilst under inflammatory 
conditions Tregs can acquire the ability to produce effector cytokines while still 
maintaining high FOXP3 expression and suppressive activity. In support of this, it has 
been demonstrated that IL-17 is produced by a subset of highly suppressive human 
Tregs that express CCR6, the chemokine receptor used by Th17 cells for their 
recruitment to sites of inflammation (Voo et al. 2009).  
Moreover, our group and others, have shown the expression of CD161, the killer cell 
lectin-like receptor subfamily B, to be expressed on a subpopulation of human Tregs, 
that produce IL-17 upon in vitro activation in the presence of IL-1β, but not IL-6. In 
addition, evidence has also supported the suppressive capacity of these cells (Afzali et 
al. 2013, Pesenacker et al. 2013). 
 
These studies highlight that Treg expression of effector cytokines alone cannot be 
simply viewed as a marker of plasticity or lack of stability, but may be a hallmark of 
their functional specialization. In this support, Campbell and Koch et al. have shown 
that Treg expression of transcription factors and cytokine specific for Th1, Th2 and 
Th17 enables them to control inflammation mediated by Th1, Th2 and Th17 cells, by 






The term ‘adoptive immunity’ was first coined in 1954 by Billingham et al. 
(Billingham et al. 1954), who were able to show that passive transfer of primed 
immune cells can generate immunity in the recipient. Subsequently, numerous animal 
studies have demonstrated the effectiveness of this adoptive transfer of immunity in 
both cancer and infectious disease (Dudley and Rosenberg 2003). 
 Moreover, in humans the isolation and manufacture of IL-2 permitted, for the first 
time, the ex vivo culture and expansion of T cells (Lotze et al. 1980) 
 In addition, many transplant researchers found that CD4+ T cells were responsible for 
donor specific tolerance and it was the study by Hall et al. which concluded that 
transplant tolerance was mediated by CD4+CD25+ cells. In this study they showed 
that in cyclosporin-treated rats with long-term cardiac allograft survival, the adoptive 
transfer of CD4+CD25+ T cells resulted in tolerance (Hall et al. 1990). 
The application of Tregs in the context of organ transplantation was further supported 
by the seminal work by Sakaguchi et al. demonstrating that Tregs from naive mice 
prevented rejection of allogeneic skin grafts in T cell deficient nude mice given 
CD25- T cells (Sakaguchi et al. 1995). 
 
Subsequently, a series of pre-clinical rodent models of skin and cardiac 
transplantation demonstrated that Tregs present in the recipient at the time of 
transplantation are critical in the induction and maintenance of tolerance (reviewed in 
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(Wood and Sakaguchi 2003). Additionally, mouse models of bone marrow 
transplantation (BMT) further supported the importance of adoptive Treg therapy, 
whereby the transfer of freshly isolated Tregs together with the bone-marrow allograft 
resulted in amelioration of GVHD and facilitated engraftment (Joffre et al. 2004, 
Hanash and Levy 2005).  
Moreover, adoptive transfer of Tregs has been shown to prevent rejection in other 




An issue for consideration in Treg cell therapy is the relevance of Treg allospecificity 
with the significant advantage that the immunomodulatory function of these cells 
would be concentrated at the site of alloantigen and immune activation (Dijke et al. 
2008). An additional advantage of alloantigen-specific cellular therapy is that 
undesirable pan-suppression, resulting in increased risk of infections and cancers, is 
less likely to occur.  
 
Although, the indirect pathway has been implicated in acute graft rejection 
(Auchincloss et al. 1993) this pathway may be the major driver of chronic allograft 
rejection (Wise et al. 1998). Indeed much experimental and clinical evidence suggests 
that for tolerance to occur this is the pathway that needs to be regulated. It is clear 
from clinical studies that regulatory T cells contribute little, if at all, to direct pathway 
hyporesponsiveness (Game et al. 2003) and in contrast depleting Tregs reveals 
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significant indirect pathway anti-donor alloresponses in stable renal transplant 
patients (Salama et al. 2003). In addition, studies in mice and humans show that the 
indirect pathway of allorecognition is used by Tregs for immunoregulation (Wise et 
al. 1998, Hara et al. 2001, Yamada et al. 2001, Quezada et al. 2003, Spadafora-
Ferreira et al. 2007).  
 
Thus, in the induction of long-term graft survival it may be required to generate 
allospecific Tregs ex vivo capable of limiting chronic allograft dysfunction. Using in 
vitro expanded Tregs with indirect pathway anti-donor allospecificity for a single 
MHC class I, my group demonstrated the induction of donor-specific transplantation 
tolerance in a murine skin transplant model following thymectomy and partial T cell 
depletion (Golshayan et al. 2007). Furthermore, using TCR gene transduction, Treg 
lines were generated in vitro, with both direct and indirect pathway allospecificities 
and it was shown that these Tregs are very effective at inducing indefinite survival of 
MHC-mismatched heart allografts (Tsang et al. 2009). While lines with direct or 
indirect specificity could prolong graft survival, indirect allospecificity was necessary 
to prevent chronic vasculopathy (Tsang et al. 2009). Moreover, Joffre et al. have 
provided additional evidence that Tregs with direct allospecificity alone cannot 
protect against chronic rejections and that both specificities are necessary (Joffre et al. 
2008). Based on such findings, therefore, Tregs with defined indirect allospecificity 
are likely to be important in long-term allograft survival.  
 
It is noteworthy to mention that although the expansion of direct-pathway allospecific 
human Tregs has been achieved (Peters et al. 2008), expansion of indirect pathway 
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Tregs has proven more difficult. This is due to the tendency of autoreactive Tregs to 
expand, a consequence of the technique used to generate these Tregs (i.e. autologous 
APCs pulsed with alloantigen) (Jiang et al. 2003, Jiang et al. 2006). Several methods 
have been reported that may help to circumvent this. They include either tetramer 
sorting (Jiang et al. 2006) or pre-use of artificial APCs (Masteller et al. 2005). An 
additional approach from my laboratory involves the retroviral transduction of genes 
encoding a known TCR with indirect specificity for alloantigen (Tsang et al. 2006). 
 
Use of currently available humanised mouse models of allotransplantation (Shultz et 
al. 2007, Issa et al. 2010, Nadig et al. 2010, Wu et al. 2013, Xiao et al. 2014) has 
further reinforced the importance of antigen specific Tregs in this settings. These 
models are based on the reconstitution of immunodeficient mice with human immune 
cells. More recently my lab has shown the efficacy of human Tregs with direct 
allospecificity in preventing alloimmune dermal tissue injury in a humanised mouse 
model of skin transplantation (Sagoo et al. 2011). In these studies, the majority using 
Tregs with direct allospecificity, it was concluded that donor antigen specific Tregs 
are more effective as compared to polyclonal Tregs.  
 
In addition to the evidence supporting the importance of antigen-specific Tregs in 
preventing solid organ rejection, after BMT donor-specific Tregs have been shown to 
preserve graft-versus tumor activity, whilst inhibiting graft versus host disease 
(GvHD) (Edinger et al. 2003). However, further studies in the context GvHD have 
reported that the transfer of Tregs enriched for alloantigen-specificity showed only 
moderately improved efficacy when compared to polyclonal Treg cell populations 
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(Trenado et al. 2003). This may reflect the fact that GvHD is a systemic disease and 
the concentration of Tregs at a localised site is not required. Based on these studies 
and the lack of antigen-specific requirement for the transferred Treg cells within this 
particular transplantation setting, phase I clinical trials, using polyclonal Tregs 
following haematopoietic stem cell transplantation have been initiated (reviewed in 
section 1.4.1). 
 
Such adoptive transfer experiments in rodents, therefore, support the notion that 
tolerance requires ‘tipping the balance’ between reactivity and regulation. Despite 
such data generated in preclinical animal models successfully showing that Tregs can 
induce and maintain transplantation tolerance, we currently face many challenges in 
the laboratory that have hindered the widespread application of Treg cell therapy in 
the transplant setting. In addition, a number of different strategies have been proposed 
for the isolation and expansion of Tregs for cellular therapy. However, there is no 
consensus on the optimal process and many such processes have their limitations 





1.3 CLINICAL APPLICATION OF AUTOLOGOUS EX VIVO EXPANDED 
REGULATORY T CELLS 
1.3.1 CHALLENGES WITH LARGE-SCALE MANUFACTURE 
 
1.3.1.1. REGULATORY T CELL ISOLATION  
 
The absence of a defining Treg-specific cell surface marker has led to significant 
research centered on the identification of a population of Tregs most suitable for 
clinical translation. 
 
Two different combinations of markers have been proposed to be promising for the 
isolation of a pure Treg population. The first seeks to isolate CD4+CD25Hi Tregs with 
the addition of an antibody to select for CD45RA+ cells and so eliminate antigen 
experienced or memory T cells (Hoffmann et al. 2006) (discussed previously in 
section 1.2.3). Moreover, this so-called naïve Treg population yields Tregs with a 
greater suppressive capacity than total CD25Hi cells (Hoffmann et al. 2009) and have 
the greatest expansion potential (Hoffmann et al. 2006). Furthermore, after three 
weeks of in vitro expansion the CD45RA+ expanded Tregs remained demethylated at 
the TSDR region, confirming their stability during expansion (Hoffmann et al. 2009, 
Putnam et al. 2009).  
Despite such studies one drawback is that the number of naïve Tregs decline in the 
peripheral blood with age (Seddiki et al. 2006) and hence isolation based on this 
approach may prove to be impractical. The second approach still uses the fundamental 
CD4+CD25hi phenotype to isolate Tregs but also includes CD127 expression (section 
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1.2.3). The rationale for using CD127 as a marker for Treg isolation is on the basis 
that in human Tregs there is a reciprocal expression of CD127 and FOXP3 and thus 
CD127 provides a sortable surrogate marker for FOXP3+ Tregs (Liu et al. 2006). 
Moreover, two elegant studies (Booth et al. 2010, Issa et al. 2010, Nadig et al. 2010) 
support the in vivo superiority of the CD4+CD25+CD127Lo Tregs in regulating 
alloreactivity compared to Tregs isolated based on expression of CD4 and CD25 
alone. Such studies have important implications for the design of future clinical 
studies.  
 
The search for further surface markers to aid the isolation of purer or more potent 
Treg populations, led to studies investigating markers such as CD121a/CD121b, TGF-
β/LAP (Tran et al. 2009). However, all these proteins are only expressed on activated 
Tregs and would only be of use to re-isolate Tregs after expansion. This may not be 
feasible in view of the costs of re-isolating billions of Tregs on a per-patient basis. 
Other studies complicate the story even further. Ito et al. showed that FOXP3+ Tregs 
could be grouped into two subsets based on the expression of the inducible T cell co-
stimulator (ICOS) (Ito et al. 2008). They showed that whilst ICOS-FOXP3+ Tregs 
mediate their suppressive function via TGF-β, ICOS+FOXP3+ Tregs additionally 
secrete IL-10.  
Such studies, therefore, paint a complicated picture that when choosing the Treg 
marker for cell isolation we should also bear in mind other factors other than just 
purity, i.e. isolating potent cells with mechanism of action to suppress the immune 
response of interest and cells with the desirable expansion profiles.  
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Despite this, however, what limits choice when devising a clinically applicable 
protocol is that isolation techniques need to be good manufacturing practice (GMP) 
compliant and GMP purification reagents for all the various markers outlined above 
are not yet available.  
 
The clinical Treg selection protocols to date used in the UK have used a combination 
of depletion and positive selection steps with the isolation tools mainly involving the 
automated CliniMACS plus system (Miltenyi Biotec, Bisley, United Kingdom). This 
enables GMP-compliant cell selection by magnetic bead-activated cell sorting 
(Wichlan et al. 2006). More specifically for the production of CD4+CD25Hi Tregs, the 
GMP grade antibodies available enable the depletion of CD19/CD8 expressing 
immune cells followed by a positive selection of CD25 expressing T cells (Di Ianni et 
al. 2009). The major drawback with such techniques is that this process does not 
guarantee the selection of CD25Hi cells compared to the FACS sorter, which allows 
the important distinction to be made between the CD4+CD25Hi and CD25Int cells. In 
addition, the process does not allow the selection of Tregs based on multiple 
parameters and the ~ 60% purity of the isolated cells (Peters et al. 2008) is not 
comparable with the >95% purity achieved using the FACS sorter (Putnam et al. 
2009). Despite the drawbacks of the current process available in the UK efforts have 
been made to establish new GMP-grade antibodies to improve the production of Tregs 
for clinical trials i.e. the recently developed GMP grade CD45RA microbeads 
(Miltenyi Biotech) for the positive selection of CD45RA+ immune cells (from the 




1.3.1.2. REGULATORY T CELL EXPANSION 
 
1.3.1.2.1. POLYCLONAL REGULATORY T CELL EXPANSION; (
One of the obstacles in the implementation of clinical protocols for adoptive Treg cell 
therapy is their relative low frequency in the circulation, with Tregs forming only 
around 1-3% of total peripheral blood CD4+ T cells. This means that for cellular 
therapy, it will almost certainly be necessary to expand these cells ex vivo, to 
clinically relevant numbers, prior to their administration. It has already been 
demonstrated that Tregs can be readily expanded using antiCD3/CD28 coated beads, 
supplemented with IL-2 (Levings et al. 2001, Hoffman et al 2004 and Putnam et al 
2009). However, under theses circumstances, effector cells have the potential to 
proliferate vigorously, posing a major problem for MACS-purified CD4+CD25+ 
Tregs, as they are often contaminated with CD25+FOXP3- cells. As such, studies 
highlight the importance of supplementing cultures with rapamycin.  
This drug inhibits the mammalian target of rapamycin (mTOR), which is downstream 
of phosphatidylinositol 3-kinase (PI3K, a signalling molecule activated by CD28 or 
IL-2 receptor engagement in T cells (Thomson et al. 2009). IL-2 receptor engagement 
activates both PI3K-mTOR and Janus kinase-STAT pathways. Biochemical analysis 
of IL-2 signalling in Tregs has shown that the PI3K-mTOR pathway is attenuated, 
whereas the Janus Kinase-STAT pathway remains intact, suggesting that Tregs 
preferentially signal through the latter thus conferring their resistance to mTOR 
inhibition (Zeiser et al. 2008). In agreement, genetic ablation and cellular experiments 
that demonstrate mTOR deficiency or the addition of rapamycin, favors the outgrowth 
and function of Tregs (Battaglia et al. 2005, Delgoffe et al. 2009). Consistent with 
these in vitro observations, it has been shown that rapamycin can potentiate the ability 
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of Tregs to inhibit transplant arteriosclerosis in a humanised mouse system (Hester et 
al. 2012). Furthermore, in transplant patients the use of rapamycin-based 
immunosuppression is also associated with an increase in Tregs as compared with 
patients on calcineurin inhibitors (CNI) (Segundo et al. 2006, Noris et al. 2007). Thus, 
by favouring Treg survival and expansion and preventing the outgrowth of 
contaminating effector T cells (Basu et al. 2008, Zeiser et al. 2008), rapamycin 
ensures the growth of a pure Treg population.  
 
Despite these advances, large scale manufacture of Tregs remains challenging in view 
of studies reporting that even highly pure Tregs lose FOXP3 expression with repeated 
stimulation, even in the presence of rapamycin (Hoffmann et al. 2009, Hippen et al. 
2011). It is believed that the loss of FOXP3 is likely owing to destabilization of 
FOXP3 expression in Tregs (Hoffmann et al. 2009). However, the cellular and 
molecular basis of Treg destabilization during in vitro stimulation is presently unclear.   
(
1.3.1.2.2. ALLOANTIGEN SPECIFIC REGULATORY T CELL EXPANSION (
Studies have shown that the frequency of direct alloreactive Tregs to be between 1% 
and 20% (Lin et al. 2008). Proof of principle experiments have shown that Tregs with 
direct allospecificity can be expanded using donor APCs such as DCs and 
unfractionated peripheral blood mononuclear cells (Peters et al. 2008, Chen et al. 
2009, Sagoo et al. 2011, Tran et al. 2012).  
Moreover, recent reports have highlighted the effectiveness of CD40 activated B cells 
in the induction and expansion of antigen specific Tregs in vitro (Adachi and Ishii 
2002, Tu et al. 2008, Zheng et al. 2010). As such, one of the aims of this thesis was to 
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develop a GMP compatible protocol, using CD40L activated allogeneic B cells to 
selectively stimulate the expansion of alloantigen-reactive Tregs (See Chapter 5). 
Although, most successes in expanding human alloantigen specific Tregs have been in 
generating Tregs with direct allospecificity, efforts have also been directed to the 
expansion of human Tregs with indirect allospecificity (Veerapathran et al. 2011).  
 
1.4.   CLINICAL APPLICATION OF REGULATORY T CELLS; PAST 
EXPERIENCE AND THE FUTURE 
 
1.4.1. REGULATORY T CELL IMMUNOTHERAPY IN BONE MARROW 
TRANSPLANTATION AND TYPE I DIABETES 
"
In spite of the potential concerns and controversies outlined with regards to Treg 
isolation and expansion protocols, as of April 2013 four clinical trials of Treg therapy 
in humans have been reported, three in the setting of GvHD and one in Type I 
diabetes, with data summarised below.  
Beneficial effects of Treg infusions on allograft survival were first described in bone 
marrow transplantation models in which donor Tregs reduced the incidence of GvHD. 
The first human trial using Treg cell therapy conducted by Trzonkowski et al. 
involved two patients. The first patient had chronic GvHD two years post bone 
marrow transplantation. After receiving 0.1x106/kg FACS purified ex vivo expanded 
Tregs from the donor, the symptoms subsided and the( patient was successfully 
withdrawn from immunosuppression without evidence of recurrence. The second 
patient had acute GvHD at one-month post transplantation, which was treated with 
several infusions of expanded donor Tregs. Despite the initial and transitory 
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improvement, the disease progressed and ultimately resulted in the patient’s death 
(Trzonkowski et al. 2009). This was the first report to show that adoptive transfer of 
Tregs is well tolerated and thus was a major breakthrough.  
Results of a larger phase I/II study were reported in which a total of 23 patients 
receiving umbilical cord blood (UCB) stem cell transplants were enrolled into a Treg 
escalation trial (Brunstein et al. 2011). 
 CD4+CD25Hi Tregs were isolated from a third party UCB graft and expanded 
polyclonally with antiCD3/CD28 coated beads and recombinant IL-2 over a period of 
18 days. Patients received expanded Tregs at doses ranging from 1 x 105/kg to 
30x105/kg. Of note, the targeted Treg dose was only achieved in 74% of cases. 
Compared with the 108 historical controls, there was a reduced incidence of grades II-
IV acute GvHD (from 61% to 43%; p=0.05), although the overall incidence of GvHD 
was not significantly different.  
In a third trial (Phase I/II) conducted by Di Ianni et al. 28 patients who had received 
haematopoietic stem cell transplantation for haematological malignancies were 
enrolled (Di Ianni et al. 2011). Patients received donor Tregs without ex vivo 
expansion and donor effector T cells (Teff) without any other adjuvant 
immunosuppression. Different dose regimens were used, ranging from 5x105/kg Teffs 
with 2x 106/kg Tregs to 2x106/kg Teffs with 4x106/kg Tregs. As two patients 
receiving the latter regimen developed acute GvHD, compared with none of the other 
patients, the authors concluded that a dose of 1x106/kg Teffs with 2x106/kg Tregs to 
be safe. Moreover, patients receiving Tregs demonstrated accelerated immune 
reconstitution, reduced CMV reactivation, and a lower incidence of tumour relapse 
and GvHD when compared to historical controls. However, it is also important to note 
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the disappointing patient survival with only 13 out of the 26 patients surviving, 
however, this may have been due to prior exposure to fungal infections and the harsh 
conditioning regimens. 
(
In the trial of Type I diabetes, Marek-Trzonkowska et al. presented the data on the 
one year follow up of 12 children with the condition, treated with autologous 
expanded ex vivo Tregs. Patients received either a single or double Treg infusion up to 
a total dose of 30x106/kg. The data supported the safety of the infused Tregs, with 
8/12 treated patients requiring lower requirements of insulin, with two children 
completely insulin independent at one year (Marek-Trzonkowska et al. 2014). 
(
1.4.2. REGULATORY T CELL IMMUNOTHERAPY IN SOLID ORGAN 
TRANSPLANTATION 
"
The results of the trials to date have highlighted the favourable safety profile of 
freshly isolated and polyclonally expanded Tregs with varied reports of efficacy. As a 
result, the prospects of Treg adoptive cell therapy are now widely recognised with the 
information gleaned from these preliminary trials now guiding the clinical progression 
of these cells into the realms of organ transplantation.  
This has seen the start of two trials at Guy’s Hospital;  
1. To prevent renal transplant rejection as part of the ONE Study (NCT02129881), a 
multicentre Phase I/II study funded by the European Union FP7 programme. This trial 
will investigate the( safety of and potential efficacy of infusing ex vivo expanded 
Tregs, amongst other regulatory cells. 
Chapter(1:(Introduction(
 79 
2. To prevent liver transplant rejection, ThRIL (NCT02166177), described in detail in 
section 1.4.2.1. 
((
1.4.2.1. THRIL; REGULATORY T CELL IMMUNOTHERAPY IN LIVER 
TRANSPLANTATION  
"
Liver transplantation remains the treatment of choice for patients with end stage liver 
disease. Despite improvements in short term outcome, the obligatory protracted use of 
powerful non-specific immunosuppressants has led to an accelerated rise in morbidity 
and mortality as a result of chronic rejection and associated toxicity. As such, the 
current standing on immunosuppression in transplantation is far from ideal. As a 
result there has been enormous interest in the minimization/complete withdrawal of 
immunosuppressive drugs in liver transplant recipients.  
As eluded to in earlier section 1.1.1 there have been reports in the literature that a 
variable proportion of liver transplant recipients develop a state of ‘operational’ 
tolerance thus forgoing the requirements of therapeutic immunosuppression. This 
phenomenon, however, only occurs late after transplantation. It is, therefore, 
necessary to find novel strategies to accelerate the spontaneous development of 
tolerance early after transplantation and in turn negate the use of lifelong 
immunosuppression.  
The liver itself, is an inherently tolerogenic organ, requiring a less aggressive 
immunosuppressive regimen post transplantation as compared to other organ 
allografts. Furthermore, acute cellular rejection in liver transplantation, albeit 
common, is readily treated and resolves without long-term sequelae (Lerut and 
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Sanchez-Fueyo 2006). In view of these features the liver proves to be an ideal 
candidate in which trials of Treg immunotherapy can be initiated. 
(
In this regard, the first combined Phase I/IIa clinical trial of Treg immunotherapy 
worldwide in the setting of liver transplantation, ThRIL (NCT02166177) has been 
initiated at King’s College London. Here, the safety, tolerability and efficacy of 
polyclonally expanded Tregs in combination with depletion of alloreactive T cells and 
short-term immunosuppression will be assessed. 
One of the key prerequisites for the success of a trial such as ThRIL is data on the 
characteristics of Tregs isolated from the patients who will be receiving the therapy 
post transplantation. In addition, for the feasibility of such a trial it is imperative to 
demonstrate that these cells can be expanded to reach numbers suitable for their 
clinical application, with maintenance of their phenotype and function post expansion. 
 
In this regard, in this thesis data is presented on the isolation, characterisation and 
expansion of Tregs from patients with alcohol related cirrhosis (ARC) since this 
diagnosis accounts for 80% of all liver cirrhosis cases in the UK and the majority of 
patients on the liver transplant waiting list. As such section 1.5 reviews the literature 
on the pathogenesis of this condition, an understanding of which is of importance in 




1. 5. END STAGE LIVER DISEASE; ALCOHOL RELATED CIRRHOSIS (
1.5.1. CLASSIFICATION OF PROGRESSION (
Chronic liver diseases derive from a wide array of pathological origins including: 
hepatitis B/C (HBV/HCV), alcoholic liver disease (ALD) and non-alcoholic fatty 
liver disease (NAFLD). Of these ALD is the major cause of chronic liver disease in 
the western world (Walsh and Alexander 2000). The disease spectrum of ALD can be 
classified according to an evolution of histological stages progressing initially from 
steatosis, to hepatitis and culminating in cirrhosis, however, the sequence of these 
events varies considerably amongst different individuals. Whilst almost all heavy 
drinkers develop steatosis, only around 10-35% show various degrees of alcoholic 
hepatitis and 8-20% progress to cirrhosis (Yip and Burt 2006) . Thus, understanding 
the pathogenesis of ALD and predisposition to cirrhosis not only has an important 
clinical, but also a social implication, since 80% of all cases of liver cirrhosis, 
necessitating transplantation, seen in the UK are secondary to ALD.  
(
1.5.2. AETIOLOGY AND PATHOGENESIS 
"
Although the association of excessive alcohol consumption and ALD is already 
clearly established the precise pathogenesis of this condition is still not fully 
understood. An individual’s susceptibility to develop ALD is thought to be a multi-
step process dependent on several factors including: genetic predisposition, 
environmental influences and immune mediated chronic alcohol toxicity (Seth et al. 
2011). While research into the genetic predisposition and external environmental 
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influences have been inconclusive (Stickel and Osterreicher 2006), immunological(
based investigation in ALD has yielded significant data supplementing the notion that 
immune-mediated injury plays a predominant role in the pathogenesis of this 
condition. 
(
1.5.2.1.  ROLE OF IMMUNITY IN THE PROGRESSION OF LIVER DAMAGE (
Whilst the role of the innate immune system in this setting has been broadly 
acknowledged, the influence of the adaptive immune system has received less 
attention (Hines and Wheeler 2004). However, early studies have shown that the 
neutrophil-rich liver infiltrates, characteristic of alcoholic hepatitis, contain both 
CD4+ and CD8+ T lymphocytes (Chedid et al. 1993). Furthermore, studies from 
alcohol-treated mice and chronic drinkers have concluded that liver infiltrating T cells 
express an activation/memory phenotype which following stimulation produce pro-
inflammatory Th-1 cytokines such as IFNγ and TNF-α (Song et al. 2001, Song et al. 
2002). Further evidence supporting the role of adaptive immunity in ALD, stems from 
studies depicting the presence of circulating antibodies against alcohol altered 
autologous hepatocytes in ALD patients (Paronetto 1993) with further studies 
indicating that the antibody profile in ALD patients bears several similarities to that of 
autoimmune hepatitis (Perperas et al. 1981, Ma et al. 1997). 
 
Recent studies have also detailed the role of Th17 effector lymphocytes in ALD and 
their implication in various autoimmune diseases. There have been reports of the 
presence of these cells in both the liver and circulation of patients with ALD, with the 
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associated IL-17 production promoting liver neutrophil infiltration during alcoholic 
hepatitis (Lemmers et al. 2009).  
Following the results of such studies, it is pertinent to also focus research on the 
adaptive immune system in ALD with the work presented in this thesis, directed at 
understanding the role of CD4+CD25+FOXP3+ regulatory T cells (Tregs) in this 
setting.  
1.5.2.2. OXIDATIVE STRESS AND IMPORTANCE OF HEME OXYGENASE-1 
"
Of importance is that alcohol related liver damage is defined by chronic 
inflammation, hepatocellular injury and cell death. This is in part due to ethanol 
metabolism and oxidative stress. Studies with hepatocytes isolated from control rats 
and from alcohol fed rats, indicated that the enzymatic reaction of alcohol 
metabolism, involving aldehyde dehydrogenase, results in the increased production of 
reactive oxygen species (ROS), hepatocyte injury and apoptosis. Moreover, all of 
these reactions could be blocked by administration of antioxidants (Adachi and Ishii 
2002, Bailey and Cunningham 2002). 
 
Based on such data and in view of the importance of oxidative stress in the 
development of liver cirrhosis (Poli 2000, Natarajan et al. 2006) it is of significance to 
determine whether alterations in the pathway important in maintaining antioxidant 
and oxidant homeostasis is altered in ARC and the relevance of this in the 




Heme oxygenase (HO) is the rate limiting enzyme involved in the metabolism of 
heme into biliverdin, carbon monoxide (CO) and free iron (Fe2+) (Choi and Alam 
1996) (Figure 1.6). Three isoforms of HO have been described; HO-1 is peripherally 
induced whereas HO-2 and HO-3 are constitutive isozymes. In general, the expression 
of HO-1 is relatively low with its upregulation evident during times of cellular stress, 
constituting a critical cytoprotective mechanism with anti-apoptotic, anti-proliferative 
properties with an important role in regulating T cell responses. In this regard, HO-1 
knock-out mice exhibit a state of chronic inflammation characterised by 
splenomegaly, lymphadenopathy and lymphocytosis, confirming the 
immunoregulatory roles of HO-1 (Poss and Tonegawa 1997, Poss and Tonegawa 
1997). In parallel, studies administrating an HO-1 inducer to mice report the 
suppression of T cell mediated cytotoxicity and Th1 mediated cytokine production 





FIGURE 1.5. SCHEMATIC DIAGRAM REPRESENTING THE ENZYMATIC 
ACTIVITY OF HO-1 AND ITS ANTI-INFLAMMATORY PRODUCTS.  
Oxidative stress results in the generation of free heme. HO-1 metabolises the heme into 
equimolar products of Fe2+, CO and biliverdin. The biliverdin is subsequently converted to 
bilirubin by biliverdin reductase and the free Fe2+, bound and sequestered as ferritin. Both CO 
and bilirubin have major anti-apoptotic/ antioxidant properties playing a critical role in the 
balance of inflammatory reactions. Abbreviations: BR- bilirubin; CO- carbon monoxide; 
Fe2+- ferrous iron; IL- interleukin; TNF-α- tumor necrosis factor-α. Adapted from (Paine et 
al. 2010) (
The role of HO-1 in modulating various human immune-dominated chronic 
inflammatory diseases has also been widely reported (Maines 1997, Song et al. 2002, 
Almolki et al. 2004, Ryter and Choi 2005, Motterlini et al. 2012). It is now broadly 
accepted that HO-1 can be induced in a variety of different cell types, although the 
expression of this enzyme in T cells is not fully understood, with reports that HO-1 is 
differentially expressed by CD4+CD25- effector T cells (Teff) and Tregs (Hori et al. 
2003, Pae et al. 2003). Moreover, data from murine models provide contradictory 
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evidence for the role of HO-1 in Treg suppressor function warranting further research. 
(Zelenay et al. 2007, Schumacher et al. 2012, Xiao et al. 2014). As such in the present 
study I sought to characterise the Tregs from patients with ARC and to determine 
whether the HO-1 pathway can account for the Treg functional properties in this 





The current standing on immunosuppression in transplantation is far from ideal. As a 
result there has been enormous interest in the minimization/complete withdrawal of 
immunosuppressive drugs in liver transplant recipients. Bearing in mind the integral 
role of Tregs in promoting immune homeostasis this thesis hypothesizes that Tregs 
are ideal candidates for tolerance induction in the setting of liver transplantation.  
 
This hypothesis is investigated by pursuing the following aims: 
1) To conduct an in-depth phenotypic and functional characterisation of Tregs 
isolated from prospective liver transplant recipients. . 
2) To utilize a GMP compatible isolation and expansion protocol for the polyclonal 
expansion of clinical grade patient-derived Tregs for cell therapy application. 
Evidence already exists in support of graft specific Tregs as compared to polyclonal 
Tregs in the setting of transplantation. As such further objectives of this thesis 
included: 
3)  
a) To devise a protocol for the clinical-grade manufacture of human alloantigen 
specific Tregs. 
b) To compare the in vivo function of antigen specific and polyclonally expanded 
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Chemicals and Solutions 
Reagents Supplier  
3,3’,5,5’ – tetramethylbenzidine  
(TMB substrate solution) 
Zymed Paisley, UK 
Bovine Serum Albumin (BSA) Sigma Aldrich St Luis, MO, 
USA 
CellTrace™ CFSE  Invitrogen Paisley, UK 
CD8 Microbeads (Research grade) Miltenyi Biotec Woking, UK 
CD25 Microbeads (Research grade) Miltenyi Biotec Woking, UK 
Dimethyl sulfoxide (DMSO) Sigma Aldrich St Luis, MO, 
USA 
Dynabeads® anti-CD3/CD28 T cell expander Invitrogen Paisley, UK 
Ethylenediaminetetraacetic acid (EDTA) Invitrogen Paisley, UK 
Fixation/permeabilisation solution eBioscience San Diego, 
CA, USA 
Foetal Calf Serum (FCS) Gibco Paisley, UK 
Human AB serum (HS) Invitrogen Paisley, UK 
Ionomycin Sigma Aldrich St Luis, MO, 
USA 
Lymphoprep™ Nycomed Pharma Zürich, 
Switzerland 
Monensin eBioscience San Diego, 
CA, USA 
Phorbol myristate acetate (PMA) Sigma Aldrich St Luis, MO, 
USA 
1X Sterile Phosphate Buffered Saline (PBS) Life Technologies Paisley, UK 
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Rapamycin Pfizer New York 
City, USA 
Radio-Immunoprecipitation Assay (RIPA) Cell 
Lysis Buffer 
Sigma Aldrich St Luis, MO, 
USA 
Recombinant human IL1-β R&D systems Abingdon, UK 
Recombinant human IL-2 R&D systems Abingdon, UK 
Recombinant human IL-6 R&D systems Abingdon, UK 
Recombinant human IL-21 Cell Sciences Canton, MA, 
USA 
Recombinant human IL-23 R&D systems Abingdon, UK 
Recombinant human TGF-β R&D systems Abingdon, UK 






RPMI-1640 Gibco Paisley, UK 
Sulphuric acid (H2SO4) R&D systems Abingdon, UK 
Trypan-blue Sigma Aldrich St Luis, MO, 
USA 
Tween® 20 Sigma Aldrich St Luis, MO, 
USA 




Specificity Conjugate Clone µL/test Supplier  
CCR6 PeCy7 R6H1 3 eBioscience San Diego, 
CA, USA 
CD4 PercP SK3 5 BD Bioscience Oxford, UK 




CD25 APC 2A3 5 BD Bioscience Oxford, UK 
CD25 PE CD25-4E3 3 eBioscience San Diego, 
CA, USA 
CD27 eFluor450®   O323 2 eBioscience San Diego, 
CA, USA 
CD39 PeCy7 eBioA1 2 eBioscience San Diego, 
CA, USA 
CD45 RA FITC JS-830 2 eBioscience San Diego, 
CA, USA 
CD62L  PeCy7 
FITC 
DREG-56 2 eBioscience San Diego, 
CA, USA 
CD127  eFluor450®   eBioRDR5 2 eBioscience San Diego, 
CA, USA 












PE 14D3 3 eBioscience San Diego, 
USA 
CXCR3 Pacific Blue   G025H7 3 Biolegend San Diego, 
USA 
FOXP3  FITC 236A/E7 5 eBioscience San Diego, 
USA 
FOXP3 PE 236A/E7 5 eBioscience San Diego, 
USA 
GARP eFluor450®   G14D9 5 eBioscience San Diego, 
USA 
GITR PE eBioAITR 5 eBioscience San Diego, 
USA 




Helios PE 22F6 5 Biolegend San Diego, 
USA 








PE ISA-3 3 eBioscience San Diego, 
USA 




2 eBioscience San Diego, 
USA 
PD-1 PE eBioJ105 3 eBioscience San Diego, 
USA 
TIM-3 PE 344823 2 R&D systems Abingdon, UK 
Galectin-9 
(Ecalectin) 
Unlabeled ECA42 1.2 MBL  Nagoya, Japan 
IgG2b PE M32404 5 (1:10) Life Technologies Paisley, UK 
 
Kits 
Minimacs CD4+CD25+ T regulatory cell Isolation Kit Miltenyi Biotec Woking, UK 
ImmunoSet™ HO-1 (human), ELISA development kit Enzo Life Sciences Exeter, UK 
IL-17 Duo-Set ELISA kit R&D systems Abingdon, UK 
 
Consumables and Instruments 
96-well round-bottom plate BD Falcon Oxford, UK 
24- well round-bottom plate BD Falcon Oxford, UK 
96-well ELISA microplate BD Falcon Oxford, UK 
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Bio-Tek EL800 Automatic Plate Reader Wolf Laboratories Pocklington, 
UK 
FACSAria™ II cell sorter BD Biosciences Oxford, UK 
FACSCaliber™ II flow cytometer BD Biosciences Oxford, UK 
LSRFortessa™ Flow Cytometer BD Biosciences Oxford, UK 






LD columns Miltenyi Biotec Woking, UK 
LS columns Miltenyi Biotec Woking, UK 
MS columns 
 
Miltenyi Biotec Woking, UK 
 
Software 
FlowJo software Tree Star Inc OR, USA 
GraphPad Prism® 5 software GraphPad La Jolla, CA, 
USA 
 
TABLE 2.1. LIST OF REAGENTS AND SUPPLIERS.  
The volume of antibody indicated in the table was chosen according to preliminary 
experiments using PBMCS, in which the volume recommended by the manufacturer was 




King’s College Hospital Research Ethics Committee approved the study and written 




TABLE 2.2. SUBJECT DEMOGRAPHICS 
Data presented as the mean ± standard deviation (SD). MELD is a scoring system for 
assessing the severity of chronic liver disease and is now widely used for prioritizing receipt 
of a liver transplant. MELD uses the patient’s laboratory values for bilirubin, serum creatinine 
and the international normalized ratio for prothrombin time (INR) to predict three month 
survival. In patients with cirrhosis, an increasing MELD score is associated with increasing 
severity of hepatic dysfunction and increased three-month mortality risk. It is calculated 
according to the following formula: MELD= 3.8 x [Ln(Bilirubin)] + 11.2 x [Ln(INR)] + 9.6 
x [Ln(creatinine)] + 6.4. Abbreviations: M:Male; F:Female; N/A: not applicable; MELD: 




A total of 25 patients with liver cirrhosis on the transplant waiting list at King’s 
College Hospital were included in this study. Of these patients 20 were diagnosed 
with alcohol related cirrhosis (ARC, having been abstinent for at least 6 months) and 
5 patients with Non-Alcoholic Steatohepatitis (NASH, served as disease controls). 
Inclusion criteria was set to include patients: able to give written informed consent, 
diagnosed with end-stage liver disease and listed for primary liver transplant; with a 
MELD score of ≤ 25 at the time of transplantation assessment.  
 Alcohol related 
Cirrhosis Patients 
Non-Alcoholic 
Steatohepatitis Healthy Controls 
Number 20 5 20 
Sex (M:F) 18:2 3:2 18:2 
Average Age (Years) 55.5±8.87 61.4 ± 5.87 55.5±8.87 
Average MELD score 13.3 ± 0.795  





Patients with HIV or RNA-positive Hepatitis C Virus infection, autoimmune liver 
disease, previous organ transplants, Epstein-Barr Virus and/or Cytomegalovirus sero-
negativity, chronic use of systemic immunosuppressants, hepatocellular carcinoma 




TABLE 2.3. PATIENT LABORATORY DATA  
Data are presented as the median (range). Abbreviations: ALP- Alkaline phosphatase; AST- 
Aspartate transaminase; γGT- gamma glutamyl transferase; INR- International Normalised 







Number of Patients 20 5 
Hb  
(nv: 115-180g/l) 
120 (83.0-144) 109 (99.0-133) 
Platelets  
(nv: 150-400x109/l) 93.5 (39.0-415) 88.0 (63.0-241) 
INR  
(nv: 0.9-1.1) 1.53 (1.04-3.31) 1.32 (1.05-1.45) 
Bilirubin  
(nv:!<20µmol/l) 40.5 (7.00-137) 57.0 (8.00-134) 
ALP  
(nv: 40-165U/l) 120 (46.0-242) 101 (78.0-220) 
AST  
(nv: <50U/l) 42.0 (19.0-94.0) 63.0 (43.0-77.0) 
γGT  
(nv: <60U/l) 51.5 (17.0-365) 270 (147-439) 
Albumin  
(nv: 35-50g/l) 
33.5 (23.0-42.0) 32.5 (29.0-47.0) 
Creatinine  





20 age and sex matched Healthy subjects, who were clinically well for at least 2 
months, served as controls (Healthy controls, HC). 
 
2.3.(PERIPHERAL(BLOOD(MONONUCLEAR(CELL((PBMC)(ISOLATION((
150 ml of whole blood, obtained from peripheral vein venipuncture, was diluted in 
sterile PBS at a ratio of 1:2 and carefully layered onto 20 ml of Lymphoprep™. The 
blood was then centrifuged at 2000 rpm for 20 minutes at 20oC. The mononuclear cell 
layer was next collected following aspiration of the cell layer at the interface and 
washed with sterile PBS twice at 1200 rpm and 1800 rpm respectively for 10 minutes 
at 4oC. Isolated PBMCs were subsequently further purified through various different 
methods as follows: 
 
2.4. REGULATORY T-CELL PURIFICATION 
 
2.4.1. GMP PURIFICATION PROTOCOL (
CD4+CD25+ Tregs were immunomagnetically isolated from freshly isolated PBMCs 
by CD8 depletion followed by CD25 positive selection, using GMP compatible 






2.4.1.1. CD4+CD25+ ISOLATION (
2.4.1.1.1. CD8+ DEPLETION (
PBMCs were first resuspended in MACS buffer (PBS containing 0.5% FCS and 2 
mM EDTA), at 10 ml/109 total cells, and incubated with CD8 microbeads, 750 µL/109 
total cells, for 30 minutes in the dark at room temperature, on a roller. Post 
incubation, the bead bound cells were washed in MACS buffer by adding 1-2ml of 
MACS buffer for 107 cells and centrifuged at 1800 rpm for 10 minutes. Subsequently 
the supernatant was aspirated completely. The cells were next resuspended in 500 µL 
of MACS buffer per 108 cells and subsequently passed through MACS LS columns 
contained within a magnet to remove the CD8 microbead labeled cells. Of note, the 
LS columns were prepared prior the application of the cell suspension, by rinsing with 
3ml of MACS buffer. 
Post application of the cell suspension onto the column, the unlabeled cells were 
collected below and the column washed three times with 3 ml of MACS buffer. The 
effluent, containing the unlabeled cells, was collected and washed with MACS buffer.  
2.4.1.1.2. CD25+ ENRICHMENT (
The cells were subsequently resuspended in MACS buffer (20 ml/ 109 total cells) and 
incubated with CD25 microbeads (750 µL/109 total cells) for 15 mins at 4oC in the 
dark. Cells were next washed with MACS buffer, by adding 1-2ml of buffer per 107 
cells and centrifuged at 1800 rpm for 5 minutes. The cells were next resuspended in 
500 µL of MACS buffer per 108 cells and passed through MACS LS columns 
contained within a magnet, to isolate CD25 microbead labeled cells. Of note, prior to 
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the application of the cell suspension, the column was placed in the magnetic field of 
a suitable MACS separator and rinsed with 3ml of MACS buffer.  
Post application of the cell suspension onto the column, the column was washed with 
3ml of MACS buffer three times. Subsequently the column was removed from the 
magnet and placed on a suitable collection tube. The labeled cells within the column 
were plunged through with 2ml of MACS buffer. The CD25+ labeled cells were 
subsequently washed in staining buffer and purity assessed by flow cytometry 
(Figure 2.1 depicts the purity of the isolated cells post CD8+ cell depletion and 
CD25+ cell enrichment).  
 
2.4.2. MINIMACS CD4+CD25+ AND CD4+CD25- ISOLATION 
 
Tregs were immunomagnetically separated from freshly isolated PBMCs using the 
Minimacs CD4+CD25+ T regulatory cell Isolation Kit. Isolated PBMCs were 
resuspended in MACS buffer at 90 µL per 107 total cells. To this suspension CD4+ T 
Cell Biotin-Antibody Cocktail at 10 µL per 107 cells, was added and subsequently 
incubated for 10 minutes at 4oC. After incubation, anti-Biotin microbeads, 20 µL per 
107 cells, were added to the suspension and incubated at 4oC for 15 minutes. MACS 
LD column was placed in the magnetic field of a suitable MACS separator and the 
column rinsed with 2ml of buffer. Subsequently the cell suspension was passed 
through the column. Next, the column was washed twice with 1 ml of MACS buffer 
and the unlabeled cells collected below, forming the pre-enriched CD4+ cell fraction. 
The unlabeled cells were washed in MACS buffer and centrifuged at 1800 rpm for 10 
minutes. The supernatant was aspirated and the cell pellet resuspended in 90µL of 
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MACS buffer per 107 cells. To this suspension 10 µL per 107 cells of CD25 
microbeads was added and incubated for 15 minutes at 4oC in the dark. The cells were 
next washed by adding 1-2ml of buffer per 107 cells, and centrifuged at 1800 rpm for 
10 minutes. Subsequently the cells were resuspended in 500 µL of MACS buffer per 
108 cells.  
Next, an MS column was placed in the magnetic field of a suitable MACS separator 
and the column rinsed by adding 500ml of MACS buffer. The cell suspension was 
then added onto the column and the effluent collected. The column was washed a 
further 3 times with 500 µL of MACS buffer.  
The effluent, forming the CD4+CD25- fraction was collected, washed with MACS 
buffer and centrifuged at 1800 rpm for 5 minutes. Subsequently, cells were counted 
and phenotyped (Figure 2.1A depicts a representative plot of purity of CD4+CD25-]. 
The proliferative capacity of the isolated cells was assessed by labelling with CFSE 
(section 2.7). Subsequently, the cells were cryopreserved for use as autologous and 
allogeneic Teffector cells in Treg suppression assays. Of note, cells were 
cryopreserved in freezing media consisting of 90% fetal calf serum (FCS) and 10% 
dimethyl sulphoxide (DMSO). Cryopreserved cells were frozen at -80⁰C (-1°C/min) 
and stored in liquid nitrogen. 
To obtain the CD4+CD25+ cells, the MS column was removed from the magnet and 
flushed with 1 mL of MACS into a separate collection tube, the isolated cells were 
washed in staining buffer and purity of the isolated CD4+CD25+ fraction assessed by 




2.4.3. CELL SORTING OF CD4+CD25+CD127LO CELLS 
 
RosetteSep® Human CD4+ T Cell Enrichment Cocktail was added at 50 µL/mL of 
whole blood and incubated for 20 minutes at room temperature. Subsequently, the 
blood was diluted with sterile PBS at a ratio of 1:2 and 25 ml of the sample layered on 
15 ml of lymphoprep and centrifuged for 20 minutes at 2000 rpm. The enriched cells 
were then removed from the plasma interface and washed with PBS twice. Cells were 
next stained with anti-CD4, anti-CD25 and anti-CD127 fluorochrome conjugated 
monoclonal antibodies. Tregs were subsequently sorted on the BD FACSAria™ II 
cytometer based on a population of CD4+CD25+CD127Lo cells (Figure 2.1C depicts a 





FIGURE 2.1. REPRESENTATIVE PURITIES OF REGULATORY T CELLS 
ISOLATED USING THE DESCRIBED TECHNIQUES.  
A Shows the purity of CD4+CD25+ Tregs following isolation in concordance with a GMP 
compatible isolation technique involving CD8+ cell depletion and subsequent CD25+ cell 
enrichment. B Panel on the left shows the purity of CD4+CD25+ Tregs isolated using the 
Minimacs CD4+CD25+ T regulatory cell Isolation Kit, with the panel on the right showing the 
purity of the CD4+CD25- fraction. C Displays the relative purity of CD4+CD25+CD127Lo cells 
following fluorescence activated cell-sorting (FACS). 
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2.5. FLOW CYTOMETRY (
Flow cytometry is a laser-dependent biotechnology, which is utilized for the 
assessment and sorting of cells. Fluorescently labeled cells are suspended in a stream 
of fluid, passing through a laser in single file. The laser excites the cells and results in 
the emission of light at variable wavelengths allowing for the detection and selection 
of different cell types. Cells are fluorescently labeled with various fluorochrome 
conjugated antibodies which may be used to detect different surface or intracellular 
markers. 
 
2.5.1. SURFACE STAINING (
Cells were stained with the fluorochrome conjugated monoclonal antibodies to CCR6, 
CD4, CD8, CD25, CD27, CD39, CD45 RA, CD62L, CD127, CD161, CD178 (FAS-
L), CD274 (PDL-1), TIM-3, CXCR3, GARP, GITR, HLA-DR, ICOS, ICOS-L 
(B7RP1), and PD-1. Cells were washed in staining buffer (PBS containing 1% FCS) 
and subsequently stained with monoclonal antibodies in a 96 well ‘u’ bottom plate 
(volumes stated in section 2.1). Cells were incubated for 20 minutes at 4oC in the 
dark. Following incubation the cells were washed and stained for intracellular 
markers. 
 
2.5.2. INTRACELLULAR STAINING (
After extracellular staining, cells were washed and resuspended in 100 µL of 
Fixation/Permeabilisation solution, incubated at 4°C in the dark for 1 hour. After 
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washing, cells were then subject to intracellular staining to CTLA-4, FOXP3, 
Granzyme-B, Galectin-9, Helios with monoclonal antibodies diluted in 90 µl staining 
buffer and 10 µl of 1 x permeabilisation buffer (Volumes stated in section 2.1).  
When staining for Galectin-9, cells were washed before the addition of a PE-
conjugated anti-mouse IgG2b secondary antibody for 20 minutes. For intracellular 
cytokine staining of IL-17 and IFN-γ, cells were initially activated with a leukocyte 
activation cocktail consisting of phorbol myristate acetate (PMA) 5 ng/ml and 
Ionomycin 1 µg/ml, which together enhance global cytokine production, as well as 
Monensin 2 µM (to prevent cytokine transport from the endoplasmic reticulum to the 
golgi apparatus, hence favoring intracellular accumulation) and incubated for 4 - 5 
hours at 37oC. Following incubation, cells were resuspended in 100 µL of 
Fixation/Permeabilisation solution and incubated at 4oC in the dark for 1hour. Cells 
were then washed and stained with antibodies specific to IL-17 and IFN-γ (section 
2.1). Antibodies were added after dilution in 90µl staining buffer and 10 µL 1x 
permeabilisation buffer. After incubation for 30minutes at 4oC in the dark, the cells 
were washed, resuspended and flow cytometric analysis conducted.  
The stained cells were analysed on the BD LSRFortessa™ cytometer and the BD 
FACSCalibur™ cytometer with the acquire data analysed using FlowJo Software. 
 
2.6. REGULATORY T CELL CELL CULTURE 
 
Tregs were isolated as previously described (section 2.4.1.) using GMP compatible 
reagents. CD4+CD25+ Tregs were then plated at 1 x 106 cells/ml, on 24-well flat 
bottom plates in culture media, X-vivo 15, supplemented with 5% human AB serum 
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(HS), and expanded in both the presence and absence of 100 nM rapamycin. Cells 
were polyclonally activated with anti-CD3 and anti-CD28 coated beads (Dynabeads®) 
at a 2:1 bead:cell ratio and cultures supplemented with IL-2 (500 IU/mL) 4 days post-
activation and replenished every 2 days thereafter. Cells were restimulated every 10-
12 days by magnetically removing the activation beads and adding fresh beads, 
rapamycin and IL-2. The expansion period was limited to 36 days with concurrent 
assessment of Treg phenotype and function throughout culture.  
 
  
FIGURE 2.2. GMP COMPATIBLE TREG ISOLATION AND EXPANSION 
PROTOCOL 
Abbreviations: FACS- Fluorescence-Activated Cell Sorting; IL-Interleukin; PBMC- 







Before use, cryopreserved responder CD4+CD25- T cells (Teff) (isolated as described 
in section 2.4.2) were thawed quickly by gently swirling cryotubes in a 37oC water 
bath. The cells were next washed twice in sterile PBS at 1800 rpm for 5 minutes and 
subsequently labeled with 2.5 nM Carboxyfluorescein succinimidyl ester (CFSE). 
1x105 Teffs/well were plated on 96 ‘u’ bottom plates either alone or in co-culture with 
CD4+CD25+ Tregs at differing ratios (Treg:Teff - 1:1, 1:5 and 1:10) in X-Vivo 15 
medium supplemented with 5% HS and activated with anti-CD3 and CD28 coated 
beads (Dynabeads®), at a ratio of 1:42 (bead:cell). In each case the number of Teffs 
was kept constant and the number of Tregs titrated down with the total volume of 
each well set at 200 µL. Cells were incubated at 37°C, 5% CO2 for 5 days. After 
harvest, proliferation of CFSE-labelled responder cells was acquired by flow 
cytometry (FACS Calibur cytometer or on LSRFortessa™ cell analyzer) and analyzed 
with FlowJo software. The suppressive ability of Treg lines was assessed as the 
percentage of decrease in Teff proliferation in the presence of Tregs. The calculation 
was based on the proliferation of responder T cells alone (Teff a) compared with the 
Teff proliferation of cultures containing a co-culture of both Teff and Treg cells (Teff 
c) (as below). 
 






Freshly isolated, untreated and rapamycin treated CD4+CD25+ T cells (5 x 105) were 
activated with anti-CD3 and anti-CD28 coated beads (Dynabeads®) at 1:1 bead:cell 
ratio  and cultured for 5 days in the presence of pro-inflammatory cytokines:  
• Mix 1: IL-2 (10 IU/ml), IL1β (10ng/ml), IL-6 (4ng/ml) and TGF-β (5ng/ml). 
• Mix 2: IL-2 (10 IU/ml), IL-21 (25ng/ml), IL-23 (25ng/ml) and TGF-β 
(5ng/ml).  
Cells cultured in X vivo medium (5% HS) supplemented with IL-2 (10 IU/ml) were 
used as a control. At the end of the culture, cells were harvested (activation beads 
removed by magnetic adherence) and analysed for IL-17 expression by intracellular 
staining. IL-17 concentrations in supernatants following culture were analysed by an 
indirect sandwich ELISA. 
(2.8.1.(INTERLEUKINC17(ENZYME(LINKED(IMMUNOSORBENT(ASSAY((ELISA)(
 
ELISA for human IL-17 was carried out using the Duo-Set ELISA kit. BD Falcon 96-
well ELISA microplates were coated with 100 µL/well of anti-IL-17 antibody (4 
µg/mL in PBS) and left overnight at room temperature. The following day plates were 
washed three times with 0.05% Tween 20 in PBS and blocked with 1% filtered BSA 
in PBS (300 µL/well) for 1 hour at room temperature. Plates were subsequently 
washed three times and blotted to dry. 100 µL/well of samples and standards were 
plated in duplicates and incubated at room temperature for two hours. The samples for 
IL-17 ELISA were prepared from thawed supernatants, stored at -20oC, of Tregs 
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cultured in IL-17 skewing conditions. The standard curve was constructed from serial 
two-fold dilution of manufacturer’s provided standards in PBS containing 1% BSA 
from 1000 pg/mL to 15.63 pg/mL with one control consisting of diluent alone (0 
pg/ml). The plates were washed and blotted dry three times and 100 µL of detection 
antibody (biotinylated anti-IL-17, 75 ng/ml) diluted in 1% BSA and PBS was added 
to each well and left at room temperature for two hours. Plates were washed and 
blotted dry three times, 100 µL of streptavidin-horse radish peroxidase (1:20 dilution 
in 1% BSA in PBS) was added to each well and the plates were incubated at room 
temperature for 20 minutes. Plates were then washed and blotted dry three times. The 
final step of the process required the addition of 100 µL of substrate solution to each 
well and incubation at room temperature for 20 minutes in the dark. The reaction was 
terminated with 50 µL of 2N sulphuric acid added to each well. The samples were 
read on an ELISA plate reader: optical density set at 450nM. The relative 
concentration of IL-17 in each sample was calculated from the standard curve, 
consisting of optical densities of known concentrations and reported relative per 
1x106 cells. 
(2.9.(HEMECOXYGENASE((HOC1)(ENZYME(LINKED(IMMUNOSORBENT(ASSAY((ELISA)((
ELISA for human HO-1 was carried out using the ImmunoSet™ HO-1 (human), 
ELISA development kit. HO-1 Capture antibody (3.5 µg/ml) was diluted (1:250) in 
coating buffer (10 mM sodium phosphate, 15 mM NaCl, pH 7.4) and plated on to a 
BD Falcon 96-well ELISA Microplate (100 µl/well) then the plate sealed and 
incubated overnight at room temperature. The wells were then aspirated and blocked 
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with 200 µl/well of 10 mM sodium phosphate, 15 mM NaCl, 1.0% BSA, 1.0% 
sucrose, pH 7.4 and the plates sealed and incubated at room temperature for at least 1 
hour.  
The samples for HO-1 ELISA were prepared from snap frozen cell pellets of 
regulatory T cells stored at -80oC and were thawed on ice.  RIPA Cell Lysis Buffer 2 
containing a protease inhibitor cocktail (1:200 dilution) was added to the cell pellet to 
achieve a concentration of 4 x 106 cells/ml.  The cell pellet was resuspended by gentle 
pipetting and homogenized by passing through a 25G needle. The suspension was 
incubated on ice for 30 minutes and mixed intermittently.  Following this the 
suspension was centrifuged at 12000 rpm for 10 minutes in a 4°C refrigerated 
microfuge. The supernatants (cell lysate) were assayed immediately. 
The plates were aspirated so as to remove the blocking solution. Subsequently, 100 
µl/well of standard and 100 µl/well of sample were added in duplicates and the plates 
sealed and incubated at room temperature for 1 hour. Standard curves were generated 
using the following concentrations of recombinant HO-1: 12.5 ng/ml, 6.25 ng/ml, 
3.12 ng/ml, 1.56 ng/ml, 0.78 ng/ml, 0.39 ng/ml, 0.19 ng/ml, 0.097 ng/ml, 0.049 ng/ml, 
0.025 ng/ml and 0 ng/ml diluted in in 100 mM sodium phosphate, 150 mM NaCl, 
1.0% BSA, 0.1% Tween-20. The wells were then aspirated and washed with 400 
µl/well of wash buffer (10 mM sodium phosphate, 15 mM NaCl, 0.1% Tween-20) 
four times. Detection antibody was diluted (1:250) in 100 mM sodium phosphate, 150 
mM NaCl, 1.0% BSA, 0.1% Tween-20, and 100 µl/well added to each well (except to 
the well containing diluent alone). The plates were sealed and incubated for 1 hour at 
room temperature. The wells were then aspirated and washed with 400 µl/well of 
wash buffer four times. 100 µl/well Streptavidin-horseradish peroxidase at 1:600 
dilution in 100 mM sodium phosphate, 150 mM NaCl, 1.0%, BSA, 0.1% Tween-20, 
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were then added and the plates sealed and incubated for 30 minutes at room 
temperature. The wells were then aspirated and washed with 400 µl/well of wash 
buffer four times. 100 µl/well of substrate solution consisting of TMB and stabilized 
hydrogen peroxide were then added and the plates incubated for a maximum of 30 
minutes in the dark at room temperature. 100 µl/well of 1M Hydrochloric acid was 
then added to stop the reaction. The plates were read using an ELISA reader at 450 
nm within 30 minutes. HO-1 concentration in the samples was determined by 
interpolation from the standard curve. 
 
2.10.(STATISTICAL(ANALYSIS((
Statistical analysis was carried out on GraphPad Prism 5.0c (GraphPad software Inc., 
USA). Parametric and nonparametric data were expressed as mean ± standard error. 
For comparison of parametric data, which were normally distributed, paired and 
unpaired students t-tests were used, for linked and unlinked data respectively. 










AN IN-DEPTH PHENOTYPIC AND FUNCTIONAL 
CHARACTERISATION OF REGULATORY T CELLS FROM 





3.1. INTRODUCTION AND OBJECTIVES (
The quintessence of clinical trials of adoptive Treg cell therapy, such as the ThRIL 
study, rests on a sure foundation of pre-clinical studies demonstrating that Tregs from 
liver transplant recipients can be isolated and expanded, reaching numbers suitable for 
their clinical translation, whilst maintaining their phenotype and function throughout. 
Moreover, since ARC is the primary indication for liver transplantation in the UK, 
this patient cohort will form the majority of subjects recruited into the ThRIL study. 
As such it is fundamentally important to firstly carry out an in-depth characterisation 
of the Tregs from patients with ARC prior to their ex vivo expansion.  
 
The pertinence of such an endeavor is also supported by studies showing a 
quantitative deficiency in Treg numbers in several liver diseases, including 
autoimmune hepatitis (Longhi et al. 2005), viral hepatitis (Xu et al. 2006) and primary 
biliary cirrhosis (Lan et al. 2006). Moreover, a defect in Treg function is also well 
documented in a number of liver diseases (Lan et al. 2006, Longhi et al. 2006, Sebode 
et al. 2014). To date, there have not been any studies on Tregs isolated from patients 
with ARC and, bearing in mind the varied similarities in immune dysfunction seen in 
liver diseases, such defects in Treg numbers and function may also become apparent 
upon investigation in this patient cohort. Moreover, and as already eluded to, research 
on immunological changes have provided abundant data to support the notion that 
immune-mediated injury plays a major role in the development, perpetuation and 





This chapter hypothesizes that there is a defect in Treg number and function in 
patients with ARC.  
The basis of this hypothesis is not only founded on the studies outlined above, but 
also in view of the environment that the cells are exposed to in vivo and its potential 
downstream effect on Treg phenotype and function. In this regard, accumulating 
evidence suggests that liver cirrhosis is associated with chronic low-grade 
inflammation. Moreover, studies have shown a positive correlation between disease 
severity in cirrhosis and the presence of advanced oxidation protein products (AOPPs) 
(Zuwala-Jagiello et al. 2011), protein markers of oxidative stress with 
proinflammatory properties, which are known to further fuel this inflammatory 
microenvironment.  
Addressing the following aims will test the hypothesis stated for this chapter: 
 
1. Isolation of Tregs from patients with ARC with comparison of Treg numbers 
and phenotype to age and sex matched healthy controls. 
2. Assessment of Treg function. 
3. Assessment of the influence of a proinflammatory milieu on the Treg stability. 






3.2. PATIENTS WITH ALCOHOL RELATED CIRRHOSIS HAVE A LOWER 
FREQUENCY OF CD4+CD25+CD127LO REGULATORY T CELLS AS 
COMPARED TO HEALTHY CONTROLS 
 
There have already been reports of decreased numbers of circulating CD4+CD25hi 
Tregs in various autoimmune liver diseases (Longhi et al. 2005, Lan et al. 2006, 
Sebode et al. 2014). In view of reports of the similarities between liver disease 
secondary to alcohol and autoimmune liver disease (Perperas et al. 1981, Chedid et al. 
1994, Ma et al. 1997). I next sought to investigate the relative number of circulating 
Tregs in ARC patients.  
To compare the percentage of circulating Tregs between ARC patients and age and 
sex matched HCs, enriched CD4+ T cells were phenotyped by flow cytometry. The 
percentage of CD25Hi in the total CD4+ population did not differ between the two 
cohorts (4.13% ± 0.932 as compared to 4.31% ± 0.889 for ARC patients and HCs, 
respectively, p=0.889) (Figure 3.1). 
 
Of note, however, several subsets of Tregs have been described to date, with reports 
that CD4+CD25hi FOXP3+ Tregs typically lack the expression of the interleukin (IL)-
7 receptor α chain, CD127 (Liu et al. 2006). The differential expression of CD127 has 
been used to denote an optimally pure population of Tregs that is inversely correlated 
with FOXP3 levels and the suppressive function of human CD4+ Tregs. As such a 
further in-depth phenotypic analysis was carried out to compare levels of 
CD4+CD25+CD127Lo Tregs between ARC and HCs. The data revealed that patients 
with ARC have a decreased frequency of CD4+CD25+CD127LoTregs as compared to 
HCs (p=0.0001) (Figure 3.2), mirroring the results seen in autoimmune hepatitis. 
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This data may provide further support to the notion that immune-mediated injury 
plays a role in the development and perpetuation of this condition (Laso et al. 1997, 
Lin et al. 2008, Gao et al. 2011, Albano 2012).  
"
FIGURE"3.1."PERCENTAGE OF CIRCULATING CD4+CD25HI TREGS 
Representative dot plot and graph denoting the circulating percentage of CD4+CD25Hi Tregs 































FIGURE 3.2. FREQUENCY OF CD4+CD25+CD127LO TREGS.  
Representative dot plot and graph denoting the relative frequency of CD4+CD25+CD127Lo 
































3.3. A DEFECTIVE REGULATORY T CELL SUPPRESSOR FUNCTION IN 
PATIENTS WITH ALCOHOL RELATED CIRRHOSIS AS COMPARED TO 
HEALTHY CONTROLS (
Alongside a deficiency in circulating Treg numbers seen in autoimmune liver 
diseases, it has also been noted that the Tregs in vivo display defective suppressor 
profiles (Lan et al. 2006, Longhi et al. 2006, Sebode et al. 2014). However, to date 
there are no studies on the functional assessment of Tregs from patients with ARC. As 
such, the suppressive function of 20 ARC patients and 20 age and sex matched HCs 
was compared.  
A CFSE dilution assay was performed to assess the ability of freshly isolated Tregs 
from ARC patients and HCs to suppress the proliferation of allogeneic Teffs (Figure 
3.3A). Freshly isolated ARC patient Tregs were found to possess an impaired capacity 
of suppression of Teff proliferation as compared to HCs at different Treg:Teff ratios 
(ARC vs HC: 1:1 19.6% ± 3.33 vs 72.7% ± 2.54, p <0.0001; 1:5 13.3% ± 3.93 vs 
40.6% ± 3.45, p <0.0001; 1:10 10.3 ± 3.19 vs 30.67± 3.65, p= 0.0002  (Figure 3.3A). 
This is the first report documenting these findings that further directed the rest of the 
study. 
ARC is the end product of a multi-step process initiated by excessive alcohol 
consumption. In view of the well-documented immunomodulatory roles of alcohol, 
we next investigated whether the evident lack of Treg suppressive function was 
attributable to a history of chronic alcohol consumption effects or the general state of 
cirrhosis. In this regard, the suppressive function of Tregs isolated from ARC patients 
was compared to Tregs from Non- Alcoholic- Steatohepatitis (NASH) patients, where 
alcohol plays no role in the development of cirrhosis.  The data clearly demonstrated 
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that the suppressive function of Tregs from both cohorts of patients was comparably 
low, suggestive that the current state of cirrhosis, common to both cohorts of patients, 
was linked with the Treg dysfunction as opposed to historic alcohol consumption in 
ARC patients (Figure 3.3B). 
I next sought to uncover any possible correlation between this novel discovery and 
each patient’s clinical history. Interestingly and of irrefutable significance was the 
association between the severity of the liver disease, as determined by the Model for 
End-stage Liver Disease (MELD) score, and Treg suppressor function (Figure 3.4A). 
However, upon dissection of the MELD score into its various components (bilirubin, 
INR and creatinine) there was no correlation between Treg function and each 
constituent in isolation (Figure 3.4B), suggesting that a combination of all 
parameters, relating to the overall severity of liver disease, was directly associated 







FIGURE"3.3."ASSESSMENT OF TREG SUPPRESSOR FUNCTION 
A. Representative histogram and graph displaying the suppressor function of freshly isolated 
Tregs from 20 HCs and 20 ARC patients. CFSE dilution assay was conducted and 3 different 
Treg:Teff ratios: 1:1, 1:5 and 1:10 investigated B. Treg Suppressor function of 10 patients 
with cirrhosis, 5 ARC and 5 NASH, was compared at different ratios of Treg:Teff. *** 













































































FIGURE 3.4. CORRELATION OF TREG SUPPRESSOR FUNCTION WITH 
SEVERITY OF LIVER DISEASE  
A. Graph correlating Treg suppressor function and the MELD score of 20 ARC patients B. 
Graphs depicting each variant of the MELD score (Bilirubin, INR, Creatinine) against Treg 
suppressor function of 20 ARC patients. Abbreviations; MELD- model for end stage liver 
disease, INR- international normalized ratio.  




































































3.4.(REGULATORY(T(CELLS(FROM(PATIENTS WITH ALCOHOL RELATED 
CIRRHOSIS EXPRESS(LOWER(LEVELS(OF(CTLAC4,(CD62L/CD27(AND(HELIOS,(WITH(SIMILAR(LEVELS(OF(ACTIVATION/MATURATION(MARKERS(AS(COMPARED(TO(HEALTHY(CONTROLS(
 
Human Tregs are known to express a wide array of different markers dependent on 
their distinct immunological role in vivo. Therefore, Tregs from both ARC patients 
and HCs were next extensively characterized in order to unmask an explanation for 
this apparent lack of suppressive function.  
 
A constitutive high expression of the cytotoxic T lymphocyte antigen 4 (CTLA-4) 
represents a well-documented component of CD4+CD25+ Tregs that has also been 
shown to contribute to their suppressive function (Annunziato et al. 2002, Manzotti et 
al. 2002). Analysis of CTLA-4 expression in Tregs from ARC patients revealed a 
significant decrease in the percentage of CD4+CD25+CTLA4+ cells, as compared to 
HCs, 12.6% ± 2.63 vs 25.3% ± 1.71, respectively p=0.0008 (Figure 3.5A). 
 
On a similar note, the co-expression of CD62L and CD27 on Tregs has been reported 
to denote a Treg population with high suppressive capabilities both in vitro and in 
vivo (Koenen et al. 2005, Koenen et al. 2008, Issa et al. 2010, Nadig et al. 2010). The 
co-expression of these two markers on ARC Tregs was again significantly lower 




Helios, the intracellular Ikaros transcription factor has been thought to delineate a 
population of thymic derived naturally occurring Tregs (Thornton et al. 2010) with 
enhanced regulatory potential (Zabransky et al. 2012). Upon investigation of this 
marker, a lower percentage of Helios+ Tregs from ARC patients 43.7% ± 3.42 as 
compared to HCs 61.3% ± 4.18, p=0.0044 was determined, suggesting a paucity of 
naturally occurring Tregs in ARC patients. However, it is pertinent to note that the use 
of this marker to identify thymic derived naturally occurring Tregs is controversial 
and has come under great scrutiny (Getnet et al. 2010, Himmel et al. 2013, Edozie et 
al. 2014).  
 
To evaluate whether differences existed in Treg activation and maturation markers 
between HCs and ARC patients, the percentage of Tregs expressing the ectoenzyme, 
CD39, and HLA-DR was investigated in both cohorts. Similar expression of both 
markers was reported following phenotypic analysis of Tregs from ARC patients as 
compared to HCs, CD39, p=0.193 and HLADR, p=0.179 (Figure 3.5A).  
 
Additionally, the expression of CXCR3, the chemokine receptor associated with Treg 
homing and migration to the liver (Oo et al. 2010) was analysed showing that a 
similar percentage of Tregs from both cohorts express this marker ARC 80.6% ± 3.74 
vs HC 82.7% ± 1.91, p=0.632.  
 
Further in-depth characterisation of the Tregs from ARC patients was carried out 
(Figure 3.5B), investigating a panel of key markers known to be employed by Tregs 
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to exert their regulatory role, namely T cell immunoglobulin mucin 3 (TIM3) 
(Sakuishi et al. 2013), FASL (Gorbachev and Fairchild 2010), granzyme B 
(Loebbermann et al. 2012), PD1 and PDL1 (Jacobs et al. 2009), GITR (McHugh et al. 
2002), ICOS and ICOSL (Busse et al. 2012) and GARP (Stockis et al. 2009). 
However, FACS analysis revealed no differences in the expression of these markers 
by Tregs between the two cohorts that could potentially account for the lack of Treg 





















FIGURE" 3.5." EXPRESSION OF DIFFERENT PHENOTYPIC AND FUNCTIONAL 
TREG MARKERS.  
A.  Pooled data from 10 ARC patients and 10 age and sex matched HCs comparing the mean 
percentage expression of each marker on CD4+CD25+ Tregs. B. Pooled data from 10 ARC 
patients and 10 HCs comparing the mean percentage of various functional markers on 
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3.5.(PATIENTS WITH ALCOHOL RELATED CIRRHOSIS HAVE(A(SIMILAR(PERCENTAGE(AND(DISTRIBUTION(OF(MARKERS(IN(REGULATORY(T(CELL(SUBPOPULATIONS(AS(COMPARED(TO(HEALTHY(CONTROLS.((
 
Human Tregs have been defined as a heterogeneous population of cells that can be 
divided into three phenotypically and functionally distinct sub-populations based on 
the differential expression of the naïve cell marker CD45RA and the level of FOXP3 
expression (Miyara et al. 2009). Figure 3.6A depicts the gating strategy used to 
delineate the human Treg compartment into population I; naïve or resting Tregs 
(CD45RA+FOXP3Lo), population II; effector Tregs (CD45RA-FOXP3Hi), both of 
which are suppressive in vitro, and population III; the non-suppressive, cytokine 
secreting non-Tregs (CD45RA-FOXP3Lo). As such and to determine whether there 
were differences in the Treg subpopulations that could potentially explain the lack of 
Treg suppressor function in patients with ARC, the percentages of each of the three 
populations was compared between ARC patients and HCs. Population III was the 
largest subpopulation from ARC patients 42.7% ± 3.05, this was comparable to HCs 
53.1% ± 5.17, p=0.101.  In addition, similar proportions of Treg subpopulations I and 
II was reported between the two groups (Figure 3.6B).  
Moreover, the expression of various markers of activation/maturation was also 
assessed on each of the defined subpopulations. In both cohorts, a step-wise increase 
in the percentage of cells expressing CD39 and HLA-DR was detected between 
population I, III and II, correlating with the maturation status. Expression of these 
markers on Treg subpopulations did not, however, differ between ARC patients and 





FIGURE 3.6. PHENOTYPIC ANALYSIS BASED ON TREG SUB-POPULATIONS.  
A. Gating strategy used to divide Foxp3+tregs into the three sub-populations adopted from 
Miyara et al. 2009 (population I: CD4+CD45RA+Foxp3lo, population II: CD4+CD45RA-
Foxp3Hi, population III: CD4+CD45RA-Foxp3lo). B. Graph depicting mean percentage of each 
Treg subpopulation (I-III) from 10 HCs and 10 ARC patients. . *p=<0.05,** p=<0.01 and *** 
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FIGURE 3.6. PHENOTYPIC ANALYSIS BASED ON TREG SUB-POPULATIONS.  
C. Graph of pooled data from 10 ARC patients showing the mean percentage expression of 
Treg surface markers based on each of the three gated subpopulations. D. Graph of pooled 
data from 10 HCs showing the mean percentage expression of Treg surface markers on the 



























































































3.6. REGULATORY T CELLS FROM PATIENTS WITH ALCOHOL RELATED 
PRODUCE INTERLEUKIN-17 AND INTERFERON-Y IN THE PRESENCE OF 
PRO-INFLAMMATORY CYTOKINES AND EXPRESS HIGH LEVELS OF CD161 
 
The plasticity of Tregs has been well documented with studies suggesting that Tregs 
can convert to cells producing inflammatory cytokines particularly when exposed to a 
pro-inflammatory milieu (Hori 2010). To assess the stability of Tregs from ARC 
patients in comparison to HCs, freshly isolated Tregs from both cohorts were cultured 
for 5 days in the presence of pro-inflammatory cytokines (described in materials and 
methods) and the percentage of IL17+ and IFN-γ+ cells analysed by FACS. As 
compared to HCs, there was an increase in the percentage of FOXP3+IL17+ and 
FOXP3+ IFN-γ+ cells when ARC patient Tregs were cultured in the presence of pro-
inflammatory cytokines (FOXP3+IL17+; Mix 1 ARC 5.86% ± 0.888 vs HC 1.45% ± 
0.324, p= 0.0002; Mix 2 4.79% ± 1.01 vs 1.45% ± 0.324, p= 0.0056 and FOXP3+ 
IFN-γ +; Mix 1 ARC 6.84% ± 0.908 vs HC 3.86% ± 0.569, p= 0.0124; Mix 2 5.25% 
± 0.644 vs 4.40% ± 0.815 p= 0.424) (Figure 3.7A, 3.7B).  
 
More recently my group and another, have identified a subpopulation of Tregs within 
population III that is responsible for the production of IL-17 by Tregs (Afzali et al. 
2013, Pesenacker et al. 2013). This marker was initially shown to be expressed by 
Th17 cells (Cosmi et al. 2008, Maggi et al. 2010). The expression of CD161 on the 
Tregs from ARC patients and HCs was investigated. We show that as compared to 
HC Tregs, 5.48% ± 1.07, there is an increased percentage of CD161+ Tregs isolated 
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from ARC patients 18.0% ± 1.94, p<0.0001 (Figure 3.7C), which, upon further 
delineation, is found to be mostly expressed on population III (Figure 3.6C).  
 
FIGURE 3.7. ASSESMENT OF TREG STABILITY. 
A. Representative dot plots from 10 HCs and 10 ARC patients depicting the gating of 
FOXP3+IL-17+ and FOXP3+IFN-γ+ Tregs. B. Graph showing the frequency of IL-17+ and 
IFN-γ+ Tregs from 10 HCs and 10 ARC patients following 5 day cultures with pro-
inflammatory cytokines (Mix 1- IL-2, IL1β, IL-6 and TGF-β and Mix 2: IL-2, IL-21, IL-23 
and TGF-β). C. Graph comparing the mean percentage of freshly isolated CD4+CD25+ Tregs 
expressing CD161 from 10 HCs and 10 ARC patients. ** p=<0.01 and *** p=<0.001. Error 
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In line with these findings, and as eluded to earlier, accumulating evidence suggests 
that liver cirrhosis is associated with a chronic state of low-grade inflammation 
(Giron-Gonzalez et al. 2004). This supports the data presented, whereby the 
environment the Tregs are exposed to in vivo during cirrhosis, may account for their 
plasticity and propensity to convert to IL-17+ and IFNγ+ cells, perpetuating the 






It has been reported that the inflammation that characterises liver cirrhosis is often 
caused by a rise in free radicals within the liver (Kirkham 2007, Videla 2009). Under 
normal circumstances, the liver maintains a supply of internal anti-oxidants to 
neutralize the free radicals generated by various endo and exogenous compounds 
processed in the liver. However, when the liver is exposed to continuous oxidative 
insults i.e. long lasting alcohol abuse, the damage from free radicals increases, 
resulting in inflammation and the formation of fibrosis (Czeczot et al. 2006, Valko et 
al. 2007). Moreover, several lines of evidence provide a link between the oxidative 
stress and the inflammatory state during cirrhosis and suggest that advanced oxidation 
protein products, present in the plasma of cirrhotic patients act as inflammatory 
mediators. In addition, and more importantly, a positive correlation between severity 
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of liver disease and the presence of such products of oxidative stress has been 
reported, with a further correlation with the inflammatory markers (Zuwala-Jagiello et 
al. 2009, Zuwala-Jagiello et al. 2011). Based on our finding of a Treg dysfunction in 
patients with ARC and its association with liver disease severity, the role of the anti-
oxidant pathway in this system was next investigated. 
In view of the wealth of data on the anti-inflammatory (Otterbein et al. 2000), anti-
oxidative (Yachie et al. 1999) and antiapoptotic (Ke et al. 2002) role of HO-1 and 
studies to suggest that Tregs also express HO-1, I next sought to determine whether a 
defect in the expression of this enzyme by Tregs isolated from ARC patients could 
contribute to the Treg dysfunction seen in this condition.  
As such, quantitative determination of HO-1 was carried out from Treg cell lysates of 
ARC patients and HCs, using ELISA. The data clearly demonstrated that freshly 
isolated Tregs, obtained from ARC patients, have decreased levels of HO-1, p= 
0.0271 Figure 3.8A.  This finding was also confined to Tregs, whereby measurement 
of HO-1 levels in CD4+CD25- effectors T cells, from the same donor as the Tregs, 








In order to confirm the role of HO-1 in Treg suppressor function, a specific 
competitive inhibitor of HO-1 activity, zinc protoporphyrin (ZnPP), was used. Studies 
have shown that ZnPP irreversibly binds and inactivates HO-1 enzymatic activity 
(Kappas and Drummond 1986) (Figure 3.8C).  
Tregs from 5 healthy donors were isolated and cultured for 24 hours in the presence 
of the inhibitor with subsequent analysis of suppressive function.  
The data obtained demonstrated that HO-1 plays an important role in the suppressive 
function of Tregs. It was shown that the inhibition of HO-1 by ZnPP resulted in a 
decreased Treg suppressive function, as compared to untreated cultures, and that this 
effect was dose dependent (Treg suppression of Teff proliferation at Treg:Teff 1:1, 
untreated cultures; 43.3% ± 7.67; 25µM ZnPP treatment; 24.5% ± 7.33 and 50µM 









FIGURE 3.8. DIFFERENTIAL EXPRESSION OF HO-1 BY T CELL POPULATIONS. 
 A. Graph comparing the relative expression of HO-1 by CD4+CD25+ Tregs. B. Graph 
comparing the relative expression of HO-1 by CD4+CD25- Teffector cells. C. Graph of 5 HCs 
showing Treg suppressor function following 24 hours of culture in the presence (25µM and 
50µM) and absence of the HO-1 inhibitor, ZnPP. Suppressor function was assessed, using a 
CFSE dilution assay at 3 different Treg:Teff ratios.1:1, 1:5 and 1:10. *p=<0.05. Error bars 





























































There has been a global rise in mortality due to alcohol related liver disease in the 
western world, with ARC being a major indication for transplantation (Seth et al. 
2011). In view of the shortage of donor organs and the several challenges currently 
facing liver transplantation, there is undoubtedly a pressing need to find novel 
modalities of treatment for tolerance induction in the setting of transplantation, with 
Treg therapy being at the forefront of research.   
The first key steps in using autologous Tregs as treatment modality for tolerance 
induction rely solely on understanding the biology of Tregs from patients who will be 
receiving the therapy. In this regard, this chapter summarises the data on the in-depth 
phenotypic and functional characterisation of Tregs isolated from patients with ARC 
with direct comparison with age and sex matched HCs.  
A decrease in frequency of Tregs expressing CD127lo was evident from ARC patients 
when compared to HCs. Moreover, and of importance was the novel finding of a 
defect in Treg suppressor function in patients with ARC and its important correlation 
with disease severity, assessed by the MELD score (Figure 3.4A). In line with these 
findings Almeida et al. have reported decreased number of peripheral blood Tregs in 
patients with alcoholic hepatitis, whilst normal numbers of these cells were reported 
in chronic alcoholics who had no signs of liver disease (Almeida et al. 2013). Such 
data may suggest that in patients with liver disease and/or cirrhosis, the decrease in 
Treg numbers could result in the perpetuation of an on-going inflammatory state, 
aggravating the disease progression.  
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In agreement, the partial penetrance of ARC whereby some, but not all, alcoholics 
develop cirrhosis alludes that other cofactors besides direct toxicity of alcohol are at 
work in determining an individual’s predisposition to developing ARC. Accumulating 
evidence indicates significant alterations in the immune response occur during 
cirrhosis that may account for the development and progression of the condition.  
ARC patients have been reported to be in an immunodeficient state, attributed to 
various non-specific immune abnormalities including defective neutrophil and 
macrophage function (Rajkovic and Williams 1986, Gomez et al. 1994), leading to an 
increased susceptibility to infection. At the same time, several studies have 
demonstrated elevated levels of pro-inflammatory cytokines in patients with liver 
cirrhosis, which have been correlated with microbial parameters and clinical 
complications (Byl et al. 1993, Le Moine et al. 1994, Genesca et al. 1999, Albillos et 
al. 2004).  
The gut microbiota is a metabolically active population of organisms complementing 
digestion and absorption of nutrients in order to preserve their mutualistic existence in 
the body. However, it has been reported that the metabolism of ethanol to its toxic 
metabolite, acetaldehyde, results in the derangement of a previously impenetrable 
endothelial barrier. This disruption subsequently results in the translocation of gut-
derived endotoxins to the portal circulation (Hines and Wheeler 2004, Rao 2009). 
Moreover, it has been reported that inflammation caused by the metabolites of 
ethanol, reactive oxygen species (ROS), aldehyde modified proteins or 
lipopolysaccharide (LPS) increase the levels of cytokines/chemokines resulting in a 
deleterious positive feedback loop that propagates liver inflammation, infiltration of 
inflammatory cells (Day and James 1998, Ma et al. 2008) and fibrosis. In support of 
this, aldehyde modified proteins (Rolla et al. 2000, Vidali et al. 2008) and endotoxin 
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(LPS) have been detected in the serum and/or livers of patients with liver disease 
secondary to alcohol. Furthermore, these substances have been shown to increase the 
release of TNF-a, interleukin-1β, and prostaglandin by kupffer cells, sinusoidal 
endothelial cells and stellate cells. In addition, increased secretion of inflammatory 
cytokines by DCs (Laso et al. 2007, Almeida et al. 2013) together with the activation 
of cytotoxic T and NK cells have also been reported (Laso et al. 1997, Jerrells 2002, 
Cook et al. 2004, Zheng and Rudensky 2007) further emphasizing the pro-
inflammatory state of play. 
Of note, evidence from rat studies also indicates that ethanol-induced ‘gut leakiness’ 
and endotoxaemia precedes the liver inflammation, with subsequent cytokine 
dysregulation (Keshavarzian et al. 2009). In view of studies in support of the role of 
Tregs in immunoregulation (Zheng and Rudensky 2007, Miyara and Sakaguchi 2011) 
it is reasonable to hypothesise that defects in Treg numbers may also be involved in 
the perpetuation of such an immune response seen in ARC. 
 
In this chapter, I have further shown a correlation with disease severity and the 
impaired immunoregulatory function of Tregs (Figure 3.4A). Therefore, it is feasible 
to also postulate that the defect in the Treg suppressor function can allow for the 
unopposed activation of various inflammatory cells, particularly: Kupffer cells, DCs 
and monocytes, in the setting of ARC (Houot et al. 2006). In agreement, studies have 
already shown the role of Tregs in inhibiting the activation, proliferation and effector 
functions of several populations of immune cells, including CD8+ cytotoxic T cells, 
NK cells and NK T cells (McNally et al. 2011).  
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As such the reduced numbers and function of the Tregs seen in ARC can contribute to 
the increased activation of such lymphoid cell populations, further fuelling the 
inflammatory environment.  
 
Interestingly, however, a positive feedback loop may be at play, whereby the 
increased proinflammatory environment can in turn alter the Treg function by 
resulting in the plasticity of these cells in patients with ARC. In support of the 
plasticity of Tregs in vivo, studies have shown that in patients with alcohol related 
liver disease there is a predominance of IL-6 cytokine, a cytokine known to inhibit the 
differentiation of Tregs and induce a Th17 T cell response (La Cava 2008). 
In line with this, it has been shown that ALD is associated with an activation of the 
IL-17 pathway (Lemmers et al. 2009). In agreement with these reports, on further 
characterisation of isolated Tregs from ARC patients it was further shown that the 
culture of these cells in the presence of Th17 skewing conditions led to an increase in 
the percentage of IL-17+FOXP3+ cells  (Figure 3.7A). Furthermore, on phenotypic 
characterisation of Tregs from ARC patients, a higher percentage of CD161+ Treg as 
compared to HCs was noted. This marker on Tregs has previously been reported to 
denote Tregs with the propensity to produce IL-17, as well as being described as a 
marker for precursors of IL-17 producing T cells (Cosmi et al. 2008, Maggi et al. 
2010, Afzali et al. 2013, Pesenacker et al. 2013). These results are suggestive of the 
susceptibility of these cells to differentiate into Th17 cells under the inflammatory 
conditions described in patients with ARC.  
In view of the importance of Tregs in this setting and the potential use of these cells 
for adoptive cell therapy, the mechanism for the Treg dysfunction in patients with 
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ARC, was next investigated. The motivation being that further understanding of the 
process/pathway involved may guide future treatment modalities.  
The chronic state of inflammation teamed with a heightened state of oxidative stress, 
crucial in the pathogenesis of cirrhosis, directed the work as to determine whether 
there was a pathway that could orchestrate the two processes and explain the Treg 
dysfunction. 
 
Accumulating evidence supporting the pivotal importance of HO-1 expression in 
mediating antioxidant and antiapoptotic effects (Brouard et al. 2002, Lee and Chau 
2002) and further work suggesting that human CD4+CD25+ cells constitutively 
express HO-1 (Pae et al. 2003) warranted the assessment of HO-1 expression in ARC 
patient Tregs. This venture was further supported by the similarities in the anti-
inflammatory functions attributed to Tregs and HO-1 enzymatic activity, raising the 
possibility that HO-1 may also be a key mediator of Treg activities. It was shown that  
Tregs from ARC patients expressed HO-1, although at significantly lower levels when 
compared with HC Tregs. As such, it was postulated that the defects seen in Treg 
numbers and function in patients with ARC may also be attributed to increased 
apoptosis in vivo secondary to the oxidative stress (Alderman et al. 2002, Witko-
Sarsat et al. 2003, Baskol et al. 2006, Fialova et al. 2006) 
In agreement, Choi et al. have shown that overexpression of HO-1 in Jurkat T cell 
lines, makes the cells resistant to Fas-mediated apoptosis and further showed that iron, 
one of the products of the heme degradation by HO-1, is critical for the survival of 
these cells. In the same study they further confirmed the importance of HO-1 
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expression against activation induced cell death in primary human CD4+ T cells (Choi 
et al. 2004). In this study, I showed that CD4+CD25- effector cells from patients 
expressed HO-1 at normal levels, suggestive that the Tregs are particularly sensitive 
to apoptosis in the environment in vivo, as compared their CD4+CD25- counterparts.  
 
It is well known that pro-inflammatory mediators such as TNF-α, IL-1, LPS and 
oxidized lipids are potent inducers of HO-1 expression in endothelial cells and 
macrophages (Camhi et al. 1998, Wagener et al. 2003). In this regard, it is reasonable 
to postulate that in patients with ARC, in view of the increased LPS in the serum and 
its associated proinflammatory milieu, the lack of HO-1 induction may be due to 
defects in the signalling pathways involved in HO-1 gene expression.  
 
Other than the antiapoptotic role of HO-1, of particular interest are publications to 
suggest that HO-1 is important in FOXP3 mediated immune suppression with reports 
showing that FOXP3 can induce HO-1 expression in a human T cell line (Choi et al. 
2005). Several studies have already tested this hypothesis through the use of various 
in vitro assays whereby application of exogenous carbon monoxide (CO), a byproduct 
of heme metabolism by HO, to murine (Song et al. 2004) and human CD4+ T cells in 
vitro has been shown to mimic Treg suppressive effects. Moreover, the suppressor 
activity of human Treg appeared enhanced or reduced when HO-1 expression and 
activity were induced or repressed, respectively (Choi et al. 2005). However, the 
evidence for the role of HO-1 in Treg mediated suppression in human and animal 




Here I provided further supporting evidence to the study by Choi et al. for the 
involvement of HO-1 in Treg mediated immunoregulation. ZnPP, an inhibitor of HO-
1 activity, decreased the suppressive function of the Tregs, as assessed by the 
proliferation of the Teffs.  
 
The data presented here, highlights the important role of Tregs in view of their 
functional defect, associated with the relative expression of HO-1, and their potential 
role in the disease progression of ARC. Therefore, to conclude, the defect in HO-1 
expression in Tregs may have important implications in aggravating the progressive 
inflammatory cascade seen in patients with ARC. As such this may present an 














Chapter 4  
EX VIVO EXPANSION OF REGULATORY T CELLS FROM 
PATIENTS WITH END STAGE LIVER DISEASE; INCREASED 




4.1. INTRODUCTION AND OBJECTIVES  
 
In view of murine models reporting an abundance of Tregs in tolerated liver allografts 
and their depletion resulting in the loss of tolerance (Li et al. 2006), it is evident that 
an increased number of Tregs is needed to tip the balance in favor of regulation. 
Concurrently in human subjects, it has been shown that stable liver allografts are 
abundant with such cells, and have been observed to increase after the resolution of a 
rejection episode (Demirkiran et al. 2007). Conversely, during acute liver transplant 
rejection, Treg cells were found to be diminished in the peripheral blood and instead 
localized to the liver (Stenard et al. 2009). As such it is evident that to achieve 
transplantation tolerance, large number of functional Tregs are required. 
 
Moreover, recent advances permitting the expansion of Tregs ex vivo presents an 
attractive opportunity in modulating immune responses, through their adoptive 
transfer. In this regard, the effective implementation of Treg therapy in transplantation 
is reliant on robust Treg manufacturing plans for the isolation and expansion of a 
functional and stable Treg product from patients who will be receiving the therapy. 
 
To date, there have not been any studies detailing the isolation and expansion of 
clinical grade autologous Tregs from liver transplant recipients. However, the GMP 
manufacture of patient-derived Tregs is of paramount importance in view of the start 
of trials such as ThRIL. It may well be that an impaired expansion profile of the 
isolated cells from patients awaiting liver transplantation may become apparent and 
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by its very nature the prospects of conducting a trial such as ThRIL may become an 
unrealistic endeavor.  
As such, here a protocol to isolate and expand Tregs at GMP standards was employed, 
with evaluation of the phenotype and function of these cells post expansion as a 
prelude for the ThRIL trial (NCT02166177). In addition, based on the data presented 
in chapter 3, it was also pertinent to ensure that not only was it possible to expand 
Tregs, reaching numbers needed for their clinical application, but that a functional and 
stable population of these cells was being expanded.  
 
This chapter describes the manufacture of clinical grade patient-derived Tregs from 
patients with ARC, for the programme of cell therapy set out in the ThRIL trial. 
In this regard, the hypothesis under investigation was: a rapamycin based GMP 
expansion protocol will permit the successful isolation and expansion of a functional 
and stable Treg cell product, reaching numbers needed for their clinical translation.  
 
The specific objectives of this chapter were to: 
 
1. Isolate Tregs, using a GMP compatible protocol reliant on CD8 depletion and 
CD25 enrichments, from patients with ARC. 
 
2. Polyclonally expand the patient-derived Tregs over 36 days in the presence of 
rapamycin, using a GMP compatible expansion protocol. 
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3. Assess the phenotype, function and stability of the ex vivo expanded Tregs to 
ensure the enrichment of a pure and functional population of cells for cell 





4.2. EFFICIENT ISOLATION AND EXPANSION OF A PURE REGULATORY T 
CELL POPULATION FROM PATIENTS(WITH(ALCOHOL(RELATED(CIRRHOSIS 
 
In preparation for the ThRIL trial, a GMP compatible protocol was firstly used to 
isolate clinical grade autologous Tregs from patient with ARC. As such, 150ml of 
peripheral blood was obtained from 9 patients with ARC and 9 age and sex matched 
HCs. Tregs were obtained following CD8+ cell depletion and enrichment for CD25+ 
cells, using GMP grade reagents and magnetic beads (Miltenyi Biotec) (Peters et al. 
2008, Afzali et al. 2013). Using this protocol, similar numbers of cells were isolated 
from ARC patients and HCs respectively, 12.6x106 ± 2.25 compared with 14.4x106 ± 











FIGURE 4.1. GMP TREG ISOLATION  
A. Numbers of cells isolated from 150ml of blood by CD8+ cell depletion and CD25+ cell 
enrichment compared between 9 ARC patients and 9 HCs. *** p=<0.001. Abbreviation, n.s- 


























One of the difficulties governing the feasibility of adoptive Treg cell therapy is their 
relative paucity in the peripheral blood, further exaggerated in patients with ARC who 
have an even lower frequency of Tregs as compared to HCs (data shown in chapter 3). 
In order to increase the number of Tregs for therapeutic use, ex vivo expansion prior 
to their clinical application is required. In this regard, the large scale ex vivo 
expansion of human Tregs by stimulation with anti-CD3/CD28 monoclonal antibody-
coated beads, high dose IL-2 and rapamycin has already been demonstrated 
successfully in my laboratory (Afzali et al. 2013, Scotta et al. 2013).  
Assessment of the purity of the cultures, evaluated by flow cytometric analysis of the 
percentages of cells expressing CD8+, CD4+ and CD25+ molecules, demonstrated on 
average a purity of 77.7% ± 10.3 CD4+CD25+ and 2.50 % ± 1.71 CD8+ cells at S1 for 
the 9 Treg lines. The data further supported the expansion of a pure population of 
cells with an increase in percentage of CD4+CD25+ T cells in culture and diminished 
levels of CD8+ T cells by final harvest. (CD4+CD25+ at final harvest, Untreated; 
87.5% ± 4.12, p=0.088 and Rapamycin; 91.3% ± 2.33, p=0.004; CD8+ at final 
harvest, Untreated; 0.292% ± 0.172, p=0.0019, Rapamycin: 0.153% ± 0.073 
p=0.008 (Figure 4.2A, 4.2B).  
In addition, since the cell sorter does not currently have GMP certification here in the 
UK, the cells could not be isolated based on CD25Hi expression. Despite this, the 
expansion protocol used resulted in the selective expansion of CD25Hi and, as evident 
from the dot plot (Figure 4.2B), the expression of CD25Hi was highest following 

























FIGURE 4.2. A GMP COMPATIBLE TREG ISOLATION TECHNIQUE, RELIANT 
ON A TWO STEP PROCESS  
A. CD8+ cell depletion. n=9 ARC patients.  S1-day 0, S2- day 12, S3- day 24, final- day 36. 






































FIGURE 4.2. A GMP COMPATIBLE TREG ISOLATION TECHNIQUE, RELIANT 
ON A TWO STEP PROCESS  
B. CD25+ cell enrichment.  In each case dots plots are representative of 9 ARC patients. 
Graphs denote the purity of the culture throughout the expansion period in both rapamycin 
and untreated cultures. S1-day 0, S2- day 12, S3- day 24, final -day 36. n= 9. Abbreviation, S- 
stimulation, n.s.- not significant. **p=<0.05, ***p=<0.001. Error bars represent SEM. 
  








































Data from animal models have clearly demonstrated that for Tregs to suppress 
immune responses a high Treg to T effector ratio is required (Hoffmann et al. 2002, 
Taylor et al. 2002).  
 
Having established that a pure population of Tregs can be isolated and expanded from 
ARC patients, I next sought to determine whether they can be expanded in vitro, 
under GMP compatible conditions, to numbers required for the maximum dose of 
Treg injection planned for the dose escalation ThRIL trial (4.5x106/Kg). 
 
Freshly isolated Tregs from the 9 ARC patients and 9 HCs were expanded in vitro in 
the presence and absence of rapamycin. Tregs from both groups expanded rapidly 
with comparable expansion profiles between ARC patient Tregs and HCs during the 
36 days of culture (Fold expansion Untreated; ARC 2080 ± 428, HC 1670 ± 359 
p=0.469; Rapamycin; ARC 1430 ± 239 and HC 1060 ± 139 p= 0.207) (Figure 
4.2C). In addition, it has previously been reported that the addition of rapamycin to 
cultures can delay the kinetics of proliferation (Battaglia et al. 2005, Hippen et al. 
2011), conceivably necessitating a prolonged period of culture to achieve the doses 
suitable for clinical application. Here, I provide data that at final harvest, despite a 
lower fold expansion of Tregs in the presence of rapamycin this difference was not 
significant when compared to the untreated cultures in both cohorts (ARC; 
Rapamycin 1427 ± 239 vs Untreated 2082 ± 428, p=0.199; HCs; Rapamycin: 1062 ± 
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139 vs Untreated: 1668 ± 359, p= 0.135). Of note, the average expansion of the 9 
different Treg lines in the presence of rapamycin was 11.2 x 109 cells ± 2.59 (Figure 
4.2D), demonstrating the feasibility of reaching numbers needed for the high dose of 

























FIGURE 4.2 GMP COMPLIANT POLYCLONAL TREG EXPANSION 
C. Comparison of Treg expansion profiles between HCs and ARC patients following 36 
days of culture. Tregs from 9 ARC patients and 9 HCs were expanded over 36 days in the 
presence and absence of rapamycin. Fold expansion was calculated from Treg numbers at 
each stimulation. D. Treg numbers over the 36 day expansion period. Graph denoting the 
number of ARC patient Tregs at each stimulation, based on fold expansion and assuming that 
all cells were expanded at each stimulation. S1-day 0, S2- day 12, S3- day 24, final -day 36. 





















































To verify the isolation and enrichment of the Tregs, freshly isolated and expanded 
Tregs were analysed for the expression of the transcription factor, FOXP3, of 
importance in Treg development and function (Hori and Sakaguchi 2004). The 
percentage of CD4+CD25+FOXP3+ cells was 92.1% ± 2.99 at baseline, and contrary 
to published data reporting a loss of FOXP3 expression with prolonged periods of 
culture (Hoffmann et al. 2009), the data showed that the expression of FOXP3 was 
maintained in culture in the presence (94.6% ±2.44) and absence (92.9% ±2.15) of 
rapamycin (Figure 4.3A). 
 
In addition, and in support of the supplementation of cultures with rapamycin, with a 
more stringent gating strategy applied (Figure 4.3B) it was shown that the percentage 
of CD4+CD25+FOXP3Hi positive cells was increased in culture in the presence of 
rapamycin (S1: 24.68% ± 2.95 vs Final harvest: 63.4% ± 4.23, p< 0.0001) as 
compared to the untreated cultures (Figure 4.3C). In agreement, the mean fluorescent 
intensity (MFI) of FOXP3 expression was also highest following exposure to 















FIGURE 4.3. EXPRESSION OF FOXP3 BY TREGS THROUGHOUT CULTURE 
A. Frequency of FOXP3+ Tregs. Graph shows the mean percentage of CD4+CD25+ cells 
expressing FOXP3+ in both untreated and rapamycin treated cultures of 9 ARC patients over 
36 days of culture. B. Flow cytometric gating strategy used to define two populations of 
FOXP3+ cells. A representative plot depicting the stringent gating strategy applied to 
delineate a population with a high expression of FOXP3 (Hi) and one with intermediate 
expression of FOXP3 (Int). C. Frequency of FOXP3Hi Tregs throughout culture. Graph 
shows the frequency of FOXP3Hi Tregs, from 9 ARC patients, throughout culture ± 
rapamycin. D. Mean fluorescent intensity (MFI) of FOXP3 expression by Tregs. FOXP3+ 
MFI within gated CD4+ CD25+ cells in 9 ARC patients. MFI shown at day 0 and at final 
harvest for Tregs expanded in both the presence and absence of rapamycin. S1-day 0, S2- day 
12, S3- day 24, final-day 36. Abbreviations, S- stimulation, n.s.-not significant. ***p=<0.001. 
Error bars represent SEM. 













































































































Apart from FOXP3, a constitutive high expression of the CTLA-4 represents another 
well-documented characteristic of CD4+CD25+ Tregs that has also been shown to 
contribute to their suppressive function (Read et al. 2000, Annunziato et al. 2002, 
Sansom and Walker 2006). Analysis of the cultures at final harvest revealed that 
rapamycin led to a significant increase in the percentage of Tregs expressing CTLA-4 
(S1 15.3% ± 2.51 vs Final harvest 70.6% ± 4.522, p <0.0001) (Figure 4.4A) with an 
increase also evident in the MFI of this marker (Figure 4.4B).  
 
An additional consideration regarding Treg therapy is the site of action of Tregs and, 
consequently, the desired homing properties of the injected cells. In the transplant 
setting, Treg lymph node homing and their ability to traffic to grafts are both required 
for their protection against graft rejection (Ochando et al. 2005). In this regard, it was 
shown that cultures of Tregs in the presence of rapamycin maintained the expression 
of the lymphoid homing receptor, CD62L (S1: 84.5% ± 1.67 and Final: 85.2% ± 1.45, 
p=0.738), which was not preserved in the untreated cultures, p=0.0076 (Figure 4.5). 
Furthermore, the percentage of Tregs expressing CXCR3, the chemokine receptor 
important for the migration and recruitment of Tregs to the liver (Oo et al. 2010) at 
baseline and after the 36 days expansion was investigated. Our data concluded a 
significant decrease in the Tregs expressing CXCR3 in the untreated cultures as 
compared baseline, p= 0.0194. This is in keeping with previous studies showing 
changes in the expression of the homing receptors with prolonged periods of culture 
(Chakraborty et al. 2012). However, it was clearly demonstrated that using the 
rapamycin based expansion protocol the expression of this marker on the Tregs was 




























FIGURE 4.4. EXPRESSION OF CTLA-4 THROUGHOUT CULTURE 
A. Gating and Frequency of CTLA-4+ Tregs. Dot plot details the frequency of CTLA-4 
expression on CD4+CD25+ Tregs from one representative sample of 9 ARC patients. The 
graph depicts the frequency of CD4+CD25+CTLA-4+ Tregs throughout culture in the presence 
of rapamycin. B MFI of CTLA-4 expression at S1 and day 36 of culture in the presence of 
rapamycin. ***p=<0.001. S1-day 0, S2- day 12, S3- day 24, final-day 36. Error bars represent 
SEM. 















































FIGURE 4.5. TREG HOMING; FREQUENCY OF CD62L+AND CXCR3 BY TREGS.  
Graph shows relative expression of CD62L and CXCR3 on CD4+CD25+ Tregs, from 9 ARC 
patients, at day 0 and at final harvest (day 36) in both the presence and absence of rapamycin. 




































One of the major concerns in Treg immunotherapy is the plasticity of the Tregs and 
their conversion to cells producing inflammatory cytokines. In this regard, several 
studies have shown that Tregs can convert to a Th17 phenotype, producing IL-17 
when exposed to a pro-inflammatory milieu (Hori 2010, Li and Boussiotis 2013). As 
such, freshly isolated and expanded Tregs were cultured for 5 days in the presence of 
Th17 skewing conditions, with the percentage of IL-17+ cells analysed by FACS 
(Figure 6A) and IL-17 production measured by ELISA (Figure 6B) of the culture’s 
supernatant. Our data clearly confirmed that over the 36 day period culture and in the 
presence of rapamycin, there was a decrease in the percentage of positive cells for IL-
17 (Mix 1: S1: 5.71% ± 0.98 and rapamycin at final harvest: 2.84% ± 0.809, 
p=0.0384; Mix 2: S1: 4.93% ± 1.12 and rapamycin at final harvest: 2.31% ± 0.436, 
p=0.0446) and diminished IL-17 production (Mix 1: S1: 1965pg/ml ± 318 and 
rapamycin at final harvest: 124pg/ml ± 34.5, p<0.0001; Mix 2: S1: 1322pg/ml ± 347 
and rapamycin at final harvest: 84.3pg/ml ± 35.3, p=0.0027 ) (Figure 6A, 6B). 
Moreover, assessment of the percentage of IFNγ+ cells also clearly demonstrated that 
rapamycin resulted in a reduction in the frequency of FOXP3+IFNγ+ cells by final 
harvest (Mix 1 S1: 6.42% ± 0.915 and rapamycin at final harvest: 2.54% ± 0.560, 
p=0.0023; Mix 2: S1: 4.61% ± 0.698 and rapamycin at final harvest: 2.82% ± 0.688, 




To better characterise the Tregs and ensure that the expansion protocol favored the 
stability of these cells in culture, the expression of CD161 on the Tregs was also 
investigated. My laboratory and others, have previously shown that Tregs expressing 
CD161 are responsible for IL-17 production (Cosmi et al. 2008, Afzali et al. 2013, 
Pesenacker et al. 2013), as well as being described as a marker for precursors of IL-17 
producing T cells (Maggi et al. 2010). 
I show that during the 36-day expansion there was a decrease in the percentage of 
CD161+ Tregs (S1: 19.6% ± 2.42 and rapamycin at final harvest: 1.48% ± 0.26, 
p=0.0001) and a decrease in the percentage of Tregs co-expressing CD161 and CCR6 
(S1: 12.5% ± 1.75 and rapamycin at final harvest: 0.500 ± 0.107, p<0.0001) in 
rapamycin treated cultures as compared to baseline (Figure 4.6D, 4.6E).  
Taken together these findings suggest that expansion of Tregs with rapamycin 



























































FIGURE 4.6. CUMULATIVE DATA FROM 9 INDIVIDUAL 
EXPERIMENTS DETAILING THE INTRACELLULAR EXPRESSION 
OF IL-17 AND IFN-Y AND PRODUCTION OF IL-17.   
A. Graph showing the frequency of IL-17+ in CD4+CD25+FOXP3+ Tregs upon 
isolation and post culture in the presence of rapamycin (day 36) when exposed 
to two separate mixes of pro-inflammatory cytokines (Mix 1: IL-2, IL1β, IL-6 
and TGF-β and Mix 2: IL-2, IL-21, IL-23 and TGF-β) B. Production of IL-17 
(pg/ml) from CD4+CD25+FOXP3+ Tregs, as assessed by ELISA. C. Graph 
showing the frequency of IFN-γ+ in CD4+CD25+FOXP3+ Tregs upon isolation 
and post ex vivo expansion in the presence of rapamycin (day 36) when exposed 
to the two separate mixes of pro-inflammatory cytokines (as above). n.s.-not 
























D. Gating strategy and Frequency of CD161+ Tregs throughout culture. Dot plot depicts 
expression of CD161 on CD4+CD25+ Tregs from a representative sample of 9 ARC patients. 
The graph shows the dynamics of CD161 expressing Tregs throughout culture.  E. Gating 
strategy and Frequency of CCR6+CD161+ Tregs throughout culture Dot plot of 
CD161+CCR6+ co-expression on CD4+CD25+ Tregs from a representative sample of 9 ARC 
patients and graph of percentage CD161+CCR6+ co-expression throughout culture. 
***p=<0.001. S1-day 0, S2- day 12, S3- day 24, final-day 36. Error bars represent SEM. 
 
































































4.7. EX VIVO EXPANDED REGULATORY T CELLS FROM PATIENTS(WIH(ALCOHOL(RELATED(CIRRHOSIS(HAVE INCREASED SUPPRESSIVE ABILITY  
 
After confirming that the cells maintained their stability during culture it was also of 
importance to assess the functional properties of the expanded patient-derived Tregs. 
CFSE dilution assay was performed to evaluate the ability of freshly isolated and ex 
vivo expanded Tregs from patients to suppress the proliferation of T effectors (Figure 
4.7).  
 
In line with previous reports (Scotta et al. 2013), the data clearly demonstrated that at 
the end of expansion, the suppressive function elicited by ARC Tregs in the presence 
of rapamycin was significantly higher as compared to freshly isolated Tregs at 
different Treg:Teffector ratios (1:1 ratio - expanded rapamycin Tregs 84.8% ± 3.96 
vs. Tregs at S1 25.4% ± 6.03, p=0.0001 suppression, 1:10 ratio – expanded 
rapamycin Tregs: 68.3% ± 6.85 vs. Tregs at S1: 16.2% ± 4.68, p=0.0001). In the 
untreated cultures, despite an increase in Treg suppressive function at S2, this increase 
did not reach similar levels as those obtained from Tregs expanded in the presence of 
rapamycin (Treg:Teff- 1:1 ratio – Untreated: 60.5% ± 7.26 vs Rapamycin: 88.2% ± 
2.76, p=0.0026; and 1:10 ratio - Untreated: 42.0% ± 8.99 vs Rapamycin: 79.1% ± 
3.90, p= 0.0016). Moreover, the increase in Treg suppressive function was not 
preserved by final harvest in the untreated cultures as compared to the cultures 
expanded in the presence of rapamycin (Treg:Teff 1:1 ratio - Untreated: 25.2% ± 
4.58 vs Rapamycin: 84.8% ± 3.96, p=0.0001; 1:10 ratio - Untreated 7.32% ± 2.32 
vs Rapamycin 68.3 ± 6.85, p=0.0001) (Figure 4.7A). These results supported the use 
of the rapamycin based GMP protocol in the expansion of autologous Tregs from 
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ARC patients for cell therapy application in view of the increased Treg suppressive 
function, which was maintained during expansion. 
 
4.8. REGULATORY T CELL EXPANSION IN THE PRESENCE OF RAPAMYCIN 
RESULTS IN AN INCREASED EXPRESSION OF HEME OXYGENASE-1 BY 
PATIENT REGULATORY T CELLS.  
 
In view of the role of HO-1, in Treg mediated suppression, described in chapter 3, and 
data presented suggesting that Tregs from ARC patients have lower expression of 
HO-1, levels of this enzyme were measured in rapamycin expanded patient derived 
Tregs by final harvest. The rationale being that if rapamycin treatment results in the 
increase of the suppressor function of Tregs from ARC patients, in parallel, 
expression of HO-1 in Tregs from patients will also increase. It was clearly 
demonstrated that by final harvest, patient Tregs expressed higher levels of HO-1, 
6.19% ± 1.05 as compared to the level of HO-1 obtained from freshly isolated patient 
Tregs, 1.76% ± 0.404, p= 0.0171. (Figure 4.7B). 
The level of HO-1 observed with rapamycin cultured Tregs from ARC patients was 
very similar to HO-1 levels in Tregs from HCs, p= 0.3609 (Figure 4.7C). Moreover, 
and of importance, our preliminary data to date has also indicated that levels of HO-1 
from HC Tregs do not increase post 36 days expansion in the presence of rapamycin 




FIGURE 4.7. ASSESSEMENT OF CD4+CD25+ TREG SUPPRESSOR FUNCTION AND CONCURRENT EXPRESSION LEVELS OF HO-1.  
A.  Representative histogram and graph from 9 ARC patients upon assessment of Treg suppressor function. The suppressive function of Tregs cultured ± 
rapamycin was assesed by CFSE dilution assay at day 0 and throughout the 36 day culture period. 




















































































FIGURE 4.7. ASSESSEMENT OF CD4+CD25+ TREG SUPPRESSOR FUNCTION 
AND CONCURRENT EXPRESSION LEVELS OF HO-1.  
B. Graph depicting the expression levels of HO-1 expression by CD4+CD25+ Tregs from 3 
ARC patients following 36 days of culture in the presence of rapamycin as compared to 
freshly isolated Tregs from patients. C. Graph comparing the mean HO-1 expression of 
rapamycin expanded Tregs, from 3 ARC patients at final harvest, with the mean expression of 
HO-1 by HC Tregs. n.s.- not significant. *p=<0.05, ***p=<0.001. S1-day 0, S2- day 12, S3- 







































One of the major drawbacks following liver transplantation is the requirement for 
lifelong treatment with immunosuppressant exposing their associated side effects. 
This contributes to a disappointing 60% patient survival rate at 10 years after 
transplantation. A potential solution to this problem is to reprogram the transplant 
recipient’s immune system so as to maintain normal graft function in the absence of 
these toxic drugs. In this regard, the use of cell-based therapies, harnessing the natural 
immunoregulatory properties of the immune system, is an emerging area of 
science/medicine and Tregs have been recognized as ideal candidates in this 
endeavor. Animal models and basic science research have already shown the 
importance of Tregs in the induction of tolerance and prevention of rejection in 
transplant models (Sakaguchi 2005). In addition, Treg therapy in the context of liver 
transplantation is supported by studies reporting an increase in the number of FOXP3+ 
cells in the liver biopsies of operationally tolerant liver transplant recipients (Li et al. 
2004, Martinez-Llordella et al. 2007) and low levels of circulating Tregs documented 
in episodes of acute rejection (Demirkiran et al. 2006). As such, to increase the 
number of these cells in vivo is an attractive concept, tipping the balance in favor of 
regulation.  
ThRIL is the leading clinical trial of autologous Treg immunotherapy in liver 
transplantation worldwide. The success of such a trial relies on a careful clinical trial 
design, incorporating a detailed Treg manufacturing plan as well as a ‘Treg 





Here, I outline the first account of the manufacture of Tregs from liver transplant 
recipients, highlighting the successful isolation and ex vivo expansion of these cells at 
GMP standards. The data presented provides evidence supporting the feasibility of 
autologous Treg cell-based therapy in liver transplantation.   
 
By adherence to the GMP-compatible protocol devised in my laboratory (Afzali et al. 
2013, Scotta et al. 2013) I was able to ensure the selection of a functionally pure 
population of Tregs (CD4+CD25+ at S1: 77.7% ± 10.3), using a two-step magnetic 
activated cell sorting (MACS) protocol.  Others have attained a higher degree of Treg 
purity; using Treg isolation techniques based on the combined expression of CD4+, 
CD25+, and CD45RA+ molecules, hence eliminating antigen experienced/memory T 
cells (Hoffmann et al. 2006), or CD4+, CD25+ and low expression of CD127 
molecules (Liu et al. 2006). Although cell isolation based on the combination of these 
markers is highly effective, the lack of GMP cell sorter facilities in the UK makes the 
isolation of Tregs based on the combination of the three markers unfeasible. In 
addition, Ukena et al. compared different Treg isolation strategies with the aim of 
defining the most favorable Treg target population for cellular therapy. They 
concluded that whilst CD4+CD25+CD127lo Tregs are promising for fresh cell 
infusions, CD4+CD25+ Tregs qualify as the best candidate for in vitro expansion 
(Ukena et al. 2011). Moreover, Marek et al. showed that during the expansion process 
Tregs were “transforming” into effector/memory like cells and proposed that 
regardless of the phenotypic markers used for Treg isolation, the only variable to 
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maintain Treg phenotype and function is to limit the duration of expansion to 2 weeks 
(Marek et al. 2011).  
In support of this study, others have also shown that the large-scale manufacture of 
Tregs remains challenging, reporting that even when starting with a highly pure 
population of Tregs, repeated stimulation results in the loss of FOXP3 expression 
(Hoffmann et al. 2009). In the clinical trial conducted by Trzonkowski et al.  a 
decrease in the percentage FOXP3+ cells after successive weekly stimulation was 
reported (Trzonkowski et al. 2009). However, the disadvantage of limiting cultures to 
two rounds of stimulation became evident in the trial of Treg immunotherapy in Type 
1 diabetes where the authors noted an insufficient Treg yield in four out of the 10 
patients (Marek-Trzonkowska et al. 2012). 
Data presented in this chapter details the manufacture of clinical grade Tregs in 
concordance with the proposed GMP protocol, expanding these cells in vitro for 36 
days with three rounds of stimulation, in the presence of rapamycin. This resulted in 
the expansion of Tregs to numbers sufficient for administration of the maximum dose 
in the program of cell therapy outlined in the ThRIL trial. Despite the three rounds of 
stimulation, and contrary to the studies outlined above, FOXP3 expression was 
maintained in culture and the data clearly demonstrated that in the presence of 
rapamycin there was an increase in the percentage of FOXP3Hi Tregs and in the level 
of expression of FOXP3 at final harvest (Figure 4.3C). Additionally, the 
supplementation of cultures with rapamycin has been supported in studies by 
Battaglia and Strauss showing that rapamycin selectively promotes the expansion of 
functional human Tregs, whilst depleting human CD4+CD25- T effectors cells 
(Battaglia et al. 2005, Strauss et al. 2007). Moreover, data from my laboratory and 
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others have shown that rapamycin has an inhibitory effect on the development of IL-
17 producing cells, both in vitro and in vivo (King et al. 2009, Scotta et al. 2013). 
The rapamycin based GMP compatible protocol further proved to be ideal in the 
expansion of Tregs from liver transplant recipients, promoting an increase and 
subsequent maintenance of Treg suppressive function throughout the 36-day culture 
(Figure 4.7A).  
Ex vivo expansion of Tregs in the presence of rapamycin further led to an increased 
expression of HO-1 by patient Tregs by final harvest, supporting the increased 
suppressive function (Figure 4.7B, 4.7C). In agreement with this data Visner et al. 
have suggested that the antiproliferative effects of rapamycin in vascular smooth 
muscle cells are mediated through the induction of HO-1 (Visner et al. 2003). The 
study by Kist et al. provides further supporting evidence, showing that culture of rat 
hepatocytes in the presence of rapamycin led to an increased expression of HO-1, 
protecting hepatocytes against ROS-induced damage (Kist et al. 2012).  
Thus, it may also be suggested that by increasing HO-1 levels by final harvest, it not 
only results in the increase in Treg suppressive function, but also ensures the 
resilience of these cells to apoptosis, a desirable characteristic of these cells for 
adoptive transfer.  
 
In addition, therapeutic strategies using Tregs have to also taken into account the need 
for appropriate tissue trafficking to enable contact with their target cells. In this 
respect, in a murine model of T cell mediated liver injury, Lapierre et al. 
demonstrated the ability of CXCR3+ Tregs to target to the liver, in turn potentiating 
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the effectiveness of Treg adoptive transfer (Lapierre et al. 2013). The data 
demonstrates the preservation of cells expressing CD62L and CXCR3, important for 
their migration to lymph nodes and the liver respectively, making the Tregs 
manufactured with this protocol desirable for application in liver transplantation 
(Figure 4.5). 
 
A major potential barrier to Treg therapy is the possibility that these cells may assume 
a pro-inflammatory phenotype and cause graft rejection on adoptive transfer. In this 
study, I confirmed that rapamycin effectively diminished the capacity of Tregs to 
produce IL-17 (Figure 4.6A, 4.6B). In line with this, a decrease in the percentage of 
cells co-expressing CD161 and CCR6 was further demonstrated. In support of our 
data Tresoldi et al. showed that only in cultures in the absence of rapamycin 
CD4+CCR6+CD161+ Th17 precursors were present (Tresoldi et al. 2011). Moreover, 
in view of the plasticity of Tregs, Kopft et al. studied the reciprocal differentiation of 
Tregs and Th17 cells and reported that rapamycin suppresses the differentiation of 
pathogenic Th17 cells (Kopf et al. 2007). These studies further confirm the benefits 
and pertinence of a rapamycin based GMP-compatible protocol when considering 
translation of autologous Treg based therapy in liver transplantation.  
Finally, recently my laboratory have provided data on the large-scale production of 
patient Tregs in the GMP Clinical Research Facility (CRF) at Guy’s Hospital, 
utilizing the CliniMACS system of Treg isolation, whilst employing the expansion 
protocol outlined in the present study. In this regard, the successful large scale 
expansion of Tregs from three liver transplant recipients has been reported, with all 
final products consistently satisfying the set release criteria (Appendix 1) necessary 
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for their clinical application in the setting of the ThRIL trial (data not shown). 
Moreover, in view of the fact that the Tregs will be cryopreserved, prior to 
intravenous infusion, in the ThRIL trial, further data has been provided supporting the 
stability of the Tregs, retaining the necessary product specifications post the freeze-
thaw process. The data generated also has important implications for future clinical 
trials. The optimal Treg dose level for efficacy in solid organ transplantation is 
currently unknown. It may well be that multiple Treg injections are required in future 
Phase II efficacy studies, hence supporting the importance of Treg cryopreservation.  
 
The clinical trial, ThRIL, is currently in the recruitment stage with plans to test the in 
vivo safety and efficacy of the Tregs expanded under the conditions described in this 
manuscript. In addition, the clinical protocol for this trial is based on a Treg 
supportive immunosuppressive regimen including the use anti-thymocyte globulin 
(ATG), to induce lymphopenia with a preferential preservation of Tregs (Lopez et al. 
2006) and rapamycin, to promote selective Treg expansion in vivo (Strauss et al. 
2007). The intention behind this strategy: to create a tolerogenic milieu thus 
maximizing the potential efficacy of the exogenously administered Tregs through 
prolongation of their in vivo survival. Tailoring the immunosuppressive regimen 
along with the administration of ex vivo expanded Tregs may potentially maintain 
post liver transplant tolerance, accomplishing the ultimate aim of the ThRIL trial.  
 
Adoptive cell therapy in the setting of liver transplantation is rapidly becoming a 
reality and we are now only a few steps away from the first Treg injection in this 
setting. However, several questions still remain to be addressed including the quantity 
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of Tregs needed for an efficacious dose, the timing and number of injections and the 
migration of these cells upon adoptive transfer before the enigma of tolerance 
induction can be decoded. These factors are discussed in detail in section 6.2. 
 
In addition, in view of the wealth of animal data from our laboratory (Sagoo et al. 
2011, Putnam et al. 2013, Xiao et al. 2014) and others in support of the importance of 
antigen specific Tregs in the setting of solid organ transplantation, chapter 5 outlines 
the GMP compatible manufacture of antigen specific Tregs with an assessment of 
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5.1. INTRODUCTION AND OBJECTIVES (
Bearing in mind the importance of antigen specific Tregs in the transplant setting and 
recent reports highlighting the utility of CD40 activated B cells in the induction and 
expansion of Tregs in vitro (Tu et al. 2008, Zheng et al. 2010), this chapter discusses 
the development of a GMP compatible protocol, for the generation of Tregs with 
direct allospecificity, using CD40L B cells as APCs with an assessment of their in 
vitro and in vivo function. The hypotheses being investigated in this chapter are:   
 
a. Clinical grade Tregs with direct allospecificity can be manufactured using 
CD40L B cells. 
b. Human Tregs with ‘direct’ allospecificity are more potent as compared to 
polyclonal Tregs at preventing rejection of human skin in a humanised mouse 
model.  
 
The objectives of this chapter: 
1. To expand B cells, using a GMP compatible CD40L-expressing K562 cell 
line. 
2. To demonstrate the GMP compatible manufacture of alloantigen specific 
Tregs, using CD40L-stimulated B cells. 
3. To test the potency of the antigen specific Tregs as compared to polyclonal 
Tregs in averting alloimmune mediated skin damage using a humanised mouse 
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Regulatory T cell (Treg) therapy has the potential to
induce transplantation tolerance so that immunosup-
pression and associated morbidity can be minimized.
Alloantigen-reactive Tregs (arTregs) are more effective
at preventing graft rejection than polyclonally expand-
ed Tregs (PolyTregs) in murine models. We have
developed a manufacturing process to expand human
arTregs in short-term cultures using goodmanufactur-
ing practice-compliant reagents. This process uses
CD40L-activated allogeneic B cells to selectively ex-
pand arTregs followed by polyclonal restimulation to
increase yield. Tregs expanded 100- to 1600-fold were
highly alloantigen reactive and expressed the pheno-
type of stable Tregs. The alloantigen-expanded Tregs
had a diverse TCR repertoire. They were more potent
than PolyTregs in vitro and more effective at control-
ling allograft injuries in vivo in a humanized mouse
model.
Keywords: Cellular therapy, clinical application, regu-
latory T cells, tolerance induction
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practice; GvHD, graft-versus-host disease; INFg, inter-
feron gamma; MLR, mixed lymphocyte reaction;
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Introduction
Regulatory T cells (Tregs) are essential for self-tolerance (1).
In experimental models of transplantation, Tregs are
necessary and, under certain experimental conditions,
sufficient in establishing transplantation tolerance (2–5).
Three Phase I trials evaluating the safety of Treg cell therapy
in graft-versus-host disease (GvHD) have been reported
and all showed minimal toxicity and suggested possible
efficacy (6–8). A Phase I trial of Treg therapy in childrenwith
new-onset type 1 diabetes also showed slower disease
progression without serious adverse events (9). These
findings inspired many to consider applying Treg therapy to
solid organ transplantations so that immunosuppression
can be minimized or withdrawn.
Alloantigen-reactive Tregs (arTregs) aremore effective than
polyclonally expanded Tregs (PolyTreg) in inducing toler-
ance in experimentalmodels of transplantation (10–12).We
have estimated that the numbers of Tregs needed for
efficacy for humans are in the range of several billion for
PolyTregs and 10 times less for arTregs (13). Several
approaches have been reported for selective expansion of
human arTregs (12,14–16), and none has demonstrated
expansion under good manufacturing practice (GMP)-
compliant conditions. In this study, we report a robust
process for manufacturing clinical-grade human arTregs.
Methods
Cells
Normal donors were consented for whole blood donation. Alternatively, de-
identified apheresis products from normal donors were obtained from the
UCSF Blood Center. Peripheral blood mononuclear cells (PBMCs) were
isolated as described previously (17) and used fresh or after cryopreservation
in CryoStor CS10 freezing medium (BioLife Solutions, Bothell, WA). Spleens
were from cadaveric organ donors with research consent. All procedures
were approved by the authorities at UCSF and King’s College London.
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Generation of CD40L-expressing K562 cells
Lentiviral vectors encoding human CD40L (NM_000074), CD64 (BC032634),
DRA (BC071659) and DRB0401 (18) were produced, and transduction and
cloning were performed as previously described (19,20). Stable expression
of transduced genes was verified by flow cytometry using antibodies to
CD40L (TRAP1), HLA-DR (G46-6) and CD64 (10.1).
Generation of CD40L-stimulated B cells (CD40L-sBc)
B cells were enriched from PBMCs or spleens using the untouched B cell
enrichment kit (Invitrogen, Carlsbad, CA), and cultured with irradiated 3T3-
CD40L cells (40Gy) as described (21). The CD40L-sBc were irradiated
(30Gy) and used to stimulate Tregs or cryopreserved in CryoStor CS10 until
use. For GMP-compliant expansions, B cells were purified using CD19
positive selection on a CliniMACS (Miltenyi Biotech, Auburn, CA), stimulated
with irradiated K562-CD40L cells (100Gy) in transferrin-containing X-VIVO15
medium (Lonza, Walkersville, MD) supplemented with 10% human AB
serum (Valley Biomedical, Winchester, PA), GMP grade IL-4 (Miltenyi) and
Cyclosporine A (Teva Pharmaceuticals, North Wales, PA).
Mixed lymphocyte reaction (MLR)
Responder PBMCs labeled with 1.25mM carboxyfluorescein succinimidyl
ester (CFSE; Invitrogen) were stimulated with irradiated allogeneic CD40L-
sBc (2 sBc per PBMC) or with irradiated allogeneic PBMCs (5 stimulators per
responder). The cultures were harvested after 84–96 h and stained with
antibodies to CD3 (clone SK7), CD4 (clone SK3), CD8 (clone SK1), a fixable
viability dye, FOXP3 (clone 206D), andHELIOS (clone 22F6). Flow cytometry
was performed on Fortessa (BD Biosciences) and analyzed using FACSdiva
(BD Biosciences) or FlowJo software (Treestar, Ashland, OR).
Treg expansion
Tregs were isolated using a BD FACSAria II (BD Biosciences) based on the
phenotype of CD4þCD127lo/"CD25þ and PolyTreg expansions were
performed as previously described (17). The clinically compliant sorting
utilized GMP mAbs generated and provided by Noel Warner (BD
Biosciences). For arTreg expansions, the cultures were maintained in
OpTmizer Medium (Invitrogen) supplemented with GlutaMAX (Invitrogen),
Penicillin/Streptomycin and 2% human AB serum or in X-VIVO15 medium
with 10% human AB serum. Fluorescence-activated cell sorting (FACS)
purified Tregs were mixed with CD40L-sBc at a 4:1 sBc to Treg ratio. The
cultures were maintained with 300 IU/ml human IL-2 until day 9 or 11, when
the cells were restimulated with new irradiated sBc or with GMP-grade anti-
CD3 and anti-CD28-coated (anti-CD3/CD28) beads at a 4:1 sBc to T cell or 1:1
bead to T cell ratio. Cultureswere fed 3 days later andharvestedon day5 after
restimulation. Viability of the cells was assessed using trypan blue exclusion.
Flow cytometry
Phenotype of expanded Tregs was assessed using the following three flow
cytometric panels: (1) CD8 (clone SK1), CD4 (clone SK3), CD3 (clone SK7)
and CD19 (clone SJ25C1); (2) CD4, CD62L (clone SK11), CD27 (clone L128)
and FOXP3 (clone 206D; BioLegend, San Diego, CA); and (3) CD4, CD25
(clone 2A3), HELIOS (clone 22F6; BioLegend) and FOXP3. For some
experiments, interferon gamma (IFNg) production by expanded arTregs
were assessed as previously described (22). The CD40L-sBc were stained
with antibodies to HLA-DR (clone G46-6), CD80 (clone L307.4), CD86
(clone 2331) and CD19 (clone HIB19). The stained cells were analyzed on a
FACSCalibur or AccuriC6 (BD Biosciences, San Diego, CA). All antibodies
were from BD Biosciences unless otherwise noted.
Treg specificity assay
Expanded Tregs were labeled with 1.25mM CFSE and stimulated with
allogeneic or autologous CD40L-sBc, anti-CD3/CD28 beads, or left
unstimulated in media containing 30 IU/mL IL-2. After 72 h, the cells were
collected and stainedwith anti-CD4 and propidium iodide and analyzed on an
AccuriC6.
TCRb repertoire analysis
Genomic DNA was extracted from 0.25# 106 to 1# 106 freshly isolated
Tregs and ex vivo expanded PolyTregs and arTregs. The DNAwas submitted
to Adaptive Biotechnologies (Seattle, WA) for survey level TCRb sequenc-
ing. Analyses of the sequencing data including determining the clonality
index and repertoire similarities were done using algorithms developed by
Adaptive Biotechnologies.
In vitro suppression assays
Titrated numbers of expanded Tregs were mixed with 3#104 PBMCs from
the Treg donor in V-bottom 96-well plates in triplicates. The cells were stimu-
latedwith irradiated PBMCs from the sBcor third-party donors for 7 days, and
incorporation of 3[H] thymidine during the final 16–20h of culturewas used to
measure proliferation. Cultures containing no Tregs were used as controls.
Treg-specific demethylated region (TSDR)methylation assay:Genomic DNA
from 0.5# 106 expanded Tregs was analyzed using licensed reagents from
Epiontis GmbH (Berlin, Germany) according to established protocol (23).
Percentages of demethylated TSDR were calculated as: [mean copy
numbers of unmethylated DNA/(mean copy numbers of unmethylatedþ
mean copy numbers of methylated DNA)]# 100. For female Tregs, the
percentages calculated above were multiplied by 2 to correct for X-
chromosome inactivation.
Humanized mouse model of skin transplantation
De-identified human skin was obtained from surgery patients with
informed consent. The skin was transplanted onto 8- to 12-week-old
BALB/c.Rag2"/"gc"/" mice and allowed to engraft for 6 weeks before the
recipientmicewere injectedwith 10# 106HLA-mismatched CD25-depleted
PBMCs. Some mice were co-injected with 2# 106 PolyTregs or arTregs.
Histological analysis of the grafts was performed 6 weeks after PBMC
injections. For the total duration of these experiments, 100mg anti-mouse
Gr1 (Bio X Cell, West Lebanon, NH) was injected intraperitoneally every 4–5
days to deplete mouse granulocytes. All procedures were conducted in
accordance with institutional guidelines. Frozen sections of human skin
grafts were fixed with 5% paraformaldehyde and stained with antibodies
against human antigens ki67 (cat. # ab15580; Abcam, Cambridge, MA),
CD45 (clone HI30; eBioscience), CD3 (cat. # A0452; Dako, Carpenteria, CA),
FOXP3 (clone 259D/C7; eBioscience), involucrin (clone SY5) and CD31 (cat.
# ab28364; Abcam), followed by incubation with appropriate fluorochrome-
conjugated secondary antibodies and mounted with Prolong Gold Anti-fade
Reagent with 4-6-diamidino-2-phenylindole (DAPI; Invitrogen). Quantitative
assessment of immunofluorescence results was done by counting four to
six nonoverlapping fields preformed by an individual blinded to the treatment
conditions.
Statistics
Statistical analyses were performed using GraphPad Prism version 5.00
(GraphPad Software, San Diego CA).
Results
CD40L-sBc are potent stimulators of arTregs
Using a one-wayMLR,we foundCD40L-sBcweremarkedly
more potent than PBMCs at stimulating proliferation of
CD4þ T cells, CD8þ T cells and CD4þFOXP3þHELIOSþ
Tregs (Figure 1A and B). To determine if the proliferation
was in response to alloantigens expressed on CD40L-sBc,
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we compared the stimulatory capacity of autologous
CD40L-sBc and allogeneic CD40L-sBc with varying degree
of HLAmismatches to the responders. We found a trend of
higher frequencies of responding CD4þ conventional T cells
(Tconv) and Tregs with more HLA-DR mismatches and
higher frequencies of responding CD8þ T cells with more
HLA-AB mismatches (Figure 1C). These results demon-
strated that CD40L-sBc were potent allogeneic stimulators
and prompted us to explore the utility of CD40L-sBc in
selective expansion of arTregs.
Generation of GMP-compliant CD40L-expressing cells
A GMP-compatible human CD40L-expressing cell line,
KT64.CD40L.HLADR0401 (abbreviated as K-CD40L), was
generated to enable manufacture of clinical-grade arTregs.
We used lentiviral transduction to express CD40L in the
myeloleukemia cell line K562, which has been used as
cancer vaccines and artificial antigen presenting cells for
clinical applications (24–27). The additional CD64 and
HLADR0401 genes were intended for other applications
and do not interfere with CD40L stimulation of sBc. Two
rounds of stimulation with the K-CD40L cells on days 0 and
7 and a constant supply of IL-4 led to 10- to 50-fold
expansion of purifiedB cells (Figure 2A).When compared to
freshly isolated B cells, the CD40L-sBc expressed signifi-
cantly higher levels of HLA-DR, CD80 and CD86 (Figure 2B
and C), consistent with their enhanced potency in
stimulating T cells.
CD40L-sBc robustly induce arTreg expansion
We have previously reported that polyclonal expansion of
FACS purified CD4þCD127lo/"CD25þ Tregs using two
rounds of stimulations (days 0 and 9) with anti-CD3/CD28
beads (17). For expanding arTregs, we compared two
rounds of stimulation with CD40L-sBc versus primary
CD40L-sBc stimulations followed by anti-CD3/CD28 re-
stimulation. Two stimulations with CD40L-sBc led to 50- to
300-fold expansion of Tregs (Figure 3A), similar to that
achieved when CD40L-sBc were replaced with beads
during restimulation (Figure 3B). Tregs expanded either
way were highly reactive to the sBc used for their expan-
sion (Figure 3C). We decided to use bead restimulation for
arTreg expansion for the ease of standardization and
implementation.
One unit of blood yields an average of 5 million Tregs after
FACSpurification.With50- to300-foldexpansions,wewould
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Figure 1: CD40L-sBc potently stimulate T cell proliferation. (A and B) PBMC and CD40L-sBc from the same donor were compared for
their ability to stimulate proliferation of alloreactive T cells in a one-way MLR. The responder PBMCs were labeled with CFSE before MLR
and the cultures were harvested on day 4 for flow cytometric analysis. Representative CFSE dilution profiles of CD4þ and CD8þ T cells (A)
and CD4þFOXP3þHELIOSþ Tregs (B) are shown. The data are a representative of at least 10 independent experiments. (C) Autologous
CD40L-sBc and allogeneic CD40L-sBc with different degree of HLA mismatches with responder cells were compared in their ability to
stimulation proliferation of CD4þ Tconv, CD8þ T cells and Treg cells. Each symbol represents the same responder. Results are a summary of
15 different stimulator and responder combinations. CD40L-sBc, CD40L-stimulated B cells; CFSE, carboxyfluorescein succinimidyl ester;
MLR, mixed lymphocyte reaction; PBMC, peripheral blood mononuclear cell; Tconv, conventional CD4þ T cells; Treg, regulatory T cell.
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which may fall short of our estimated efficacy dose (13). We
therefore explored conditions to improve arTreg expansion.
The CD40L-sBc-stimulated Tregs continued to cluster and
blast on day 9 after stimulation (Figure 3D), suggesting that
the Tregs were still activated and might undergo activation-
induced cell death if restimulated at this time. Delaying
restimulation until day 11 when the cells appeared more
rested (Figure 3E) consistently improved overall expansion
(Figure 3F). The source of the anti-CD3/CD28 beads also
affected the rate of Treg expansion (Figure 3G). In contrast,
we found that variation in HLA-DR, CD80 and CD86
expression on CD40L-sBc did not correlate with arTreg
expansion (Figure 3H), suggesting that the potency of the
CD40L-sBc was not strictly correlated with the absolute
amount of these molecules as long as a threshold was met.
Overall, by optimizing restimulation timing and restimulation
regents, arTregs routinely expanded 100- to 1600-fold.
In vitro characterization of arTregs
High-throughput TCR sequencingwas used to compare the
repertoires of freshly isolated Tregs and various expanded
Tregs. arTregswere less diverse than freshly isolated Tregs
and PolyTregs (Table 1), consistent with selective expan-
sion using the CD40L-sBc stimulation. arTreg repertoire
remained diverse with cumulative frequencies of top 10
clones representing less than 7% of the total repertoire and
very low clonality indexes. We found 85% TCR repertoire
similarity between the Tregs after primary CD40L-sBc
stimulation and after additional anti-CD3/CD28 bead
restimulation (Figure 4A). Consistently, arTregs expanded
with two rounds of CD40L-sBc or primary CD40L-sBc and
secondary bead restimulation had 93% similarity in TCRb
usage (Figure 4B). These results suggest that polyclonal
restimulation did not appreciably alter the arTreg repertoire.
Last, Tregs isolated from the same individual expanded
using two distinct allogeneic CD40L-sBc have very little
overlap in their TCR repertoires (Figure 4C), demonstrating
alloantigen selective Treg expansion and effective deple-
tion of nonreactive cells using this protocol.
Tregs expanded with this protocol are on average >95%
viable and CD3þCD4þ with minimal contamination with
CD8þ T cells and CD19þB cells (Figure 5A and Table 2). The
majority of the CD4þ T cells were FOXP3þHELIOSþ and co-
expressed CD27 and CD62L (Figure 5B and Table 2),
distinct from the pattern expressed by similarly expanded
Tconv cells (Figure 5B). Themajority of the expanded Tregs
had demethylated TSDR (Figure 5C, Table 2) and did not
produce IFNg after TCR or mitogenic stimulations (Figure
5D). These results suggested that arTreg were stable and
the ex vivo expansion did not lead to increase IFNg
expression as we previously reported (22). To determine
the reactivity of the expanded Tregs,we restimulated Tregs
harvested on day 16with CD40L-sBc from the same donor.
On average 87.5% (range 72.5–95.2%) of the alloantigen
expanded Tregs proliferated in response to restimulation by
the same sBc, similar to the proliferation induced using anti-
CD3/CD28 beads (average 88.8%, range 73.6–96%),
demonstrating that the vast majority of the Tregs were
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Figure 2: Generation of CD40L-sBc using K-CD40L cells. (A) The expansion of purified B cells in the 10-day culture is shown. The arrow
indicates the time of restimulation. (B and C) Expression of HLA-DR, CD80, and CD86 in freshly isolated B cells and day 10 CD40L-sBc was
compared using flow cytometry. Sample overlay histograms are shown in (B), and charts summarizing results from independent
experiments are shown in (C). The data are summary of six independent experiments. CD40L-sBc, CD40L-stimulated B cells; K-CD40L,
CD40L-expressing cell line; KT64.CD40L.HLADR0401; MFI, mean fluorescence intensity.
Clinical Grade Alloantigen-Reactive Tregs
3013American Journal of Transplantation 2013; 13: 3010–3020






























M vs I p=0.25



















































































































Figure 3: Selective expansion of arTregs usingCD40L-sBc. (A) Allogeneic sBcwere used to stimulate FACSpurified Tregs on days 0 and
9. Fold expansion of Treg in the 14-day culture in six independent experiments is shown. The arrow indicates the time of restimulation. (B)
Tregs were stimulated with CD40L-sBc for 9 days and then the cultures were split with half restimulated with CD40L-sBc from the same
donor and the other half with anti-CD3 and anti-CD28-coated beads. Fold expansion on day 14 of three independent paired cultures is shown
(p¼0.75, Wilcoxon matched-pairs signed rank test). (C) Alloreactivity of expanded Tregs was determined by labeling the expanded Tregs
with CFSE before restimulationwith the sameCD40L-sBc used for expansion (thick line), anti-CD3 and anti-CD28-coated beads (thin line) or
syngeneic CD40L-sBc (shaded histogram). (D and E) Appearances of Treg cultures on days 9 (D) and 11 (E) after primary stimulation are
shown. Data represent results from at least 10 independent cultures. (F) Tregs were stimulated with CD40L-sBc for 9 or 11 days before
restimulation with anti-CD3 and anti-CD28-coated beads. The cultures were harvested 5 days after restimulation, and total fold expansions
in three paired cultureswere compared (p¼0.25,Wilcoxonmatched-pairs signed rank test). (G) Tregswere stimulatedwith CD40L-sBc for
11 days before restimulationwith anti-CD3 and anti-CD28-coated beads from Invitrogen (open symbols) orMiltenyi Biotec (closed symbols).
Cell expansions over time in three paired cultures are shown.Wilcoxonmatched-pairs signed rank test was used to compare the difference
in total fold expansion on day 16 (p¼0.25). (H) XY scatterplots showing a correlation of arTreg expansion and mean fluorescence intensity
(MFI) of HLA-DR, CD80 and CD86 expressed on different CD40L-sBc preparations. The data are a summary of 11 independent arTreg
cultures. arTregs, arTreg, alloantigen-reactive Tregs; CD40L-sBc, CD40L-stimulated B cells; CFSE, carboxyfluorescein succinimidyl ester;
FACS, fluorescence activated cell sorting; Tregs, regulatory T cells.
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reactive to the alloantigens expressed by the CD40L-sBc
(Figure 5E and F).
Consistent with the phenotype and the enhanced alloanti-
gen recognition, the expanded arTregs were highly
suppressive when activated in vitro by PBMCs from the
same donor as the CD40L-sBc (Figure 5G). arTregs were 5-
to 25-fold more potent at suppressing MLR than PolyTregs
(Figure 5G), consistent with previous reports of 5- to 32-fold
increase in potency by alloreactive Tregs (12,14,28–30).
arTreg expanded by restimulation with CD40L-sBc or anti-
CD3/CD28 beads had identical suppressive activity (Figure
5G), demonstrating that polyclonal restimulation did not
alter their alloreactivity or suppressive activity in vitro. In
addition, arTregs were 9–27 times more suppressive when
stimulated by the relevant PBMC than when stimulated by
third-party cells (Figure 5H). Together, our results show that
CD40L-sBc expanded Tregs had enriched reactivity and
suppressive activity toward the alloantigens expressed by
the B cells used for their expansion.
arTregs are superior at protecting skin allografts
in vivo
Using our recently described model of alloimmune-
mediated injury of human skin allografts (12), we compared
the potency of arTregs and PolyTregs. BALB/c.Rag2!/!
gc!/! mice were transplanted with human skin from a
HLA-DR0401þ donor before adoptive transfer of allogeneic
PBMCdepleted of CD25þ cells alone or in combinationwith
different preparations of syngeneic Tregs at a ratio 5:1
effector cells/Treg. PBMC donors were HLA-DR0401! and
arTregs from these donors were expanded using HLA-
DR0401þCD40L-sBc. Graftsweremonitored until rejection
or until 6 weeks after PBMC reconstitutionwhen theywere
collected for histological analysis. Levels of human leuko-
cyte engraftment in spleens were similar in mice that
received PBMCs alone or in combinationwith Tregs (Figure
6A). For the duration of these experiments, all mice
maintained stable body weight, suggesting a lack of
GvHD (Figure 6B), consistent with our previous report of
this model (31).
Table 1: TCR repertoire analysis of Tregs using high-throughput TCR b chain sequencing
18 stim 28 stim n % Unique reads Frequency of top 10 clones (%) Clonality1
None None 5 10.23#5.39 1.77#0.96 0.037#0.007
Poly Poly 3 11.36#2.09 1.37#0.71 0.036#0.018
Allo None 2 5.87#1.45 6.41#2.09 0.122#0.016
Allo Allo 2 2.34#1.31 5.76#1.82 0.133#0.025
Allo Poly 4 3.12#1.39 6.86#2.27 0.127#0.027
1Clonality is a measurement of repertoire diversity calculated using an ImmunoSeq online analysis tool. The value is between 0 and 1.
Clonality of 0 indicates most diverse repertoire, and clonality of 1 indicates monoclonality. Tregs, regulatory T cells.





















































Figure 4: Treg TCR repertoire analyses using high-throughput TCR b chain sequencing. (A) An xy scatterplot was used to compare
TCR b chain usage by Tregs after primary CD40L-sBc (Allo) stimulation (x-axis) or after CD40L-sBc (Allo) stimulation and anti-CD3/28 bead
(Poly) restimulation (y-axis), showing 85% similarity between the two samples. Each circle represent one unique TCR b chain nucleotide
sequence, and data points on the x- and y-axis are present in one sample but absent in the other. The data represent results from two
independent experiments. (B) An xy scatterplot was used to compare TCR b chain usage by Tregs after primary CD40L-sBc stimulation and
anti-CD3/CD28 bead restimulations (x-axis) and after two rounds of alloantigen stimulations (y-axis) showing 93% similarity between the
two samples. The data represent results from two independent experiments. (C) Tregs purified from one donor was split into two equal
parts and subjected to primary stimulation with CD40L-sBc from two different allogeneic B cell donors (Allo and Third party) followed by
polyclonal restimulation. A comparison of TCR b chain usage by the two arTreg preparations showed 2% overlap. similarity CD40L-sBc,
CD40L-stimulated B cells; Treg, regulatory T cell.
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Compared to the skin grafts in no PBMC control animals
(Figure 6C), grafts in the PBMC alone group showed
intense human CD45þ mononuclear cell infiltrates with
concomitant increase in keratinocyte proliferation, loss of
involucrin and decreased vascularization as indicated by
the reduction in clustered CD31þ cells in the dermis
(Figure 6D). These changes revealed active inflammation
and loss of dermo-epidermal integrity mediated by the
allogeneic human leukocytes. All these inflammatory
parameters were reduced by co-injection of PolyTregs,
correlating with an increase in FOXP3þ cells (Figure 6E).
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completely protected from histological features of graft
injuries and were indistinguishable from those in control
grafts except for the infiltration of FOXP3þ cells (Figure 6F).
Quantitative analysis of histological findings demonstrated
significant reduction in Ki67þ keratinocytes and an increase
in CD31þ cell clusters, correlating with significantly higher
FOXP3þ to CD3þ cell ratio in grafts of arTreg-treated mice
when comparedwith the PolyTreg group (Figure 6G). These
results suggest improved efficacy of arTregs in protecting
allografts in vivo.
Discussion
Producing sufficient Tregs during ex vivo expansion has
been a major challenge in applying Treg therapy to humans
(13). By stimulating highly purified Tregs with potently
antigenic CD40L-sBc, we were able to achieve 100- to
1600-fold expansion in 16 days. The expanded Tregs had
diverse TCR repertoire; retained Treg-specific phenotype
were enriched for alloantigen reactivity, and were more
potent at suppressing alloimmune responses in vitro and in
vivo when compared to expanded PolyTregs. Critical
parameters that contributed to the success of this protocol
were the purity of the Tregs at the beginning of the culture,
the potency of the CD40L-sBc and the conditions of
restimulation.
Na€ıve B cells failed to induce expansion of Tregs without
the addition of anti-CD28 agonist antibodies (30), consistent
with the notion that Treg expansion depends on costimu-
lation through CD28 (32). We found that stimulating B cells
with CD40L induced nearly 20-fold increase of CD80 and
CD86 expression, whichmay underlie their potency as Treg
stimulators. One advantage of using B cells is their relative
abundance and ease of expansion when compared to
dendritic cells. In the setting of living donor transplant, we
estimate that 100mL of peripheral blood from an organ
donor would generate enough CD40L-sBc to expand
5" 106 Tregs purified from 1U of blood, which could yield
1 billion arTregs after 200-fold expansion. For deceased
donor transplant, donor spleen can be used as a source of
CD40L-sBc without prior purification of B cells because
their high abundance (data not shown). Our results
demonstrate that it is feasible to mass produce highly
pure and potent arTregs using GMP-compliant reagents in
short-term cultures. Previous reports show Tregs can be
expanded from uremic pretransplant patients (33,34).
Current efforts are focused on applying this protocol to
expand Tregs isolated from pretransplant patient with end-
stage organ diseases to enable two planned phase I trials in
liver and kidney transplantations. We believe that efficacy
of Treg therapy in transplantation depends on the number
and quality of Treg products in addition to the timing of Treg
infusion and adjunct immunosuppression (5,13).
Table 2: Phenotype of expanded arTregs
CD3þ CD4þ FOXP3þ TSDR HELIOSþ CD62Lþ CD27þ CD8þ CD19þ
Mean 97.1 97.1 83.0 94.0 88.2 85.4 0.5 0.2
SD 2.6 1.9 10.8 15.5 6.6 6.4 0.2 0.2
N 14 14 14 10 14 10 14 14
arTregs, arTreg, alloantigen-reactive Tregs; TSDR, Treg-specific demethylated region.
Figure 5: Phenotype, alloantigen reactivity, and in vitro function of Tregs expanded with CD40L-sBc. (A and B) Flow cytometric
profiles of ungated (A) and CD4 gated (B) Treg cultures. Data are representative of at least 14 independent experiments. (C) Correlation
between percentages of demethylated TSDR and FOXP3 from 11 independent cultures. (D) IFNg expression by arTregs after 4 h in vitro
stimulation as indicated. (E) Alloreactivity of Tregs expandedwith primary allogeneic sBc stimulation and polyclonal restimulation on day 11
was determined as described in Figure 3B. An example of overlay histogram is shown. (F) A summary of seven independent cultures
analyzed as described in (C) is shown. Each symbol represents one independent Treg culture. (G) A summary of in vitro suppression by Tregs
expanded with two rounds of stimulation with allogeneic CD40L-sBc (closed circles, Allo-a, n¼3), allogeneic sBc primary stimulation
followed by polyclonal restimulation (open circles, Allo-p, n¼8), or two rounds of polyclonal stimulations (open squares, Poly, n¼5) is
shown. Responders are PBMC from the Treg donor, and stimulators are PBMC from the sBc donor. Data shown are mean$SEM
suppression observed in three to eight independent experiments. Two-way analysis of variance (ANOVA) with Bonferroni multiple
comparison test was used to determine the statistical significance of the differences. Suppression at 1:5 ratio by different groups of Tregs is
not significantly different. Suppression by PolyTregs is significantly lower when compared to Allo-a Tregs (p<0.001 at 1:25 ratio and
p<0.01 at 1:125 ratio), or when compared to Allo-p Tregs (p<0.0001 at 1:25 ratio and p<0.001 at 1:125 ratio). Allo-a and Allo-p Tregs are
not significantly different from each other at all ratios. (H) Suppression by CD40L-sBc expanded Tregs stimulated by PBMC from the sBc
donors (closed circles) or third-party donors (open triangles) is shown. Data shown are mean$SEM suppression observed in six
independent experiments. Two-way ANOVAwith Bonferroni multiple comparison test was used to determine the statistical significance of
the differences. Suppression at 1:1 and 1:3 ratios stimulated by sBc and third-party donors is not significantly different. Suppression
stimulated by sBc donor at 1:9 and 1:27 ratios is significantly lowerwhen compared to that stimulated by third-party donors (p<0.001 at 1:9
ratio and p<0.001 at 1:27 ratio). arTregs, arTreg, alloantigen-reactive Tregs; CD40L-sBc, CD40L-stimulated B cells; CFSE,
carboxyfluorescein succinimidyl ester; INFg, interferon gamma; PBMC, peripheral blood mononuclear cells; PolyTregs, polyclonally
expanded Tregs; Tconv, conventional CD4þ T cells; Tregs, regulatory T cells; TSDR, Treg-specific demethylated region.
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Figure 6: Suppression of skin allograft injury by PolyTregs and arTregs in vivo in a humanizedmousemodel.BALB/c.Rag2!/!gc!/!
mice were transplanted with human skin and reconstituted with PBMC allogeneic to the skin donor. (A) PBMC reconstitution was
determined at the end of the experiment, demonstrating that co-infusion of Tregs did not significantly alter the extent of PBMC
reconstitution. (B) Body weight of the BALB/c.Rag2!/!gc!/! mice in four experimental groups was assessed to determine general health
status, demonstrating that PBMC infusion did not induceGvHD. (C–F) Skin graft injurywas assessedusing three-color immunofluorescence
microscopy and representative results are shown. (G) Immunofluorescence micrograph imageswere analyzed by counting four to six high-
powered visual fields per stain for each graft. Quantitative results from four experimental groupswere then compared. One-way analysis of
variance with Kruskal–Wallis test and Dunn’s multiple comparison posttest was used to determine the statistical significance of the
differences ("p<0.05, ""p<0.01, """p<0.001). arTregs, arTreg, alloantigen-reactive Tregs; GvHD, graft-versus-host disease; PBMC,
peripheral blood mononuclear cells; PolyTregs, polyclonally expanded Tregs; Tregs, regulatory T cells.
3018 American Journal of Transplantation 2013; 13: 3010–3020
Putnam et al
Acknowledgments
This studywas supported by research funds from the Nicholas Family, UCSF
Department of Surgery, JDRF, UCSF CTSI, NIH (R34 AI095135,
P30DK063720) and British Heart Foundation, UK. MW was a recipient of
a Genentech Graduate Student Fellowship, NS is the recipient of a Clinical
Research Fellowship from the Medical Research Council (MRC). The
research was also funded by the National Institute for Health Research
(NIHR), Biomedical Research Centre based at Guy’s, St Thomas’ NHS
Foundation Trust, and King’s College London. The views expressed are
those of the author(s) and not necessarily those of the NHS, the NIHR or the
Department of Health. The authors acknowledge the support of the MRC
Centre for Transplantation.
Authorship Contributions
ALP, NS, AM, ML, MW, GLS, ET, MAM, WL, A Lares, KL,
and A Laing performed experiments and analyzed data. RIL,
JLR and JAB provided critical advice and review of the
studies. QT and GL directed the research and wrote the
manuscript together with ALP and NS.
Disclosure
The authors of this manuscript have conflicts of interests to
disclose as described by the American Journal of Trans-
plantation. JAB and QT are co-inventors on two patents on
regulatory T cell therapy. JAB has received reagents and
equipment from BD Biosciences in support of developing
regulatory T cell therapy.
References
1. Sakaguchi S. Naturally arising Foxp3-expressing CD25þCD4þ
regulatory T cells in immunological tolerance to self and non-self.
Nat Immunol 2005; 6: 345–352.
2. Wood KJ, Sakaguchi S. Regulatory T cells in transplantation
tolerance. Nat Rev Immunol 2003; 3: 199–210.
3. Walsh PT, Taylor DK, Turka LA. Tregs and transplantation
tolerance. J Clin Invest 2004; 114: 1398–1403.
4. Waldmann H, Adams E, Cobbold S. Reprogramming the immune
system: Co-receptor blockade as a paradigm for harnessing
tolerance mechanisms. Immunol Rev 2008; 223: 361–370.
5. Tang Q, Bluestone JA, Kang SM. CD4(þ)Foxp3(þ) regulatory T cell
therapy in transplantation. J Mol Cell Biol 2011; 4: 11–21.
6. Trzonkowski P, Bieniaszewska M, Juscinska J, et al. First-in-man
clinical results of the treatment of patients with graft versus host
disease with human ex vivo expanded CD4þCD25þCD127" T
regulatory cells. Clin Immunol 2009; 133: 22–26.
7. Brunstein CG, Miller JS, Cao Q, et al. Infusion of ex vivo
expanded T regulatory cells in adults transplanted with umbilical
cord blood: Safety profile and detection kinetics. Blood 2010; 117:
1061–1070.
8. Di Ianni M, Falzetti F, Carotti A, et al. Tregs prevent GVHD and
promote immune reconstitution in HLA-haploidentical transplan-
tation. Blood 2011; 117: 3921–3928.
9. Marek-Trzonkowska N, Mysliwiec M, Dobyszuk A, et al. Adminis-
tration of CD4þCD25highCD127" regulatory T cells preserves
beta-cell function in type 1 diabetes in children. Diabetes Care
2012; 35: 1817–1820.
10. Sanchez-Fueyo A, Sandner S, Habicht A, et al. Specificity of
CD4þCD25þ regulatory T cell function in alloimmunity. J Immunol
2006; 176: 329–334.
11. Tsang JY, Tanriver Y, Jiang S, et al. Conferring indirect
allospecificity on CD4þCD25þ Tregs by TCR gene transfer favors
transplantation tolerance in mice. J Clin Invest 2008; 118: 3619–
3628.
12. Sagoo P, Ali N, Garg G, Nestle FO, Lechler RI, Lombardi G. Human
regulatory T cells with alloantigen specificity are more potent
inhibitors of alloimmune skin graft damage than polyclonal
regulatory T cells. Sci Transl Med 2011; 3: 83ra42.
13. Tang Q, Lee K. Regulatory T-cell therapy for transplantation: How
many cells do we need? Curr Opin Organ Transplant 2012; 17:
349–354.
14. Peters JH, Hilbrands LB, Koenen HJ, Joosten I. Ex vivo generation
of human alloantigen-specific regulatory T cells from CD4(pos)
CD25(high) T cells for immunotherapy. PLoS ONE 2008; 3: e2233.
15. Koenen HJ, Fasse E, Joosten I. CD27/CFSE-based ex vivo
selection of highly suppressive alloantigen-specific human regula-
tory T cells. J Immunol 2005; 174: 7573–7583.
16. Banerjee DK, Dhodapkar MV, Matayeva E, Steinman RM,
Dhodapkar KM. Expansion of FOXP3high regulatory T cells by
human dendritic cells (DCs) in vitro and after injection of cytokine-
matured DCs in myeloma patients. Blood 2006; 108: 2655–2661.
17. Putnam AL, Brusko TM, Lee MR, et al. Expansion of human
regulatory T-cells from patients with type 1 diabetes. Diabetes
2009; 58: 652–662.
18. Novak EJ, Liu AW, NepomGT, KwokWW.MHC class II tetramers
identify peptide-specific human CD4(þ) T cells proliferating in
response to influenza A antigen. J Clin Invest 1999; 104: R63–
R67.
19. Parry RV, Rumbley CA, Vandenberghe LH, June CH, Riley JL.
CD28 and inducible costimulatory protein Src homology 2 binding
domains show distinct regulation of phosphatidylinositol 3-kinase,
Bcl-xL, and IL-2 expression in primary human CD4 T lymphocytes.
J Immunol 2003; 171: 166–174.
20. Suhoski MM, Golovina TN, Aqui NA, et al. Engineering artificial
antigen-presenting cells to express a diverse array of co-
stimulatory molecules. Mol Ther 2007; 15: 981–988.
21. ZandMS, Bose A, Vo T, et al. A renewable source of donor cells for
repetitivemonitoring of T- and B-cell alloreactivity. Am J Transplant
2005; 5: 76–86.
22. McClymont SA, Putnam AL, Lee MR, et al. Plasticity of human
regulatory T cells in healthy subjects and patients with type 1
diabetes. J Immunol 2010; 186: 3918–3926.
23. Wieczorek G, Asemissen A, Model F, et al. Quantitative DNA
methylation analysis of FOXP3 as a new method for counting
regulatory T cells in peripheral blood and solid tissue. Cancer Res
2009; 69: 599–608.
24. Ye Q, Loisiou M, Levine BL, et al. Engineered artificial antigen
presenting cells facilitate direct and efficient expansion of tumor
infiltrating lymphocytes. J Transl Med 2011; 9: 131.
25. Butler MO, Friedlander P, Milstein MI, et al. Establishment of
antitumor memory in humans using in vitro-educated CD8þ T
cells. Sci Transl Med 2011; 3: 80ra34.
26. Smith BD, Kasamon YL, Kowalski J, et al. K562/GM-CSF
immunotherapy reduces tumor burden in chronic myeloid leuke-
mia patients with residual disease on imatinib mesylate. Clin
Cancer Res 2010; 16: 338–347.
27. Borrello IM, Levitsky HI, Stock W, et al. Granulocyte-
macrophage colony-stimulating factor (GM-CSF)-secreting cellular
Clinical Grade Alloantigen-Reactive Tregs
3019American Journal of Transplantation 2013; 13: 3010–3020
immunotherapy in combination with autologous stem cell
transplantation (ASCT) as postremission therapy for acute myeloid
leukemia (AML). Blood 2009; 114: 1736–1745.
28. Veerapathran A, Pidala J, Beato F, Yu XZ, Anasetti C. Ex vivo
expansion of human Tregs specific for alloantigens presented
directly or indirectly. Blood 2011; 118: 5671–5680.
29. Tran GT, Hodgkinson SJ, Carter NM, et al. Interleukin-5
(IL-5) promotes induction of antigen specific CD4þCD25þ
T regulatory cells that suppress autoimmunity. Blood 2012; 119:
4441–4450.
30. Chen LC, Delgado JC, Jensen PE, Chen X. Direct expansion of
human allospecific FoxP3þCD4þ regulatory T cells with allogeneic
B cells for therapeutic application. J Immunol 2009; 183: 4094–
4102.
31. Ali N, Flutter B, Sanchez Rodriguez R, et al. Xenogeneic graft-
versus-host-disease in NOD-scid IL-2Rgammanull mice display a
T-effector memory phenotype. PLoS ONE 2012; 7: e44219.
32. Golovina TN, Mikheeva T, Suhoski MM, et al. CD28 costimulation
is essential for human T regulatory expansion and function. J
Immunol 2008; 181: 2855–2868.
33. Berglund D, Korsgren O, Lorant T, Schneider K, Tufveson G,
Carlsson B. Isolation, expansion and functional assessment of
CD4þCD25þFoxP3þ regulatory T cells and Tr1 cells from uremic
patients awaiting kidney transplantation. Transpl Immunol 2012;
26: 27–33.
34. Berglund D, Karlsson M, Biglarnia AR, et al. Obtaining regulatory T
cells from uraemic patients awaiting kidney transplantation for use
in clinical trials. Clin Exp Immunol 2013; 173: 310–322.
Putnam et al






















6.1 SUMMARY OF DATA PRESENTED 
 
This thesis has focused on the study of Treg immunotherapy in patients with end stage 
liver disease, awaiting transplantation. In the UK, ALD is the primary indication for 
liver transplantation (data from NHS Blood and Transplant Services) and as a result 
patients with cirrhosis secondary to alcohol (ARC) defined the majority of patients 
enrolled in this study. 
Research in the field of transplantation has focused on effective ways by which to 
induce tolerance, thereby allowing for the reduction or withdrawal of toxic, non-
specific immunosuppressants, currently being used in clinical practice. Whilst there 
have been many strategies aimed at tolerance induction, cellular therapy with Tregs 
holds great promise. 
 
The initial aim of this thesis was to characterise Tregs from patients with ARC. 
However, prior to the ex vivo expansion of these cells it was noted that patients with 
ARC have defects in Treg suppressor function. This novel finding stirred great 
interest and a programme of work directed as to delineate the mechanism behind this 
defect, also of importance when considering the clinical translation of these cells.  
 
In this pursuit, cells were subject to an in-depth phenotypic characterization and, in 
view of studies highlighting the significance of oxidative stress in the development of 
liver cirrhosis, pathways known to be important in the maintenance of oxidant 
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homeostasis were also studied. The hypothesis being that dysfunction in the 
antioxidant pathway correlates with the severity of liver disease in cirrhosis. 
In this regard, the role of HO-1 was investigated with data showing that freshly 
isolated Tregs from patients with ARC had lower expression of HO-1 as compared to 
age and sex matched HCs.  
 
This thesis also reports the successful GMP compatible isolation and expansion of 
autologous Tregs from patients with ARC for cell therapy application. In parallel, 
with the support of the data presented in this thesis, the clinical trial of Treg therapy in 
liver transplantation, ThRIL, has recently commenced at Guy’s Hospital.  
Of significance, the rapamycin-based GMP expansion protocol, used in chapter 4, 
promoted an increase in Treg suppressive function by final harvest, thus guaranteeing 
that the final product satisfied the set release criteria, essential for the clinical 
application of these cells in the setting of the ThRIL trial. Interestingly, when 
correlating HO-1 levels post expansion with Treg suppressive function it was revealed 
that at final harvest Tregs expressed higher levels of HO-1. Thus, the baseline 
deficiency of HO-1 expression in Tregs from ARC patients was considered to 
partially explain their defective suppressor function. This was further supported by 
data which demonstrated that competitive inhibition of the HO-1 enzyme in HC Tregs 
decreased their suppressive function. These findings are of relevance not only in 
defining a mechanism for the Treg defect seen in ARC, but also in aiding the overall 




Moreover, an in-depth phenotypic characterisation of freshly isolated Tregs from 
patients saw an increased frequency of CD161+ Tregs with a decrease in Tregs, 
expressing CTLA-4 as compared to Tregs from healthy controls. In addition, post 
exposure of freshly isolated Tregs from patients to a Th17 skewing environment an 
increase in IL17+FOXP3+ cells was evident. However, in chapter 4, ex vivo expansion 
of Tregs in the presence of rapamycin saw a decrease in the frequency of CD161+ 
Tregs. In line with these findings, culture of Tregs by final harvest in the presence of a 
pro-inflammatory milieu saw a decrease in IL-17+FOXP3+ Tregs with diminished 
levels of IL-17 production by Tregs.  
 
Lastly, I provide evidence detailing the relative merits of Tregs generated with direct 
allospecificity, with regards to their potency, as compared to polyclonal Tregs (when 
injected in equal numbers) in the prevention of alloimmune mediated skin damage in 
a humanized mouse model of skin transplantation.  
 
In view of Treg immunotherapy in the context of liver transplantation, the next few 
years will see the results from the ThRIL trial and in parallel, the clinical trial of 
antigen specific Tregs generated in accordance with the protocol outlined in chapter 5, 
initiated at UCSF (NCT02188719). Based on my preliminary data detailing that an 
initial highly pure population of Tregs is required for the generation of antigen 
specific Tregs, it is important to note that for the ThRIL trial, since GMP compliant 
sorting technology is not currently available in the UK, the application of antigen 
specific Tregs is not possible. However, data on the safety and potential efficacy of 
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polyclonally expanded Tregs (Chapter 4) and antigen specific Tregs (chapter 5) in the 
setting of liver transplantation will be compared between the two trials.  
Of note, in the past, considerable effort has been focused on defining an optimal 
technique to isolate and expand Tregs from peripheral or cord blood. The data 
provided in this thesis has shown that expansion of therapeutically relevant numbers 
of polyclonal or alloantigen specific Tregs is feasible. While the data here is 
extremely encouraging, there are still many questions yet to be answered. In section 
6.2 some of these key issues have been addressed.  
 
6.2 CHALLENGES AND FUTURE DIRECTIONS OF REGULATORY T CELL 
IMMUNOTHERAPY 
 
The clinical trials of Treg cell therapy initiated in the setting of liver transplantation 
will report primarily on the safety of the injected cells but will also speculate on their 
relative therapeutic efficacy, with aims of progressing to larger phase II/III studies in 
the near future. The success of such trials and the outlook of Treg therapy as an 
entirety will be defined from effective and informative clinical trial designs with 
adherence to hard efficacy end points. Thus, key issues will need to be addressed prior 
to the design of such trials including: adjunct immunosuppressive regimens, the 
timing and number of injections, the dose of Tregs with the desired specificity and the 





6.2.1. ADJUNCT IMMUNOSUPPRESSION AND TIMING OF REGULATORY T CELL 
ADMINISTRATION (
Despite the initial confidence in adoptive Treg cell therapy as a self-sufficient entity, 
experimental data has shown that Tregs alone are inadequate in protecting a major 
MHC-mismatched graft from rejection in a normal, otherwise untreated host.(Wells et 
al. 1999, Xia et al. 2008). As such adjunct immunosuppressive therapy is needed to 
create a therapeutic window in which Tregs stand the best chance of inducing 
tolerance.  Moreover, it is now clear that Tregs contribute little, if at all, to direct 
pathway hyporesponsiveness and, as discussed in chapter 1, it is in fact the indirect 
pathway of allorecognition used by Tregs for immunoregulation. Thus, drugs that 
induce a significant reduction in donor-reactive CD4+ and CD8+ T cells, especially 
those with direct specificity, are likely essential prerequisites for Tregs to induce and 
maintain graft tolerance (Wells et al. 1999, Xia et al. 2008).  
 
In the clinical setting, most transplant recipients are treated with a combination of 
immunosuppressive drugs and biological agents to control rejection and/or GvHD 
responses. Immunosuppressive regimens vary, dependant on the organ being 
transplanted as well as the individual protocols followed at respective transplant 
centres. However, bearing in mind the nature of pharmacological immunosuppression 
it is not surprising that some of these immunosuppressive drugs also antagonise Treg 
function and survival. At the same time, a select few immunosuppressants have been 
shown to preserve Treg survival (Demirkiran et al. 2009, Boenisch et al. 2012, Satake 
et al. 2014), thus, the careful complement of adjunct immunosuppression is of utmost 
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importance, ensuring the selection of a ‘Treg supportive immunosuppressive regimen’ 
to be used alongside adoptive Treg cellular therapy.  
In some countries immunosuppressive induction therapy is preferentially conducted 
with a monoclonal or polyclonal antibody preparation such as alemtuzumab or ATG 
at the time of transplantation. This treatment markedly depletes most of the leukocyte 
populations in the peripheral blood. Interestingly, this rather non-specific eradication 
of leukocytes has the potential to tip the balance in favour of immune regulation by 
creating a situation whereby regulatory immune cells outnumber the effector cells.   
Taking the example of ATG, data indicates that in both adults and children, ATG 
causes a rapid decrease in naïve CD4+ and CD8+ T cells which usually persist for at 
least two months (Gurkan et al. 2010). In addition, it has been shown that treatment 
with ATG is associated with the expansion of FOXP3+ T cells in vivo endorsing a 
shift in the Treg to Teffector ratio. Despite this, memory CD4+ and CD8+ cells are 
resistant to depletion by ATG and these cell subsets expand over the initial 6 months 
post transplantation (Gurkan et al. 2010). The fact that memory cells survive deletion 
may explain why patients do not suffer from opportunistic infections post ATG 
therapy. However, these cells can contribute to early graft injury/loss and, of 
significance, these cells are more resistant to the suppressive capabilities of Tregs in 
comparison to naïve T cells (Yang et al. 2007, Afzali et al. 2011). However, to limit 
memory T cell expansion (post induction therapy), transplant recipients are 
maintained on other immunosuppressive drugs, most commonly calcineurin inhibitors 
(CNI), such as tacrolimus or cyclosporine A. It is well documented that CNIs inhibit 
the generation and function of Tregs (Segundo et al. 2006, Li et al. 2011). Despite 
this, animal models, in the context of autoimmunity, have concluded that in order for 
Tregs to exert their suppressive function, tissue inflammation needs to be controlled 
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(Korn et al. 2007) and for Tregs to expand in vivo and exert their suppressive 
function, they require a tolerogenic milieu. In support of this, a recent study analysing 
the dynamics of the alloimmune response in vivo demonstrated that in the absence of 
immunosuppression a rapid invasion of effector cells in the grafts was followed by the 
delayed arrival of Tregs, which were ineffective at controlling tissue damage (Fan et 
al. 2010). In contrast, when the recipient mice were treated with anti-CD40L mAb and 
rapamycin, effector T cell infiltration was delayed and over 30% of the graft 
infiltrating T cells were Tregs.  
Of note, there is good evidence in the literature indicating that rapamycin is superior 
to tacrolimus for the thymic export and survival of Tregs (Baan et al. 2005, Gao et al. 
2007). As such this may suggest that rapamycin is the ideal candidate for short-term 
therapy post depletion in humans. However, in renal transplantation, rapamycin 
monotherapy post depletion has been associated with a high risk of acute rejection 
(Knechtle et al. 2003). Moreover, it is not yet clear whether its concomitant therapy 
with Tregs would be sufficient to prevent this or whether further immunosuppression 
will be required in the short term.   
 The use of combinations of immunosuppressive agents in the clinical setting 
highlight the challenge associated with designing protocols that include the infusion 
of Tregs. Thus the competing actions of each immunosuppressive drug may have to 
be considered together with the key question of the timing of cell injection.  
 
Most of the preclinical Treg therapy studies published to date have administered 
Tregs prior to or at the time of transplantation, in contrast to studies of autoimmune 
disease where it has been shown that Treg therapy after disease initiation can 
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effectively reverse the disease course (Tang and Bluestone 2006). The intensity of the 
anti-allograft response and the fragility of the transplanted organ may explain the lack 
of efficacy when Treg infusion is delayed. One caveat to this, however, is in the 
setting of liver transplantation, where it is speculated that tolerance may be achieved 
relatively easier because of the inherent resilience and regenerative ability of the liver 
graft to withstand immune attack. In this regard, histological analysis of the grafts in 
mouse models that spontaneously tolerated allogeneic liver grafts, showed clear 
evidence of initial damage, which however, resolved after 2 weeks as the immune 
response waned (Bluestone, unpublished data). As such, in the setting of liver 
transplantation, there is more flexibility in view of timing of injection. 
Another point of consideration, regarding the timing of injection, is the differential 
use of T cell depleting reagents, such as ATG. In this regard it may also be possible to 
delay Treg infusion until lymphocyte numbers start to recover two months or more 
after transplantation. This might tip the balance between Tregs and Teff cells and help 
promote a tolerant state.  
Delaying the administration of Tregs has its own advantages in view of the 
implementation in the clinical setting, particularly if prior expansion of donor specific 










6.2.2. LOCATION OF REGULATORY T CELL FUNCTION AND SITE OF 
REGULATORY T CELL INJECTION 
 
An additional consideration regarding Treg therapy is the required site of action of 
Tregs and, consequently, their relative homing properties. In the transplant setting, 
Treg lymph node homing and their ability to traffic to grafts are both required for 
their protection against graft rejection (Ochando et al. 2005). Interestingly, in a mouse 
islet transplant model, it has been shown that therapeutically, Tregs function initially 
at the graft site (preventing the exit of donor-derived DCs), and then traffic to the 
draining lymph node and continue to exert their suppressive function there (Zhang et 
al. 2009). In so doing they prevent the exit and migration of donor derived DCs to the 
lymph nodes, thereby reducing alloimmune priming. The translation of such a study 
to the clinic may mean that to ensure that Tregs exert their suppressive function we 
need to either inject the cells at the graft site or ensure that the cells reach the 
graft/lymph node either due to their alloantigen specificity or homing receptor 
expression. Bearing in mind the serious and potentially fatal complications associated 
with injection of the cells directly at the graft site, i.e. risk of bleeding if cells are 
injected via the portal vein in the case of liver transplantation, the preferred route of 
administration is via a peripheral vein. 
 
There is a wealth of reports, together with the data presented in Chapter 5 that donor-
specific Tregs are more effective in controlling graft rejection in preclinical models 
than non-specific Tregs (Trenado et al. 2003, Golshayan et al. 2007, Tsang et al. 
2008, Nadig et al. 2010, Sagoo et al. 2011). Moreover, Tregs with direct specificity 
are known to be more potent in preventing acute rejection early after transplantation, 
Chapter(6:(General(Discussion(
 184 
whilst Tregs with indirect specificity seem to be crucial to prevent chronic rejection 
(Golshayan et al. 2007, Joffre et al. 2008). As discussed earlier, using antigen specific 
Tregs in the setting of transplantation has additional advantages in view of offering 
targeted therapy instead of indiscriminate regulation. 
 
To-date, the generation and expansion of alloantigen specific Tregs has proved to be 
an arduous task. However, more recently there have been advances in the propagation 
of Tregs with direct allospecificity (Chen et al. 2009, Feng et al. 2011, Sagoo et al. 
2011), with the protocol presented in Chapter 5, providing further data in this regard. 
However, given the experimental evidence detailing the synergy of direct and indirect 
Tregs in the setting of transplantation tolerance, considerable efforts have been 
concentrated on generating and expanding Tregs with indirect allospecificity to 
further assist in this endeavour (Jiang et al. 2003, Veerapathran et al. 2011). In 
contrast to the definitive selective expansion of indirect Tregs from the existing 
repertoire, studies have contended with the possibility of pressuring the expression of 
TCRs with indirect alloreactivity during expansion of direct alloreactive Tregs so as 
to generate Tregs with dual specificity, with promising results (Tsang et al. 2008, 
Brusko et al. 2010).  
Contrary to the studies discussed, in GvHD the transfer of Tregs enriched for 
alloantigen-specificity showed only moderate improved efficacy when compared to a 
polyclonal Treg cell population (Trenado et al. 2003). In the same setting however, 
Ukena et al. showed that tolerant patients without GvHD, after haematopoietic stem 
cell (HSC) transplantation, expressed significantly higher levels of the chemokine 
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receptors, CCR5 and CXCR3 in Tregs as compared with patients with acute GvHD 
early after HSC transplantation (Ukena et al. 2011).  
Such studies, therefore highlight, that whilst Treg suppressive function is considered a 
priority, concurrent tissue trafficking of the cells is of equal importance to ensure 
contact with their target cells.  
Therefore, if the Tregs are to be injected via a peripheral vein then it is important that 
they express the molecules such as CD62L and CCR7 which are crucial for their 
migration to the lymph nodes and other chemokine receptors e.g. CXCR3 for liver 
homing (Oo et al. 2010). Moreover, Tregs vary in their expression of trafficking and 
homing receptors according to their individual histories and state of activation. They 
have been shown to variously express CCR2, CCR4, CCR7, CCR8, CCR9, CXCR1 
and CXCR4 [reviewed in (Ding et al. 2012)]. In addition, it is now known that within 
the pool of FOXP3 expressing cells, functionally diverse Treg subsets can be 
identified on the basis of chemokine receptor expression (Duhen et al. 2012). In view 
of the importance of Treg expression of chemokine receptor and trafficking on their in 
vivo suppression function, efforts have been made to date at understanding the 
influence of culture conditions on the expression pattern of these receptors on Tregs. 
In this regard, studies to date have shown that Treg migration can be predicted and 
engineered by tailored ex vivo expansion regimens. For example, rapamycin induces 
expression of CD62L, CCR4 and CLA on Tregs, favouring skin homing, whilst 
retinoic acid induces CCR9 and α4β7 that favour migration to the gut (Scotta et al. 
2013). This may have important implications for the broader application of Tregs in 




The studies reviewed in this section highlight the importance of antigen specificity 
and Treg homing receptor expression in the induction of transplant tolerance. With 
the impending certification of the GMP cell sorter here in the UK, therapeutic 
approaches in liver transplantation at generating antigen specific Tregs expressing the 
relevant homing receptor, CXCR3 will soon become a reality. The future will also see 
studies defining the trafficking patterns of infused Tregs in vivo. In this regard, in a 
recent clinical trial of Treg immunotherapy in Type I diabetes conducted at UCSF, 
Tregs were labelled with deuterium and their relative homing and survival period was 
recorded in vivo (Bluestone et al. unpublished data). In parallel, micro-PET computed 
tomography fusion has been used clinically to track infused T cells in the body and 
has further been refined to focus on distinct T cell populations, in particular Tregs 
(Ribas and Koya 2010). While these technologies are relatively new, the information 
gleaned from their inclusion in clinical trial protocols of Treg cell therapy will be 
invaluable, allowing for virtual visualisation of these cells in vivo.  
The future of cell therapy is also moving in such a way through cellular engineering, 
introducing concepts of traceable markers, tunable TCRs, chemotactic receptors to 
synthetic ligands and drug inducible suicidal enzymes (Lim 2010). These designer 
features would not only allow for the monitoring of infused Tregs, whilst also 
controlling their activities and trafficking patterns, but also for elimination if and 
when they become pathogenic (Sato et al. 2007, Guillot-Delost et al. 2008). 
Nonetheless, further advances in gene therapy would be required for these approaches 







6.2.3. DOSE OF REGULATORY T CELLS, NUMBER OF INJECTIONS AND 
MONITORING OUTCOMES 
 
Aside from the timing and site of injection what is also of paramount importance is to 
determine an efficacious dose for Treg cell therapy.  
As in the ThRIL trial, the first trials of Treg therapy in solid organ transplantation 
have started with a dose escalation study to assess the safety and tolerability of Tregs 
at various doses. It is anticipated that high Treg doses are needed for tolerance 
induction in view of preclinical studies in mouse models of transplantation where a 
high ratio of Tregs to Teffectors, in the order of 1:1-1:2, i.e. 33-50% of Tregs, is 
needed to prevent transplant rejection (Hara et al. 2001, Graca et al. 2002). Moreover, 
it has been suggested that, combined with ATG induction, a single infusion of 3-
5x109 Tregs can effectively increase Treg percentage to more than 33% (Tang and 
Lee 2012). One caveat being the use of or antigen-specific Tregs, where studies have 
shown that lower numbers are needed to achieve the same functional efficacy as 
larger numbers of polyclonal Tregs (Tang et al. 2004, Tarbell et al. 2004). 
Irrespectively, producing such large numbers of Tregs remains technically 
challenging, especially in view of studies showing a loss of FOXP3 expression after 
several rounds of stimulation. In this regard, more research is needed to understand 
Treg commitment and epigenetic regulation of FOXP3 expression so that the 
mechanisms can be harnessed to stabilise the Tregs. 
Another point of consideration is if a single injection of Tregs is sufficient or whether 
multiple injections are required. This may be determined in larger phase II efficacy 
studies, where patient outcomes should also be measured and an in-depth patient 
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monitoring system planned. In this regard, molecular diagnostic tools can be utilised 
to assess a broad panel of biomarkers, associated with operational tolerance, to serve 
as surrogate end-points of efficacy (Brouard et al. 2007, Martinez-Llordella et al. 
2008, Sagoo et al. 2010).  
In this regard, high-throughput, highly-sensitive flow cytometric analysis can also be 
used to determine if the number of Tregs in the peripheral blood of recipients have 
increased or relatively quantify the composition of the T cell compartment following 
the intervention (Hoffmann et al. 2012). Furthermore, the cytokine profile secretion 
capacity of these cells can be analysed and thus their plasticity evaluated. 
Investigations using the complementarity-determining region 3 (CDR3) length 
distribution analysis can be used to explore the diversity of the TCR, in view of 
studies suggesting that the TCR repertoire might be a good predictor of graft outcome. 
In this regard, it has been suggested that the majority of kidney transplant patients 
with chronic rejection have an accumulation of oligo or monoclonal Vβ expansions 
while operationally tolerant recipients have a TCR repertoire like that of healthy 
individuals (Miqueu et al. 2010).  
As such, a comprehensive immune monitoring plan of patients should be an integral 
part of a Treg therapy trial in order to gain mechanistic insight on the Treg function in 
patients. In addition, success in defining optimal ways of measuring tolerance would 
set the scene for subsequent trials in which accelerated drug minimisation is the 








6.2.4. STABILITY AND LONGEVITY OF THE INJECTED CELLS IN VIVO (
For Treg cellular therapy to be a viable therapeutic avenue, two key factors need to be 
addressed. The first being that, following injection, the Tregs are stable in the graft 
and draining lymph nodes, despite the inflammation present during transplantation, 
and secondly whether these cells are either long-lived or able to impart their tolerance 
to the host immune system.  
As the function of Tregs is highly dependent on the constitutively high expression of 
FOXP3 (Allan et al. 2007) many groups have sought to find ways to stabilise its 
expression. As discussed in chapter 1, epigenetic modification of the FOXP3 locus 
has a major role in controlling FOXP3 transcription, with demethylation of key 
regions correlated with suppressive function and lineage stability (Floess et al. 2007). 
In this regard, in vitro treatment with demethylating agents such as azacytidine have 
shown to promote the stability of FOXP3 expression in Tregs, resulting in the potent 
ability of these treated cells to protect from GvHD (Sanchez-Abarca et al. 2010). In 
addition, a recent phase I trial has shown that patients with acute myeloid leukaemia, 
treated with azacytidine immediately after allogeneic stem cell transplantation had a 
higher proportion of Tregs as compared time-matched controls (Goodyear et al. 
2012). 
FOXP3 levels are not only regulated through transcriptional control, but also through 
post-translational modifications. In the context of transplantation most work has 
focused on acetylation of lysine residues, which is known to stabilize the FOXP3 
protein (Kwon et al. 2012, Liu et al. 2012). It has been shown that inhibiting 
deacetylation with histone deacetylase (HDAC) inhibitors or genetically removing 
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Sirtuin-1, a histone and protein deacetylase, leads to an improvement in Treg function 
and stability, ultimately leading to improved allograft survival (Beier et al. 2011). 
Thus, future directions of adoptive Treg cell therapy will necessitate further 
understanding of factors that cause Tregs to lose FOXP3 expression and ways to 
stabilise its expression.  
 
The question of how long transferred Tregs survive in vivo is also of critical 
importance. It is understood that in order to establish long term dominant tolerance, 
adoptively transferred Tregs must either survive and expand in the recipient, or be 
able to induce a tolerogenic phenotype on other T cells, a process known as infectious 
tolerance (Kendal and Waldmann 2010). It has been shown that some subpopulation 
of Tregs, such as those producing soluble factors such as TGF-β (Andersson et al. 
2008), IL10 and IL35 (Chaturvedi et al. 2011) and the ongoing presence of recipient 
‘infected’ Tregs are required to prevent allograft rejection (Kendal et al. 2011, 
Gagliani et al. 2013). 
 
In the recent clinical trial of Treg therapy in hematopoietic stem cell transplantation, 
the transferred cells were no longer detected in the circulation after 2 weeks 
(Brunstein et al. 2011). Moreover, in the paediatric trial of Treg therapy in Type I 
diabetes, infusion of 30x106/kg polyclonally expanded Tregs resulted in doubling of 
the percentage of circulating Tregs and a trend of increase at 2 weeks (Marek-
Trzonkowska et al. 2014). In these trials it is not known whether the cells migrated to 
tissues or died. In this regard, my group have recently used single photon emission 
computed tomography to image adoptively transferred Tregs in mice and reported that 
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24 hours after intravenous injection, the cells were primarily localized in the spleen 
(Sharif-Paghaleh et al. 2011).  
Therefore, to maximize the efficacy of Treg therapy efforts will need to focus on 
finding ways to support the in vivo survival, engraftment and function of the infused 
Tregs. Since Tregs depend on exogenous IL-2 for survival, a suggested approach has 
been to use low dose IL-2, which lacks the toxicity and immunostimulatory effects of 
the higher IL-2 doses used to treat cancer patients (Boyman and Sprent 2012). This 
approach has recently shown to increase the number of Tregs in patients with chronic 
GvHD (Koreth et al. 2011), supporting the notion that low dose IL-2 may be an ideal 
adjuvant to adoptive Treg cell therapy, by promoting Treg expansion in an otherwise 
inflammatory setting. 
A final point to consider is how immunosuppression may affect the longevity and 
function of the transferred cells. As eluded to earlier, there is a general consensus that 
calcineurin targeted immunosuppression will be detrimental to Tregs (Segundo et al. 
2006, Zeiser et al. 2006) as a result there is much interest in tailoring 
immunosuppression to use drugs such as rapamycin, ATG and/or mycophenolate 
mofetil.  
In this regard, in the ThRIL clinical trial, prior to Treg injection, patients will be 
maintained on low dose tacrolimus and started on rapamycin. In view of the data 
presented in chapter 3, it is known that Tregs cultured in the presence of rapamycin 
have enhanced FOXP3 and suppressive capacity, it is also reassuring that these cells 
will be injected in a ‘Treg supportive’ environment, centered around the inclusion of 
rapamycin. Such a clinical protocol highlights the importance of strategies to tailor 
immunosuppressive therapy to enhance the Treg longevity in vivo. In this regard, 
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animal models will be required to test strategies such as low dose IL-2 or HDAC 
inhibitors and if and how these can be combined with Treg therapy to improve its 
effect.  
(
6.2.5 ANTICIPATED COST AND THE FUTURE 
 
At present the cost to manufacture a single ‘personalised’ injection of Tregs in the 
GMP facility is over £20,000 in the UK. The data soon emerging on the safety of 
these cells in the setting of transplantation will provide the basis for progression to a 
larger phase II/III study. The future progression of the cell therapy programme will 
also see efforts focused on the optimization of the process development and potential 
commercialization of the cell based therapies, through collaborations with industry 
and other organisations. It is anticipated that the future optimization of the 
manufacturing process for larger scale trials and commercialization would reduce the 
costs, making this modality of treatment broadly available and applicable in other 
disease settings.  
 
6.3. OTHER NOVEL APPROACHES TO TOLERANCE INDUCTION  
 
Regulatory T cell therapy, whether it be the adoptive transfer of ex vivo expanded 
cells or induction of Tregs from naïve precursors in vivo, has proved its worth as an 
effective approach to tolerance induction. However these cells are far from the be all 
and end all, with various other immunoregulatory cellular therapies having also 
shown considerable promise in inducing tolerance in humans. From a rational 
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perspective, these can be divided into: strategies aimed at the depletion of donor-
reactive lymphocytes, schemes of negative vaccination by injection of non-
immunogenic cells, such as modified DCs, and the recent application of mesenchymal 
stromal cells (MSCs) and regulatory macrophages. 
 
To achieve tolerance in the face of MHC incompatibility it is probable that both T cell 
deletion and the induction of T cell regulation will be required. Depletion can be 
either polyclonal, using reagents such as anti-CD3, anti-CD52 (Campath-1), anti-
CD25 and anti-CD20 alone, or antigen specific as achieved by haematopoietic 
chimerism. In the latter approach, the recipient is pre-conditioned with a combination 
of myeloablative therapy and anti-T cell treatment prior to the infusion of mixed 
donor and recipient bone marrow, resulting in stable long-term mixed chimerism 
(Sykes and Sachs 1988). This process tolerises the recipient to alloantigen of the 
donor and can be followed up by solid organ transplantation. Although, translation of 
this work in man results in the formation of only a temporary chimerism which 
appears to cause a wave of deletion of alloreactive T cells in the thymus. This may be 
accompanied by the thymic selection of a cohort of Tregs that contribute to the 
subsequent maintenance of tolerance. Needless to say, however, the drawbacks of 
myeloablative therapy make this an untenable treatment for most patients at present, 
although a case series published recently demonstrated that a non-myeloablative 
conditioning regime of cyclophosphamide and anti-CD52 ± anti-CD20 resulted in 
mixed chimerism that was able to support immunosuppression-free renal allograft 
transplantation in single-haplotype HLA mismatched donor-recipient pairs. Of the 5 
patients treated, 4 retained their grafts whereas one lost the transplant as a result of 
irreversible humoral rejection in the early post-transplant period (Kawai et al. 2008). 
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Moreover, several small clinical studies in patients with multiple myeloma and end 
stage renal failure confirmed the possibility of drug-free renal allograft survival in 
combination with BMT (Spitzer et al. 2011). These promising results have since 
provided the impetus for the development of less toxic myeloablative conditioning in 
solid organ transplantation outside of the setting of haematological malignancy. 
Several such recent proof-of-concept human studies have demonstrated complete 
withdrawal of immunosuppressive drugs in a significant proportion of recipients 
(Scandling et al. 2012, Leventhal et al. 2013, Schneeberger et al. 2013), with long 
term follow up data currently awaited.  
 
Tolerance induction may also be achieved through the specific targeting and 
manipulation of DC populations. Although there is no reliable clinically applicable 
method of depleting donor DCs from grafts, injections of tolerogenic populations of 
recipient DCs, pulsed with alloantigen, in animal models have yielded encouraging 
results (Ochando et al. 2006). The concept of tolerogenic DC came from the 
observation that these cells have an immature phenotypes, holding the capacity to 
induce antigen-specific tolerance both in central and peripheral lymphoid tissue, 
(Colonna et al. 2004) However, it was also realised that in vivo and in an 
inflammatory environment there was the risk of these cell adopting a mature 
phenotype, turning a regulatory response into a potential immunogenic one. In this 
regard, efforts have focused on developing strategies and using pharmacological 
agents in order to maintain DCs in an immature state and these generate tolerogenic 
DCs (Adorini and Penna 2009, Buckland and Lombardi 2009). Additional points of 
consideration in particular in the transplantation setting is the source of DCs, whether 
the tolerogenic DC should be of donor or recipient origin (Sun et al. 1996, Beriou et 
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al. 2005, Peche et al. 2005). Interestingly, my group have shown that donor 
tolerogenic DCs generated by dexamethasone and vitamin D3 treatment, failed to 
induce prolongation of skin allograft survival in vivo and rather primed the recipient’s 
immune system, despite demonstrating tolerogenic capacity in vitro (Smyth et al. 
2013). Such studies merely highlight the challenges currently facing this treatment 
modality for tolerance induction in the transplant setting.  
Of note, however, in the context of the ONE study, the safety and potential efficacy of 
the administration of recipient tolerogenic DCs in kidney transplant recipients will be 
addressed (Moreau et al. 2012). 
 
Plasmacytoid DCs (pDC) are a sub-population of DCs, which rapidly produce type I 
interferon (predominantly IFN-α) in response to viral encounter. Although their 
antigen presenting capability remains contentious, these cells have several modes of 
action (Villadangos and Young 2008) including the inhibition of effector T cell 
responses whilst enhancing the expansion/ induction of Tregs (Nikolic et al. 2009). 
Furthermore, my group have recently shown the selective depletion of alloreactive T 
cells, with indirect allospecificity, by targeting the MHC class I monomers to 
quiescent myeloid DCs in vivo (Tanriver et al. 2010). This led to the inhibition of the 
indirect pathway of allorecognition and the production of IgG alloantibodies, leading 
to long-term skin graft survival.  
An alternative approach, blocking APC co-stimulation, by selective targeting of the 
CD28-CD80/86 interaction or the CD40-CD154 pathway may also have a role to play 




Furthermore, the selective depletion of B cells through the administration of chimeric 
anti-CD20 has been considered as yet another mechanism by which to induce 
tolerance. Of note however, the exact mechanism of action of anti-CD20, apart from 
B cell depletion, is incompletely understood and diverse activities, including 
downregulation of the BCR, have been postulated. The exact niche for anti-CD20 has 
yet to be fully explored, however, most centres reserve its use for induction therapy in 
highly sensitised individuals to transplant antigens (including ABO blood group 
incompatible transplants), antibody mediated rejection and for the treatment of 
rejection resistant to other therapies. The use of anti-CD20 as induction therapy is 
currently controversial given a report concluding that administration of this agent on 
the day of transplantation actually increases rates of acute rejection (this study was 
terminated early as a result) (Clatworthy et al. 2009). Nevertheless, other reports on 
the use of anti-CD20 in transplantation have been more favourable, with a Swedish 
study showing a reduction in acute rejection risk when using this agent before 
transplantation (Tyden et al. 2009). Anti-CD20 is currently under investigation (the 
RituxiCan study) as a treatment for chronic allograft dysfunction.  
It is also important to highlight the growing body of evidence in support of the 
regulatory activity of a subset of human B cells (Bregs), the CD19+CD24HiCD38Hi 
subpopulation, that include immature transitional and shown to reduce CD4+ T cell 
activation at least in part via IL-10 secretion (Blair et al. 2010). Interestingly, in renal 
transplantation patients, increased frequency of CD19+CD24HiCD38Hi has been 
associated with positive outcome (Newell et al. 2010). As such one of the challenges 
facing B cell depletion therapy is the ability to discriminate regulatory and effector B 
cells and hence provide B cell targeted therapy. In keeping with this notion, a recent 
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study using rituximab, a chimeric monoclonal antibody directed towards CD20, 
reported a higher incidence of acute rejection in the rituximab treated patients as 
compared to the control group, and those patients who did not receive induction 
therapy (Clatworthy et al. 2009). Such studies, therefore, demonstrate that total B cell 
depletion therapy should be avoided and novel approaches considered that manipulate 
the different B cell subsets.  
 
Over the last few years much interest has focused on the use of mesenchymal stromal 
cells (MSC) as potential candidates for cellular therapy in solid organ transplantation 
(Dahlke et al. 2009, Hoogduijn et al. 2010, Roemeling-van Rhijn et al. 2012). MSCs 
are multipotent stromal cells localised in virtually every tissue and have recently been 
recognised for their immunomodulatory properties both in vitro and in vivo (Burr et 
al. 2013).The precise mechanism by which these cells regulate immune responses is 
as yet unclear, although the focus of intense research. Whilst traditionally harvested 
from the bone marrow (Hanley et al. 2013), studies have shown these cells can now 
be obtained by less invasive approaches, including from adipose tissue (Melief et al. 
2013), oral mucosa (Davies et al. 2012), umbilical cord (Karlsson et al. 2012) and 
dental pulp (Laing et al. manuscript in preparation). The safety of intravenous MSC 
infusion in autoimmune diseases has already been confirmed in several early phase I 
clinical trials, with some promise of efficacy (Sun et al. 2009, Duijvestein et al. 2010, 
Karussis et al. 2010, Ciccocioppo et al. 2011, Bernardo and Fibbe 2012, Connick et 
al. 2012). However, the observation that these cells can differentiate to sarcoma cells 
in vitro (Rubio et al. 2013) poses significant safety concerns. As such, these cells are 




The past few years has also seen efforts focused on developing a cell based medicinal 
product for use in promoting transplant tolerance in renal transplant patients, using 
regulatory macrophages (Mregs). The protocol used for the generation of these cells 
involves the culture of CD14+ peripheral blood monocytes, for 7 days in the presence 
of M-CSF, 10% human serum and a final 24 hour pulse of IFN-γ (Hutchinson et al. 
2011). Mregs derived in this manner have been shown to be homogeneously CD14-/low 
HLADR+ CD80-/low CD86+ CD16- CD64+ TLR2- TLR4- and CD163-/low (Hutchinson 
et al. 2011). Moreover, functional analysis of these cells has shown a potent 
suppressive ability of T cell proliferation in vitro, both through IFN-γ induced IDO 
activity and contact dependent deletion of activated T cells (Hutchinson et al. 2011). 
Of note, the feasibility of using Mregs to promote allograft acceptance in solid organ 
transplant recipients has been demonstrated in two clinical trials, the TAIC-I 
(NCT00223093) and TAIC-II (NCT00223067), in which infusion of donor-derived 
Mregs, in a range between 7 and 8 x 106 cells/kg body weight, were well tolerated and 
did not raise any safety concerns (Hutchinson et al. 2008, Hutchinson et al. 2008, 
Hutchinson et al. 2009, Hutchinson et al. 2011). Even still in its infancy, these results 
are now to be prospectively tested as part of the ONE study.  
 
As outlined in this section, the emerging field of cellular-based medicine offers a 
broad scope of future immunomodulatory treatment options. Without a doubt, 
however, preclinical investigations still need to be carried out to answer critical 
questions addressing bioavailability, in vivo distribution, purification, stability, 
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homogeneity and functional properties of cellular medicinal products must be 
performed. 
 
6.4. FUTURE WORK   (
6.4.1. AN IN-DEPTH PHENOTYPIC AND FUNCTIONAL CHARACTERISATION OF 
REGULATORY T CELLS FROM PATIENTS WITH ALCOHOL RELATED CIRRHOSIS 
 
Whilst the activation of inflammatory responses is a central theme of alcoholic liver 
injury, excessive generation of ROS has also been reported to play an equally 
significant role in alcohol induced cellular damage (Zima and Kalousova 2005). In 
fact, recent studies have suggested a closely-linked relationship between these 
pathways (Ambade and Mandrekar 2012). Moreover, the contribution of oxidative 
stress to the chronic inflammatory state, and its steady escalation linked with 
progression to end stage liver disease, has also been reported with consistent evidence 
put forward detailing defects in the antioxidant systems early in the course of chronic 
liver failure (Kirkham 2007, Videla 2009). 
 In this regard and in view of the expression of HO-1 in many different cell types, 
induced by ROS, acidosis, proinflammatory cytokines and endotoxins (Pae et al. 
2003, Gozzelino et al. 2010), the importance of this enzyme was studied in the 
context of ARC. The main aim to ascertain whether defects in the expression of this 
cytoprotective enzyme by patient Tregs can explain the Treg dysfunction reported in 




The future additional series of experiments that are planned are outlined below: 
1. To investigate whether defects in the pathways of HO-1 induction can explain 
the lower expression of this enzyme in patient Tregs (Figure 6.1). 
Previous studies have shown that increased gene expression of HO-1 is 
coordinately controlled by the actions of the transcription factor nuclear 
factor-erythroid 2-related factor 2 (Nrf2), which binds to the antioxidant 
response element (ARE) on the promoter regions of the HO-1 gene (Paine et 
al. 2010). Of note, under basal conditions, the Ketch-like ECH-associated 
protein-1 (Keap1) forms a complex with Nrf2. The presence of 
inflammation/oxidative stress stimuli results in a dissociation of Nrf2 from 
Keap1 and subsequent activation of HO-1 gene expression. As such, Treg cell 
lysates will be obtained and analysed under basal conditions and in response to 
lipid peroxidation product 4-hydroxynonenal (4-HNE) known to activate Nrf2 
dependent endogenous antioxidant defenses. If shown that 4-HNE induced 
activation and downstream ARE gene/protein expression is impaired in patient 























FIGURE 6.1. REGULATION OF HO-1 GENE EXPRESSION.  
Diagram depicts the major signalling pathways involved in the regulation of HO-1 gene 
expression through the transcription factors (TF) Nrf2 and Bach1. These TFs have counter 
regulatory functions which are controlled by various signalling pathways. At baseline the 
transcription repressor, Bach1, constitutively binds to the ARE preventing HO-1 gene 
expression. However, upon activation of certain signalling cascades and high levels of 
intracellular heme and stress stimuli, the TF Nrf2 dissociates from its complex with Keap1 
and translocates to the nucleus, displacing Bach1 at the ARE. As a result HO-1 expression is 
promoted. While most signalling cascades promote the dissociation of Nrf2, MAPK p38a 
both activates and inhibits Nrf2 and GSK3β-mediated phosphorylation has been reported to 
negatively regulate Nrf2 and Bach1. Abbreviations: ARE-antioxidant response element;, 
Bach1- BTB and CNC homologue 1; ERK-extracellular-regulated kinase; GSK3β-glycogen 
synthase kinase-3β; Keap1-Kelch-like ECH-associated protein 1; Nrf2-NF-E2-related factor 




2. To identify the relationship between the mTOR pathway and the pathway 
involved in HO-1 induction, in view of the data demonstrating an increased 
expression of HO-1 in patient Tregs post expansion in the presence of 
rapamycin.  
The principal mechanism of the immunosuppressant rapamycin, is the direct 
inhibition of the mechanistic target of rapamycin complex 1 (mTORC1), 
thereby disrupting the mTOR pathway (Figure 6.2A). Inhibition of this 
pathway precludes the phosphorylation of the downstream protein S6 kinase-1 
(S6K1) indirectly activating phosphatidylinositol 3-kinase (PI3K) (Figure 
6.2B). Following release of its constitutive inhibition, PI3K leads to the 
activation of protein kinase B (Akt), which in turn promotes the dissociation 
of Keap1 from the Nrf2 complex. Nrf2 subsequently translocates to the 
nucleus, binding to the ARE in the promoter region of the HO-1 gene, thus 





FIGURE 6.2. MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1 SIGNALLING PATHWAY. 
mTOR is a serine/threonine protein kinase that regulates cell growth, proliferation, survival as well as protein synthesis and transcription. It exists in at least two complexes 
mTORC1, highly sensitive to inhibition by rapamycin, and mTORC2, resistant to rapamycin for reasons that are unknown. A.Diverse signals, arising from growth factors, 
cytokines as well as hypoxia, cellular stress.(DNA damage determines mTORC1 activity. These signals mediate their effects through the TSC1-TSC2 complex, which is the 
main negative regulator of mTORC1. Activation of RAS-MAPK and PI3K-AKT signalling results in inhibitory phosphorylation of TSC2 and removes the repression of RHEB, 
which is the mTORC1 stimulator. Activated mTORC1 promotes mRNA translation by stimulating S6K1 and inhibiting EIF4EBP1. Activated S6K1 can also feed back to 
negatively regulate input from PI3K-AKT. In view of the fact the PI3K-AKT signalling cascade is involved in the regulation of HO-1 gene expression, inhibition of this pathway 
will in turn impair HO-1 gene expression.  B. mTORC1 is the direct target of the rapamyicn-FK506 complex. This results in inhibition of mTORC1, thus inhibiting S6K1 
activation, which in turn leads to the loss of the inhibitory signal on the PI3K-AKT pathway. As such, the activation of the PI3K-AKT signalling cascade results in HO-1 
induction either directly or via the inhibition of the GSK3β pathway. It has bee suggested that the PI3K-AKT and GSK3β signalling pathways may have counter-regulatory 
functions in HO-1 gene regulation. As such, the inhibition of the GSK3β signalling cascade will result in HO-1 induction. Abbreviations: EIF4EBP1-eukaryotic translation 
initiation factor-binding protein 1; GSK3-Glycogen synthase kinase 3; HO-1-Heme-oxygenase 1; mTOR-mammalian target of rapamycin; mTORC- mTOR complex); PI3K- 
phosphoinositide 3-kinase, FKBP12-  rapamyicn-FK506-binding protein 1A, 12kDa complex; RAS-MAPK- RAS-mitogen-activated protein kinase; RHEB-RAS homologue 
enriched in brain; S6K1-Serine/threonine protein kinase ; TSC1-TSC2-Tuberous sclerosis complex 1-2. Adapted from (Thomson et al. 2009).  
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3. To delineate the specific mechanism by which Treg suppressive function is 
linked with the expression of HO-1.  
One potential avenue that may be pursued is the decreased production of IL-10 
by Tregs post HO-1 inhibition. A positive feedback circuit between IL-10 and 
HO-1 has been shown to be functional, amplifying the anti-inflammatory 
effects of IL-10 (Lee and Chau 2002, Chauveau et al. 2005) (Figure 1.6) a 
process that in part depends on STAT3 activation (Mashreghi et al. 2008). As 
such it is hypothesized that HO-1 mediated Treg suppression is associated 
with a release of IL-10 by Tregs. In line with this, De Wilde et al. showed that 
LPS induced myeloid- derived suppressor cells (MDSCs) inhibited 
alloimmune mediated skin graft damage via HO-1 and IL-10 production, 
whereby the inhibition of HO-1 resulted in decreased IL-10 production, 
abrogating the inhibition of allograft rejection (De Wilde et al. 2009). 
Although, to unearth the definitive mechanism of HO-1 mediated Treg 
suppression may prove to be an arduous task in view of the individual anti-
inflammatory attributes of each of the downstream products of HO-1 
(Otterbein et al. 2000)  (Figure 1.6). 
 
4. To determine whether a defect in HO-1 expression in Tregs can also explain 
the reduced Treg numbers in patients with ARC.  
The antiapoptotic properties of HO-1 have been widely reported (Brouard et 
al. 2002, Choi et al. 2004). As such, it can be hypothesized that decreased 
levels of HO-1 expressed by Tregs from patients with ARC renders these cells 
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prone to apoptosis, thus reflecting their relative deficiency. Future experiments 
characterising the susceptibility of patient Tregs to apoptosis will be carried 
out to confirm/refute this hypothesis and potentially propose an explanation 
for the low Treg numbers.  
It is of importance, however, to also note that in several liver diseases 
including primary biliary cirrhosis and autoimmune hepatitis, there is a 
sequestration of Tregs, amongst other infiltrating lymphocytes, in the liver 
itself ((Sasaki et al. 2007, Sakaki et al. 2008, Speletas et al. 2011)). As such it 
may be alternatively hypothesized that the decreased number of circulating 
Tregs reported here is the result of increased migration of these cells into the 
liver. As the pattern of distribution or function of Tregs in peripheral blood 
may not necessarily correlate with those found in the liver. As such, further 
studies will be conducted with an evaluation of Tregs from paired peripheral 
blood and liver biopsy samples of patients with ARC.  
 
5. In parallel the data presented in chapter 3 also showed that CD4+CD25- 
Teffector cells from ARC patients expressed comparable levels of HO-1 to 
age and sex matched HCs, despite autologous Tregs expressing lower levels of 
HO-1. As such, it can be hypothesized that CD4+CD25- T effectors are 
protected against apoptosis, as compared to their autologous Treg 
counterparts. Future experiments will be conducted to test this hypothesis. 
Moreover, although the focus of this thesis has been on Tregs, interestingly, an 
initial analysis of the T effector cells from patients with ARC showed that 
these cells were resistant to Treg suppression (Appendix 2A), whilst 
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maintaining similar proliferation potential as CD4+CD25- effectors isolated 
from HCs (Appendix 2B). Future work will also include an in-depth 
phenotypic analysis of the T effector cells from ARC patients with a study into 
the mechanism for this resistance. Interestingly, a study by Goodman et al. 
recently reported that STAT3 phosphorylation mediated the resistance of 
effector T cells to Treg suppression. In this regard, the next planned 
experiments will investigate STAT3 signalling in this system (Goodman et al. 
2011).  
 
6. Other than the presence of ROS and liver injury mediated by oxidative stress, 
it is important to highlight that liver cirrhosis has also been associated with a 
chronic low-grade inflammation (Giron-Gonzalez et al. 2004).  
In this support, there are reports that patients with ARC have elevated levels of 
pro-inflammatory cytokines in the circulation (Daniluk et al. 2001, Tung et al. 
2010). Moreover, the suggestion that in the presence of inflammatory stressors 
Tregs convert to non-suppressive, pro-inflammatory cytokine-producing cells, 
whilst retaining FOXP3 expression, (d'Hennezel and Piccirillo 2012, Hamann 
2012) has stirred considerable controversy with regard to the inherent stability 
of these cells. IFN-γ producing Tregs with reduced function have been 
identified in the peripheral blood of diabetic (McClymont et al. 2011) and 
multiple sclerosis patients (Dominguez-Villar et al. 2011). This ‘Th1-like’ 
Treg phenotype was recapitulated in vitro when Tregs from healthy 
individuals were exposed to IL-12 with the subsequent removal of IL-12 
resulting in the reversion back to the classical Treg phenotype (Dominguez-
Villar et al. 2011). Such data supports the lineage instability of FOXP3+ Tregs, 
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highlighting their propensity to adopt Th1 and Th17 phenotypes in 
inflammatory microenvironments.  
In this regard, the epigenetic status of the TSDR of the FOXP3 gene of the 
freshly isolated Tregs from patients should also be assessed. Key data reported 
in this thesis supporting this line of investigation, is of an increased propensity 
of freshly isolated Tregs to produce IL-17 and the increased percentage of 
IL17+FOXP3+ cells, in patients with ARC, after culture in the presence of pro-
inflammatory cytokines, as compared to healthy controls.  
Moreover, the data presented revealed an increased frequency of CD161+ 
Tregs from ARC patients as compared to healthy controls. Despite recent 
reports that CD161+ Tregs produce IL-17 and yet maintain suppressive 
function (Afzali et al. 2013, Pesenacker et al. 2013), the role of these cells in 
ARC has not yet been fully elucidated. The increased frequency of these cells 
in ARC patients warrants further investigation with regards to suppressive 
function and cytokine production. In agreement, the data presented further 
demonstrated that by final harvest, post expansion in the presence of 
rapamycin, there was a decrease in frequency of CD161+ Tregs. Whether this 
finding also correlates with the increased Treg suppressor function remains to 









6.4.2. EX VIVO EXPANSION OF REGULATORY T CELLS FROM PATIENTS WITH 
END STAGE LIVER DISEASE; INCREASED SUPPRESSOR FUNCTION AND 
CLINICAL APPLICATION  
 
Chapter 4 saw the successful isolation and expansion of patient-derived Tregs for 
clinical application. The data presented provided support to the current evidence 
(Strauss et al. 2007) that rapamycin protects against plasticity to a Th17 phenotype, 
whilst maintaining regulatory phenotype and suppressive capacity of the expanded 
Tregs. It is also encouraging that for the ThRIL trial; patients will be started on a Treg 
supportive immunosuppressive regimen, one that incorporates rapamycin prior to 
Treg injection. Despite the rapamycin- based GMP compatible expansion protocol 
and the clinical protocol, optimised for maintaining a stable Treg phenotype and 
function in vitro and in vivo, the stability of the expanded Tregs should be tested by 
analysing the epigenetic status of the TSDR of the FOXP3 gene.  
 
6.4.3. CLINICAL GRADE MANUFACTURING OF HUMAN ALLOANTIGEN-
REACTIVE REGULATORY T CELLS FOR USE IN TRANSPLANTATION. 
 
Chapter 5 outlines a protocol that can reliably produce large numbers of clinical 
grade, highly pure, and stable donor-specific Tregs using short-term cultures. In this 
regard, CD40L stimulated human B cells were shown to be potent APCs in the 
generation of allogeneic Tregs. This data provided further support to published reports 
highlighting the utility of CD40 activated B cells in the induction and expansion of 
Tregs in vitro (Tu et al. 2008, Zheng et al. 2010). Traditionally PBMCs (Peters et al. 
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2008) and DCs (Yamazaki et al. 2003) have been used in the expansion of alloantigen 
reactive Tregs, with reports of the unparalleled superiority of DCs in this regard 
(Veerapathran et al. 2011). In addition, an innovative approach to selective expansion 
of donor reactive human Tregs, using LPS matured human myeloid BDCA-1+ (CD1c) 
DCs has been previously published by my group (Sagoo et al. 2011). However, it yet 
remains to be determined how B cells and DCs compare in their relative potency as 
APCs in the generation of Tregs with direct allospecificity. This investigation can be 
conducted by pursuing the following aims: 
 
1. In-depth characterisation of APCs to allow for the identification of the optimal 
B cell subset and DC maturation state. 
In view of the ever-growing knowledge and understanding of B cell biology, 
definitive research into their antigen presenting capacities is now all the more 
plausible with various subsets already identified (Jackson et al. 2008, Perez-Andres et 
al. 2010, Leandro 2013). As a result, investigation into an optimal B cell subset for 
the generation of alloantigen reactive Treg may prove to be invaluable.  
Moreover the variable maturation states of DCs and their influences on Treg 
expansion, potency and phenotype will be tested. When considering the clinical 
translation of this work, it is worth noting that there are already reports of carefully 
constructed GMP-compliant cytokine cocktails used for the maturation of DCs 






2. Comparison of the phenotype, function, stability and expansion profile of B 
cell expanded vs DC expanded Tregs in vitro. 
Once the optimal APCs have been elucidated additional series of experiments will 
investigate differences between B cell expanded Tregs vs DC expanded Tregs. 
Namely, studying the expression of regulatory molecules on Tregs, the chemokine 
receptor expression and the Treg TCR repertoire. In addition, the antigen specific 
suppressive function of the B cell expanded Tregs and DC expanded Tregs will be 
assessed, and the stability of the Tregs studied by analysing the epigenetic status of 
the TSDR of the FOXP3 gene.  
 
3. The in vivo function of B cell expanded vs. DC expanded Tregs. 
It will be pertinent to determine how DC-expanded Tregs compare in preventing 
transplant rejection in vivo, as compared B cell-expanded Tregs. As such, future work 
assessing Treg homing, survival, function and stability in vivo will be assessed, using 
the well established humanised mouse model of skin transplantation developed in my 
laboratory. In addition, future work will see investigation into the mechanisms by 
which one APC is superior over the other with regards to the generation of the 







Other points for consideration in view of the data presented in chapter 5; 
 
1. In chapter 5, it has been shown that B cell expanded Tregs are more potent as 
compared to polyclonal Tregs at averting alloimmune mediated skin damage. 
However, in the experiments outlined, similar numbers of both polyclonal and antigen 
specific Tregs were injected. In view of reports that alloantigen reactive Tregs are 10-
100 times more effective at suppressing T effector proliferation to alloantigens than 
polyclonal Tregs in in vitro suppression assays (Peters et al. 2008, Sagoo et al. 2011, 
Veerapathran et al. 2011), to make a true comparison between their in vivo function, 
1/100-1/10th of antigen specific Tregs needs to be injected as compared polyclonal 
Tregs.  
2. One of the concerns with the clinical application of polyclonal Tregs in the setting 
of transplantation is their potential to induce non-specific, ‘pan’ suppression as 
compared to the targeted therapy offered by antigen specific Tregs. In future work, 
using the same humanised mouse model of skin transplantation, mice will be 
challenged with an infective agent, with levels of immune response mounted 










Clinically, acute allograft rejection can be successfully prevented with the use of 
immunosuppressive agents. However, such treatment is associated with chronic 
complications, including, infection, malignancy and renal failure. Long-term allograft 
rejection, either due to persisting alloantigen recognition via the indirect (and possibly 
semi-direct) pathway or a failure of tolerogenic mechanisms to fully control 
alloresponses, remains a fundamental barrier to achieving immunosuppression-free 
transplantation protocols. Each component of the allorecognition-alloresponse 
pathway can in theory be manipulated to achieve tolerance. 
We are now entering an exciting era in the study of immunological tolerance. Several 
cellular and molecular strategies of tolerance induction have been developed in non-
human transplant models that have shown considerable promise and are just now 
appearing in clinical trials. As such the recent progress in Treg biology and the 
successes in the clinical grade manufacture of these cells has seen the start of clinical 
trials of Treg therapy in solid organ transplantation. Such trials will provide the basis 
for progression to a larger phase II/III study with a comprehensive patient immune 
monitoring plan and the use of biomarkers that can predict the successful induction of 
immune tolerance, allowing for the safe minimisation/withdrawal of 
immunosuppression. With this all said, it is no secret that the panacea of 
immunological tolerance in transplantation is now ordained as we take steps ever 
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APPENDIX 1.  SET RELEASE CRITERIA FOR CLINICAL TRANSLATION OF 





























APPENDIX 2. ASSESSMENT OF T EFFECTOR CELL FUNCTION.  
A. Representative histogram and graph comparing the proliferation of CD4+CD25- Teffs from 
5 ARC patients and 5 HCs. Percentage Teff proliferation was quantified from a CFSE dilution 
assay. B. Graph displaying the relative resistance of ARC CD4+CD25- Teffs to Treg 
suppression. Each line represents the mean percentage suppression following a CFSE dilution 
suppression assay with CD4+CD25+ Tregs and CD4+CD25- Teffs. The black line displays the 
mean suppressive function of HC Tregs when co-cultured with autologous HC effectors. The 
blue line shows the mean suppression of ARC Tregs when co-cultured with allogeneic HC 
Tregs. The purple line depicts the mean suppression of ARC Tregs when co-cultured with 
autologous ARC CD4+CD25- effectors. The green line shows the mean percentage 
suppression of HC Tregs when co-cultured with ARC patient CD4+CD25- Teffs. n= 5. Treg 
suppressive function was compared at 3 different Treg:Teff ratios: 1:1, 1:5 and 1:10.  n.s.: not 



























ARC Treg: ARC Teff
HC Treg: ARC Teff
HC Treg: HC Teff 
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